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CHAPTER I 
 
Introduction 
 
EVOLUTION OF TUMOR TREATMENT STRATEGIES 
Anti-Cancer Agents, Old and New 
The paradigms for cancer treatment have vastly evolved over the past century as 
the result of a deeper understanding of the underlying genetic, epigenetic and tumor-
stroma interactions associated with different cancer types.  Traditionally, tumors were 
pharmacologically managed using a myriad of chemotherapy agents that disrupt not 
only the biological processes of tumor cells, but also those of non-tumor cells.  These 
generalized chemotherapy agents include anti-folates (methotrexate) (1), anti-mitotics 
(vinca alkaloids, taxanes) (2, 3), topoisomerase inhibitors (camptothecin against 
topoisomerase I, etoposide against topoisomerase II) (4, 5), DNA cross-linking agents 
(platinum-based drugs) (6), and nucleoside analogues (5-fluorouracil) (7), among 
others; many are still in clinical use today.  In the mid-1990’s, however, genetic 
information began to be linked with drug design strategies, bringing both cancer 
research and cancer care into the era of “targeted therapy”.  The most famous example 
of this convergence, perhaps, is the finding that chronic myelogenous leukemias 
(CMLs) harboring a genomic rearrangement of the ABL (Abelson murine leukemia viral 
oncogene homolog 1) kinase gene to the BCR (breakpoint cluster region) gene are 
sensitive to the ABL tyrosine kinase inhibitor (TKI), imatinib (8).  This achievement 
represented the culmination of 40 years of basic science and clinical research (9). 
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Linking Driver Mutations with Targeted Agents 
Since the discovery of imatinib, much of the field has focused on identifying 
analogous cancer targets.  In particular, researchers have most recently focused their 
efforts toward the identification of somatic alterations that create a constitutively active, 
oncogenic protein product, which we refer to as “driver mutations”.    Driver alterations 
most commonly are the result of point mutations, insertions, deletions, or structural 
rearrangements (i.e. BCR-ABL above).  Furthermore, the vast majority of driver 
mutations occur in tyrosine or serine-threonine kinase proteins which are prime 
candidates for rational drug design (10).  From a therapeutic standpoint, tumor cells 
harboring driver-mutated protein kinases become dependent on the activated signaling 
pathways induced by the drivers (e.g. “oncogene addiction”).  Inhibition of these 
pathways with specific, small-molecule kinase inhibitors attenuates cellular survival 
and/or proliferation to ultimately elicit cell death (10).  Because these pathways are 
typically not activated in non-tumor cells, a “therapeutic window” is created that is not 
possible with traditional chemotherapy.  From a drug-design standpoint, driver 
mutations typically alter the kinase domain of the protein.  Specifically, the adenosine 
triphosphate (ATP) binding pocket is positioned to continuously receive ATP, allowing 
transfer of the ATP γ-phosphate to the hydroxyl group of tyrosine, serine or threonine 
residues on effector proteins (11).  Therefore, kinase inhibitors are rationally designed 
to compete with ATP and/or the substrate in the active site of the kinase, or bind in an 
allosteric fashion to induce a conformational change not amenable to ATP binding (12). 
After the human genome was sequenced in 2001 (13, 14), researchers had a 
reference sequence against which they could identify putative driver mutations in tumor 
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gene sequences with potential therapeutic implications.  This feat drastically 
accelerated basic and translational research focused on identifying druggable targets in 
cancers and brought the field into the era of personalized, precision medicine.  In other 
words, treating the right patient, with the right drug, at the right time.  For example, the 
kinase inhibitors erlotinib and gefitinib are ATP-competitive inhibitors of the epidermal 
growth factor receptor (EGFR).  For non-small-cell lung cancer (NSCLC) patients whose 
tumors harbor specific driver mutations in the kinase domain of EGFR (exon 19 short 
deletions and exon 21 L858R point mutations) (15-17), these agents can cause drastic 
tumor shrinkage and improve progression-free survival (PFS) over traditional 
chemotherapy.  Thus, effective treatment of this disease has drastically improved (18, 
19).  Other driver mutation/targeted therapy success stories have been observed in  
ALK (anaplastic lymphoma kinase) fusion-positive lung cancer (crizotinib) (20), BRAF 
(v-Raf murine Sarcoma viral oncogene homolog B) codon V600-mutant melanoma 
(vemurafenib, dabrafenib) (21), PDGFRα- (platelet-derived growth factor α) and KIT- 
(a.k.a. stem cell factor) mutant gastrointestinal stromal tumors (imatinib) (22, 23), 
among others.  A larger summary of well-known drivers in cancer and their respective 
kinase inhibitors can be found in Table 1.1 (24). 
 
Acquired Resistance to Targeted Therapy 
As promising as targeted kinase inhibitors seem, many tumors will ultimately 
become resistant to these agents.  There are several mechanisms of acquired 
resistance, including modification of the drug target (i.e. second-site mutations, 
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Table 1.1.  Alterations in Signaling Enzymes Known to be Associated with Sensitivity to 
Available Kinase Targeting Therapies.  Modified from Meador, et al., Clinical Cancer Res, 
2014 (24). 
Acute Lymphoblastic Leukemia (ALL) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
CRLF2 Fusions Sirolimus Preclinical data Tasian, et al., ASCO Annual 
Meeting, 2012 
JAK2 R683G/S/T Ruxolitinib  Preclinical data Tasian, et al., ASCO Annual 
Meeting, 2012 
          
Acute Myeloid Leukemia (AML) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
FLT3 Internal 
Tandem 
Duplication 
Quizartinib  Phase II Cortes, et al., Am Soc Hematol 
Annual Meeting, 2012 
      Levis, et al., Am Soc Hematol 
Annual Meeting, 2012 
  Sorafenib Phase I Man, et al., Blood, 2012 
          
Bladder Cancer 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
TSC1 E636fs Everolimus Case report Iyer et al., Science, 2012 
          
Breast Cancer 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
HER2 Amplification / 
overexpression 
Trastuzumab FDA approved FDA, 1998 
  Pertuzumab FDA approved FDA, 2012 
  Lapatinib FDA approved FDA, 2007 
  Neratinib Phase II trial Burstein et al., J Clin Oncol, 2010 
PIK3CA E542K GDC-0941 Preclinical data O’Brien et al., Clin Cancer Res, 
2010 
  E545A/G/K/Q/
V 
      
  H1047L/R       
          
Chronic Myelogenous Leukemia (CML) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
ABL1 BCR-ABL1 
fusion 
Imatinib FDA approved FDA, 2001, new diagnoses 
    Dasatinib FDA approved FDA, 2006, new diagnoses & 
imatinib resistant 
    Nilotinib FDA approved FDA, 2010, new diagnoses & 
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imatinib resistant 
    Bosutinib FDA approved FDA, 2012, resistance to imatinib 
or imatinib followed by dasatinib 
and/or nilotinib 
  ABL1 T315I Ponatinib FDA approved FDA 2012, imatinib resistant CML 
mediated by ABL T315I gatekeeper 
mutation 
          
Colorectal Cancer (CRC) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
BRAF V600Ea Vemurafenib 
+ gefitinib / 
cetuximab / 
erlotinib 
Preclinical data Prahallad, et al., Nature, 2012 
        Yang, et al., Cancer Res, 2012 
NRAS G12A/C/D/S/V AZD6244 Preclinical data Davies, et al., Mol Cancer Ther, 
2007 
  Q61K/R CI-1040 Preclinical data Solit, et al., Nature, 2006 
          
Gastric Cancer 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
HER2 amplification Trastuzumab Phase III Bang, et al., Lancet, 2010 
          
Gastrointestinal Stromal Tumor (GIST) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
KIT Exon 9 (ECD) 
mutation 
Sunitinib Phase I/II Heinrich, et al., J Clin Oncol, 2008 
  Exon 11 (JM) 
mutation 
Imatinib Phase III Corless, et al., ASCO Annual 
Meeting, 2010 
  Exon 13 (KD) 
mutation 
Sunitinib Phase III Heinrich, et al., J Clin Oncol, 2008 
  Exon 14 (KD) 
mutation 
      
PDGFRA Exon 12 (JM) 
mutation 
Imatinib Phase II Heinrich, et al., J Clin Oncol, 2003 
  Exon 14 (KD) 
mutation 
Imatinib Preclinical data Corless, et al., J Clin Oncol, 2005 
  Exon 18 (KD) 
mutation 
      
          
Inflammatory Myofibroblastic Tumor (IMT) 
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Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
ALK Fusions Crizotinib Case report Butrynski, et al., New Engl J Med, 
2010 
ROS1 Fusions Crizotinib  Case report Lovly, et al., Cancer Discovery, 
2014 
    
Melanoma 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
BRAF V600E/K/M/R
/Db 
Vemurafenib Phase III trial Chapman et al., NEJM, 2011 
      FDA approved FDA, 2011 
    Dabrafenib Phase III trial Hauschild et al., Lancet, 2012 
      FDA approved FDA, 2013 
    Trametinib Phase III trial Flaherty et al., NEJM, 2012 
      FDA approved FDA, 2013 
    Dabrafenib + 
trametinib 
Phase I/II trial Flaherty et al., NEJM, 2012 
      FDA approved FDA, 2014 
KIT L576P Imatinib Phase II trial Carvajal et al., JAMA, 2011 
  K642E   Phase II trial Hodi et al., J Clin Oncol,, 2013 
  V559A Imatinib Case report Terheyden et al., J Invest 
Dermatol., 2010 
  W557R Imatinib Preclinical data Beadling et al., Clin Cancer 
Research, 2008 
  V559D       
  L576P Dasatinib Case report Woodman et al., Mol Cancer Ther, 
2009 
  L576P Sunitinib Retrospective 
analysis 
Minor et al., Clin Cancer Res, 2012 
  W557G       
  V560D Sorafenib Case report Quintas-Cardama et al., Nat Clin 
Pract Oncol, 2008 
  L576P Nilotinib Phase II Trial Cho et al., Invest New Drugs, 2012 
  V559A       
NRAS Q61L/K/Rc MEK162 Phase II trial Ascierto et al., Lancet Oncol, 2013 
    Selumetinib Phase I trial Adjei et al., J Clin Oncol, 2008 
    Trametinib + 
PD-0332991 
Preclinical data Kwong et al., Nat Med, 2012 
          
Neuroblastoma 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
ALK R1275Qd Crizotinib Preclinical data Bresler, et al., Sci Transl Med, 
7 
 
2011 
        Schonherr, et al., Biochem J, 2011 
    TAE-684 Preclinical data Schonherr, et al., Biochem J, 2011 
    
Non-Small-Cell Lung Cancer (NSCLC) 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
ALK Fusions Crizotinib Phase III trial Shaw et al., NEJM 2013 
FDA approved FDA, 2013 
IPI-504 Phase II trial Sequist et al., J Clin Oncol, 2010 
Ganetespibe Phase II trial Socinski et al., Clin Cancer 
Research, 2013 
LDK378 Phase II trial Shaw et al., J Clin Oncol, 2013 
  FDA approved FDA, 2014 (for crizotinib-resistant 
tumors) 
AP26113 Phase I trial Camidge et al, World Conf Lung 
Cancer, 2013 
  FDA approved FDA, 2014 
CH5424802 Phase I/II trial Seto et al., Lancet Oncol, 2013 
ALK  Fusion + 
G1269A 
Ganetespibe Case report Sang et al., Cancer Discov., 2013 
BRAF Y472C Dasatinib Case report Sen et al. Sci Tranl Med, 2012 
  V600E Vemurafenib Case report Gautschi et al. J Thorac Oncol, 
2012 
    Dabrafenib Case report Rudin et al. J Thorac Oncol, 2013 
DDR2 S768R Dasatinib Case report Pitini et al., Lung Cancer, 2013 
    Dasatinib + 
erlotinib 
Case report Hammerman et al., Cancer Discov, 
2011 
EGFR Exon19del/ Gefitinib Phase III trial Mok et al., NEJM, 2009 
  L858R  FDA approved Mitsudomi et al., Lancet Oncol, 
2010 
      Maemondo et al., NEJM, 2010 
       FDA, 2005 
     Erlotinib Phase III trial Zhou et al., Lancet Oncol, 2011 
       FDA approved Rosell et al., Lancet Oncol, 2012 
       FDA, 2013 
     Afatinib Phase III trial Sequist et al., J Clin Oncol, 2013 
       FDA approved FDA, 2013 
     Dacomitinib Phase II trial Ramalingam et al., J Clin Oncol, 
2012 
  Exon 19ins Erlotinib Retrospective 
analysis 
He et al., Clin Cancer Research, 
2012 
    Gefitinib     
    Afatinib     
  G719A/C/S Gefitinib Retrospective Lynch, et al., NEJM, 2004 
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analysis 
    Erlotinib   Rosell, et al., Lung Cancer, 2005 
    Neratinib Phase II trial Sequist et al., J Clin Oncol, 2010 
  L861Q Gefitinib Case reports Lynch, et al., NEJM, 2004 
    Erlotinib     
  T790M CO-1686 Phase I trial Sequist et al., ASCO Annual 
Meeting, 2014 
    AZD9291 Phase I trial Ranson et al., ECCO 2013 
ERBB2 Exon20ins/ Afatinib Phase II trial De Greve et al. Lung Cancer, 2012 
  G776L Trastuzumab 
+ 
Case report Cappuzzo et al. NEJM, 2006  
     paclitaxelf     
     Trastuzumab 
+ chemof 
Retrospective 
analysis 
Mazieres et al. Cancer Res, 2008 
FGFR1 Amplification BGJ398 Case report Malchers et al., Cancer Discov, 
2013 
          
KRAS G12A/R/D/C/S
/Vg 
Selumetinib + 
docetaxelf 
Phase II trial Janne et al., Lancet Oncol, 2013 
  G13Dg       
MEK1 K57N Selumetinib Preclinical data Marks et al., Cancer Res, 2008 
MET Amplification Crizotinib Case report Ou et al., J Thorac Oncol, 2011 
NRAS Q61L/R/Kh Selumetinib Preclinical data Ohashi et al., Clin Cancer Res, 
2013 
    Trametinib     
PIK3CA H1047R BKM120 Phase I trial Bendell et al., J Clin Oncol, 2012 
RET  Fusions Cabozantinib Phase II trial Drilon et al., Cancer Discov, 2013 
    Vandetinib Case report Gautschi et al., J Thorac Oncol, 
2013 
    Ganetespibe Preclinical data Sang et al., Cancer Discov., 2013 
ROS1 Fusions Crizotinib Case report Bergethon et al., J Clin Oncol, 
2012 
     Case report Davies et al., Clin Cancer Res, 
2013 
    Ganetespibe Preclinical data Sang et al., Cancer Discov., 2013 
    
Thyroid Carcinoma 
Oncogene Targeted therapy 
Level of 
evidence 
Publications/Abstracts/FDA 
Approval Date 
BRAF V600E Sorafenib  Phase II Kloos, et al., J Clin Oncol, 2009 
  K601E     Hoftijzer, et al., Eur J Endocrinol, 
2009 
NRAS Q61R/K AZD-6244 Biological study Ho, et al., NEJM, 2013 
RET Fusions  Sorafenib Phase II Lam, et al., J Clin Oncol, 2010 
    Vandetanib Phase II Wells, et al., J Clin Oncol, 2010 
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        FDA approved, 2011 
aUnlike melanoma, CRCs harboring BRAF V600E mutations are not sensitive to single-agent BRAF 
inhibitors such as vemurafenib, dabrafenib, etc. 
bV600M/R/D substitutions occur less frequently than V600E/K; specific outcomes for V600M/R/D are not 
included in these clinical trial data; sensitivity is predicted based on preclinical data and case reports. 
cSpecific mutations listed are those found in references cited. Other substitutions in NRAS codons 12, 13, 
and 61 have been found in NSCLC; differences in their sensitivity to selumetinib and trametinib are 
unknown at this time. 
dSpecific mutations listed are those found in references cited.  Other substitutions are observed in ALK, 
however, sensitivity to ALK inhibitors is not well delineated at this time. 
eGanetespib is an inhibitor of heat shock protein 90 (HSP90), not a kinase inhibitor. 
fpaclitaxel and docetaxel are not kinase inhibitors; they are chemotherapies. 
gSpecific mutations listed are those found in references cited. Other substitutions in KRAS codons 12, 13, 
and 61 have been found in NSCLC; differences in their sensitivity to selumetinib + docetaxel are 
unknown at this time. 
hSpecific mutations listed are those found in references cited. Other substitutions in NRAS codons 12, 13, 
and 61 have been found in melanoma; differences in their sensitivity to MEK inhibitors are unknown at 
this time. 
Abbreviations:  ECD, extracellular domain; JM, juxtamembrane domain; KD, kinase domain 
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amplification), activation of bypass, or compensatory, signaling pathways, 
transformation from an epithelial to mesenchymal histology, or increased production of 
receptor ligands (25). Many tumors are also intrinsically resistant to targeted therapy.  
De novo resistance mechanisms can be similar in that despite harboring an actionable 
driver mutation, these tumors may already harbor second-site mutations in the drug 
target, or harbor concurrent mutations/amplifications of compensatory signaling 
molecules (25).  Tumor resistance to targeted interventions is not a focus of the work 
described herein, however, it could be the center of future studies (see Chapter V). 
 
Next-Generation Sequencing Technologies and Cancer 
Most recently, the power of next-generation sequencing (NGS) technologies has 
allowed for a deeper understanding of the complexity of cancer genomes (26).  Like 
traditional sequencing methods, these technologies can identify point mutations and 
small insertions and deletions, but at much greater resolution (i.e. very low allelic 
frequency mutations).  Furthermore, NGS can also provide information on copy number 
variations (CNVs), large genomic insertions or deletions, genomic rearrangements and 
alternatively spliced isoforms, and transcript expression (RNA sequencing)  (27).  As will 
be described herein, NGS can be very useful to identify potentially novel and actionable 
driver mutations, as well as underlying passenger alterations. 
 
Clinical Detection of Actionable Driver Mutations 
For personalized/precision medicine efforts to be most effective, there is a need 
for timely clinical detection of actionable drivers.  Many assays are now clinically 
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available that rapidly and reliably detect multiple driver mutations in several different 
genes.  At Vanderbilt, for example, tumors from patients with colorectal, breast, lung or 
skin cancers automatically undergo genotyping with the polymerase chain reaction 
(PCR) and capillary electrophoresis-based SNaPshotTM assay to identify known driver 
point mutations in order to quickly assign an appropriate therapy (28-31).  These usually 
assay for known drivers in fewer than 10 genes. 
More recently, however, some institutions and diagnostic companies have 
refined NGS techniques to detect not only point mutations and insertions/deletions, but 
also genomic rearrangements in more than 300 genes at a time.  These include the 
targeted NGS assays, FoundationOneTM and FoundationOne HemeTM from Foundation 
Medicine, Incorporated (Cambridge, Massachusetts) (32, 33), and the Integrated 
Mutation Profiling of Actionable Cancer Targets (IMPACT) assay from the Berger Lab at 
Memorial Sloan-Kettering Cancer Center (MSKCC) (34).  These comprehensive tests 
are often referred to as “companion diagnostics”, as they usually serve as a supplement 
to less comprehensive tests (i.e. SNaPshot) in the event that no actionable mutations 
are identified. 
 
Driver-Negative Tumors and Remaining Goals 
Clearly, the standards of cancer treatment have drastically improved thanks to an 
enhanced understanding of molecular driver events associated with certain cancer 
types, as well as improved drug-development methods.  Unfortunately, many tumors 
remain without a known obvious and/or druggable driver mutation (i.e. “pan-negative”).  
As a result, patients with pan-negative disease are ineligible for treatment with targeted 
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agents and must resort to traditional chemotherapeutic and/or surgical management 
methods.  Prime examples of cancers with large rates of pan-negative disease include 
melanoma and pancreatic acinar cell carcinoma (PACC).  Details of our current 
knowledge of these cancer types will be described in respective sections below.  Briefly, 
however, approximately 70% of melanomas harbor a potentially actionable driver 
mutation.  Therefore, Chapters II-IV, herein, will highlight our recent efforts to uncover 
novel and druggable alterations in the remaining one-third of pan-negative melanomas.  
In contrast to melanoma, there are no known drivers of PACC (Chapter VI).  Thus, 
identifying actionable targets in these cancer types is of critical need. 
 
MELANOMA 
Melanoma Pathogenesis 
Melanoma, a malignant neoplasm of melanocytes, is the most frequently 
diagnosed skin cancer in the world.  Representing 5% of all cancer diagnoses in men 
and 4% of all cancer diagnoses in women, it is anticipated that >76,000 new cases of 
cutaneous melanoma will be diagnosed in 2014 in the United States with >9,700 
expected deaths (35).  For patients with metastatic disease, the five-year survival rate is 
only 14% (36). Historically, melanoma was classified according to clinical and 
pathological characteristics such as histology and anatomic site of origin.  Initial steps in 
the classic model of progression show that proliferation of normal melanocytes leads to 
the formation of a benign nevus (Figure 1.1).  Interestingly, many nevi may harbor 
oncogenic BRAF mutations, but can only progress beyond the melanoma in situ phase 
and cross the basement membrane following acquisition of additional molecular “hits” 
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such as the loss of the tumor suppressors PTEN and/or CDKN2A (36).  Given the highly 
migratory nature of neural crest cell types, from which melanocytes are derived, it is 
unsurprising that the most aggressive metastatic melanomas have lost cell adhesion 
control and are highly de-differentiated (36).  Previously, the severity of cutaneous 
melanomas was categorized based on histologic characteristics such as Breslow depth 
and Clark level, which each assess depth of invasion into the dermal layers, as well as 
ulceration (36, 37).  More recently, however, the American Joint Committee on Cancer 
(AJCC) adapted a tumor, node, metastasis (TNM)-like method for clinical staging of 
melanoma (38), which is summarized in Table 1.2. 
 Like other cancers, there are several subtypes of melanoma.  For example, ultraviolet 
radiation-associated melanomas usually arise from epithelial melanocytes in the form of 
desmoplastic or spitzoid melanomas, which are marked by spindle-shaped and mixed 
epitheliod/spindle-like morphologies, respectively (39).  Other non-UV-associated 
epithelial melanomas occur on acral and mucosal surfaces.  Interestingly, uveal 
melanoma is neither epithelial nor UV-associated, arising from pigmented melanocytes 
in the iris, choroid and ciliary body of the eye (39).  As discussed below, particular driver 
alterations often associate with certain anatomical locations of melanoma. 
 
 Molecular Subsets of Melanoma 
As addressed in “Evolution of Tumor Treatment Strategies”, improvements to 
traditional sequencing methods have allowed scientists and clinicians to identify somatic 
alterations that drive tumors and may have implications for therapy.  This is especially 
true for melanoma, which can be classified beyond histopathological staining methods
14 
 
  
Figure 1.1.  Diagram of Progression to Melanoma.  Figure modified from Miller & Mihm, New Engl J Med, 2006 (36).  
Potentially due to an oncogenic mutation, normal epidermal melanocytes proliferate to form a benign nevus.  In the transition to 
the dysplastic stage, single benign nevi begin to split and form multiple benign nevi.  During the radial growth phase, proliferating 
melanocytes begin to lose control of cell adhesion.  In the vertical growth phase, abnormal melanocytes begin crossing the 
basement membrane.  Metastatic melanoma is marked by clear disruption of the basement membrane by the tumor cells, 
intravasation into the blood stream, and ultimate establishment of metastases, often to the brain, liver or lungs. 
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Table 1.2.  TNM (Tumor, Node, Metastasis) Staging Categories for Cutaneous Melanoma  
(Adapted from Balch, et al., J Clin Oncol, 2009 (38)) 
Classification Thickness (millimeters) Ulceration Status/Mitoses 
T     
Tis NA NA 
T1 ≤ 1.00 a:  without ulceration, mitoses < 1/mm2 
    b:  with ulceration or mitoses ≥ 1/mm2 
T2 1.01 - 2.00 a:  without ulceration 
    b:  with ulceration 
T3 2.01 - 4.00 a:  without ulceration 
    b:  with ulceration 
T4 > 4.00 a:  without ulceration 
  b:  with ulceration 
N No. Metastatic Nodes Nodal Metastatic Burden 
N0 0 NA 
N1 1 a:  micrometastasis (as diagnosed following 
sentinel lymph node biopsy)   
    b:  macrometastasis (as diagnosed by 
clinically detectable nodal metastases) 
N2 2-3 a:  micrometastasis 
  b:  macrometastasis 
    c:  in transit metastases/satellites without metastatic nodes 
N3 4+ metastatic nodes/matted nodes/in transit 
metastases/satellites with 
metastatic nodes 
   
 
M Site Serum lactate dehydrogenase (LDH) 
M0 No distant metastases NA 
M1a Distant skin, subcutaneous, 
or nodal metastases Normal  
M1b Lung metastases Normal 
M1c All other visceral metastases Normal 
  Any distant metastases Elevated 
mm, millimeters; NA, not applicable; Tis, tumor in situ; elevated serum LDH is a predictor of metastatic 
status and survival outcome among patients with late-stage disease 
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by specific driver mutations found in the serine-threonine kinase encoded by BRAF, the 
GTPase encoded by NRAS, the tyrosine kinase encoded by KIT, and the Gα proteins 
encoded by GNAQ and GNA11 (40-44).  Mutations in these genes are usually mutually 
exclusive of one another and are differentially associated with anatomical location in 
that cutaneous melanomas are most often associated with BRAF, NRAS and KIT (acral 
and mucosal) alterations, whereas GNAQ and GNA11 mutations are linked to uveal 
melanoma.  Collectively, these mutations are present in ~70% of melanomas (Figure 
1.2).  Importantly, all of these alterations have been shown to activate the mitogen-
activated protein kinase (MAPK) signaling pathway, which leads to aberrant cell 
proliferation, evasion of programmed cell death, and metastatic spread (45).   
The most common alteration is observed at codon valine 600 of BRAF and 
occurs in 40-50% of all melanomas (46) (Figure 1.2, Figure 1.3).  Activation of BRAF in 
the wild-type (WT) setting is rather complex and still not fully understood, however, 
understanding the basics of BRAF activation aid our comprehension of BRAF V600 
mutant-mediated MAPK pathway activity.  BRAF is one of three members of a family of 
intracellular serine-threonine kinases which also includes ARAF and CRAF (or, RAF1).  
These proteins share a remarkable structural similarity and activation process, however, 
their role in tumorigenesis differs.  In contrast to BRAF V600 mutations, ARAF and 
CRAF alterations occur in only ~2-4% of melanomas, and instead of kinase-domain 
concentrated mutations, the mutations are scattered throughout, likely conferring no or 
weak gain-of-function properties in these proteins (cBioPortal for Cancer Genomics / 
The Cancer Genome Atlas).  Furthermore, ARAF and CRAF require an extra 
phosphorylation event to elicit protein activity.  This is not required for BRAF activation 
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Figure 1.2.  Anatomic and Molecular Classifications of Melanoma.  (A)  Historically, in 
addition to histological classifications of melanoma such as Clark level, Breslow depth, and 
ulceration, melanoma was classified based on its anatomical location:  cutaneous, mucosal, 
acral, or uveal.  The identification of recurrent, constitutively-activating driver mutations 
allows for further classification.  Oncogenic BRAF, NRAS, and KIT mutations typically occur 
in cutaneous, mucosal or acral melanomas, whereas GNAQ and GNA11 mutations are 
typically exclusive to uveal melanoma.  (B)  This pie chart represents the current percentage 
distribution of known melanoma driver alterations in melanoma (includes all anatomical 
subtypes). 
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Figure 1.3.  Diagrams of Proteins Known to Harbor Recurrent and Oncogenic Driver 
Mutations in Melanoma.  The length of each protein and the spanning regions of indicated 
functional domains are denoted by numbered, black text.  Amino acids or locations important 
for protein activity / function are denoted by blue text.  Driver mutations are indicated by red 
text. BRAF domains were determined from Roskoski, Biochem & Biophys Res Comm, 2010 
(48) and Pfam/Uniprot (Protein ID, P15056).  KIT domains were determined from Roskoski 
et al., Biochem & Biophys Res Comm, 2005 (58) and Pfam/Uniprot (Protein ID, P10721).  
NRAS, GNAQ and GNA11 domains were determined from Pfam/Uniprot Protein IDs 
P01111, P50148, and P29992, respectively.  CRD, cysteine rich domain; DFG, aspartate-
phenylalanine-glycine motif (see text for more information); JM, juxtamembrane domain; 
RBD, Ras-binding domain; RKTR, arginine-lysine-threonine-arginine dimerization domain 
(see text for more information); Ser, serine; SSDD, serine-serine-aspartate-aspartate domain 
(see text for more information); Thr, threonine; TM, transmembrane domain; Tyr, tyrosine. 
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and thus, is likely why BRAF is the predominant RAF activator of the MAPK pathway 
(47).   
In its inactive state, the N- and C-terminal domains of BRAF are positioned in an 
autoinhibitory fashion stabilized by binding of regulatory 14-3-3 protein dimers at 
phosphorylated serines 365 and 729 (48).  Binding of activated RAS (RAS-GTP) to the 
negative-regulatory RAS-binding domain (RBD) of BRAF initiates a series of 
dephosphorylation and phosphorylation events, including dephosphorylation of S365 
and S729.  This action causes BRAF to de-couple from the 14-3-3 dimers, causing a 
conformational shift appropriate for BRAF-BRAF homodimerization or BRAF-CRAF 
heterodimerization through BRAF’s endogenous RKTR (arginine-lysine-threonine-
arginine) dimerization motif (residues 506-509) (49).  BRAF activation is dependent 
upon phosphorylation of residues at two locations:  the SSDD (serine-serine-aspartate-
aspartate) motif and the activation loop.  Unlike the SSYY (serine-serine-tyrosine-
tyrosine) motifs of ARAF and CRAF, S446 of the SSDD motif of BRAF (residues 446-
449) is constitutively phosphorylated and the aspartate residues resemble 
phosphorylated tyrosine residues (50).  As mentioned above, BRAF activation therefore 
requires fewer phosphorylation events.  This may also explain the higher baseline 
activity of BRAF compared with ARAF or CRAF.  Further, a RAS-GTP-induced 
conformational shift allows for cis-autophosphorylation of threonine 599 and serine 602 
within the activation loop, destabilizing the interaction between it and the P-loop 
(residues 464-469) and shifting the kinase into an active state (51, 52).  In the case of 
heterodimerization, BRAF can also transactivate CRAF at this point (50).  During the 
RAS-mediated conformational shift, phenylalanine 595 of BRAF’s DFG (aspartate-
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phenylalanine-glycine) motif is displaced from the ATP-binding pocket, allowing ATP to 
bind and be stabilized by D594 for transfer of the γ-phosphate to its substrates, MEK1 
and MEK2 (47) (Figure 1.4). 
There are several possible V600 mutations, with BRAF V600E (valine to 
glutamate) being the most prevalent, and V600R/K/M/D (arginine, lysine, methionine, 
aspartate) occurring less frequently (30, 53) (Figure 1.3).  In the case of BRAF 
V600E/D, altering valine, a non-polar hydrophobic residue, to glutamate or aspartate 
(i.e. relatively large, acidic residues) disrupts the hydrophobic interactions of the DFG 
motif, forcing the activation loop into a constitutively active conformation and conferring 
RAS-independent activation of MEK1/2 (47).  V600R/K/M mutations result in larger 
residues that are either polar and hydrophilic (R/K), or non-polar and hydrophobic (M), 
respectively.  As mentioned briefly above (“Evolution of Tumor Treatment Strategies”), 
BRAF V600-mutant inhibitors have been very successful in the clinic and will be 
discussed in greater detail below.  
Mutations at NRAS glycines 12 and 13 (G12/13) and at glutamine 61 (Q61), 
occur in ~20% of all melanomas (41) (Figure 1.2, Figure 1.3, Figure 1.4).  Like its 
family members HRAS and KRAS, NRAS must be anchored to the plasma membrane 
prior to activation.  Following protein translation, a farnesyl group is added by 
farnesyltransferase to the cysteine residue in the CaaX motif (cysteine-aliphatic-
aliphatic-any amino acid) of NRAS.  This allows NRAS to anchor to the endoplasmic 
reticulum (54).  After endoprotease cleavage of the remaining aaX residues and 
methylation of the remaining cysteine residue, proximal cysteine residues are 
palmitoylated on the Golgi surface and transferred to the cell membrane (54).  In the 
21 
 
  
Figure 1.4.  Signaling Pathways and Modes of Driver-Induced Signaling Inhibition in 
Melanoma.  In the non-cancer setting, receptor tyrosine kinase (RTK)-mediated signaling 
only begins when RTK ligands bind an RTK, such as KIT.  Exact details of KIT activation are 
described in the text, but generally, ligand-bound KIT homodimerizes and is 
autophosphorylated, allowing the binding of adaptor proteins such as GRB2 and SOS.  
These adaptor proteins recruit a RAS protein (NRAS) to the cell membrane, allowing for RAS 
activation and downstream signaling through the PI3K/AKT or RAF/MEK/ERK (MAPK) 
pathway to ultimately induce proliferation and survival mechanisms.  Alternatively, G protein-
coupled receptors (GPCRs) are ligand bound and activated, releasing components of the 
heterotrimeric G-protein complex.  The G-α component (in the case of melanoma, GNA11 or 
GNAQ) becomes GTP-bound and activated, and can then activate MAPK pathway signaling 
by binding with phospholipase C (PLC), which in turn recruits protein kinase C (PKC) for 
eventual RAF activation.  Imatinib and nilotinib are small-molecule inhibitors of KIT.  The 
kinase inhibitors vemurafenib and dabrafenib were specifically designed to inhibit BRAF 
mutated at codon V600.  Downstream of BRAF, trametinib inhibits MEK1/2 to diminish MAPK 
pathway signaling. 
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NRAS WT setting, NRAS requires interaction with an active, upstream receptor tyrosine 
kinase (RTK) mediated by GRB2 and SOS adaptor proteins.  Specifically, a SRC 
homology 2 (SH2) domain in GRB2 recognizes phosphorylated tyrosines on the ligand-
activated RTK and GRB2 SH3 domains interact with proline-rich sites on SOS.  SOS is 
therefore perfectly positioned at the membrane to enact its guanine nucleotide 
exchange factor (GEF) activity, removing the GDP (guanosine diphosphate) molecule 
bound to inactive NRAS and replacing it with GTP (guanosine triphosphate), resulting in 
NRAS activation.  Once activated, NRAS is configured to catalyze activation of RAF 
proteins, as described above, or of PI3K (phosphatidylinositol 3-kinase) to elicit MAPK 
pathway or AKT pathway signaling, respectively.  NRAS harbors an intrinsic GTPase 
activity that is disrupted by G12/13 or Q61 mutations, which are in close proximity to the 
γ-phosphate of GTP.  Therefore, upstream RTK and adaptor protein inputs are not 
needed for mutant NRAS to induce signaling (55). 
Currently, KIT is the only RTK with recurrent driver mutations important for 
melanoma pathogenesis, occurring in 2-6% of all melanomas (40, 56, 57) (Figure 1.2, 
Figure 1.3).  In normal cells, binding of the KIT ligand, stem cell factor (SCF), to the 
extracellular domain of KIT results in dimerization of two KIT receptors (58).  
Transphosphorylation of tyrosines 568 and 570 in the juxtamembrane domain (JM) 
induce a conformational shift, releasing the JM domain’s inhibitory effects on the kinase 
portion of KIT (59-61) and allowing phosphorylation of tyrosine 823 in the activation loop 
by Src kinase (61, 62).  Y823 phosphorylation is thought to stabilize the “open” 
conformation of the activation loop for KIT kinase activity.  Several additional 
phosphorylation sites serve as docking sites for multiple adaptor molecules that induce 
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signaling through the PI3K/AKT and MAPK pathways (Figure 1.4) (63).  KIT driver 
mutations in melanoma are found in the tyrosine kinase domain (K642E, D816H), 
conferring constitutive kinase activity, but can also occur in the JM domain (W557R, 
V559A/D, L576P), mediating ligand-independent dimerization and auto-activation of the 
receptor (Figure 1.3) (64, 65). 
Although GNAQ and GNA11 driver mutations (codon glutamine/Q209) occur in 
less than 3% of all malignant melanomas, they are identified in 50% and 36% of uveal 
melanomas, respectively (Figure 1.2, Figure 1.3) (43, 44, 66).  GNAQ and GNA11 are 
guanine nucleotide-binding Gα proteins (i.e. bind GDP/GTP) that, in a WT, inactive 
state, associate with Gβ and Gγ proteins to form a heterotrimeric G-protein complex.  
When a G protein-coupled receptor (GPCR) interacts with its respective ligand, a 
conformational shift allows the GPCR to act as a GEF (described above) to exchange 
GDP for GTP on the Gα.  As a result, Gα dissociates from the Gβ/Gγ subunits to elicit 
downstream signaling through the MAPK and PI3K/AKT pathways (67).  Like NRAS 
driver mutations, driver mutations in GNAQ and GNA11 lead to disabled intrinsic 
GTPase activity, keeping these proteins in a GTP-bound, active state (43, 44) (Figure 
1.4).  
In addition to the well-known drivers observed in BRAF, NRAS, KIT, GNAQ and 
GNA11, molecular alterations in cell cycle and tumor suppressor proteins can also 
influence the pathogenesis of melanoma.  For example, concurrent inactivation of the 
tumor suppressor CDKN2Ap16/INK4A and upregulation of the cyclin dependent kinase 
CDK4 inherently leads to increase cell cycling (68).  Amplification of cyclin D1 (CCND1) 
produces similar effects (41).  The tumor suppressor and AKT inhibitor, PTEN, is often 
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deleted in melanoma allowing increased signaling through the PI3K/AKT pathway (69, 
70).  Similarly, loss or deleterious truncations of the Ras inhibitor, NF1 
(neurofibromatosis type 1), have been implicated in resistance to RAF inhibition in the 
setting of BRAF-mutant tumors.  In addition to BRAF V600 mutations, these NF1 
mutations also seem to co-occur with NRAS drivers (71-73). 
 
Current Therapies for Melanoma 
Prior to the identification of somatic drivers of melanomas, the primary treatment 
modalities for this disease involved resection of localized lesions with or without 
chemotherapy.  Melanoma is generally considered to be resistant to chemotherapy (74); 
only one chemotherapeutic alkylating agent, dacarbazine (DTIC), is currently approved 
for use in metastatic melanoma and even its efficacy is modest (median survival time ~6 
months) (75, 76).  Within the past two decades, however, several targeted agents 
against melanoma drivers have been developed (Figure 1.4, Table 1.3).  For example, 
multiple clinical trials have demonstrated that more than half of all patients whose 
metastatic melanomas were BRAF V600E-positive exhibited a clinical response to the 
V600-specific inhibitor, vemurafenib (PLX4032), regardless of prior treatment (77, 78).  
Additionally, another BRAF V600-specific small molecule inhibitor, dabrafenib 
(GSK2118436), was shown to have significant responses in BRAF-mutant melanoma 
(79).  Based on their remarkable efficacy in BRAF V600-mutant melanoma, both 
vemurafenib and dabrafenib have recently been FDA-approved for the treatment of 
patients with metastatic melanoma harboring this specific mutation (80, 81).   Both 
agents are effective in tumors harboring V600K variants, as well (78, 79).   
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Like BRAF V600-mutant melanoma, small molecule inhibitors have also been 
effective in KIT-mutant melanoma.  Tumors harboring JM domain KIT mutations 
(W557R, V559A/D, L576P) and the K642E kinase domain mutation (Figure 1.4, Table 
1.3) have demonstrated sensitivity to the ABL, KIT and PDGFRβ (platelet-derived 
growth factor-β) inhibitor, imatinib, both preclinically and clinically (40, 56, 82-86).  Case 
reports and small trials have also documented activity of dasatinib (BCR-ABL and Src 
kinase inhibitor) (87) and sunitinib (promiscuous inhibitor of KIT, PDGFRs, VEGFs 
(vascular endothelial growth factors), RET, CSF-1R and FLT3) (88) against these 
particular variants.  Emerging data also suggest that the novel BCR-ABL inhibitor, 
nilotinib, is effective against these tumors (89).  Interestingly, however, tumors harboring 
the kinase domain D816H mutation are relatively resistant to imatinib (90), and in fact, 
this mutation has been documented in tumors following acquired resistance to imatinib 
(91). 
Unlike BRAF- and KIT-mutations, specific pharmacological inhibition of mutant 
NRAS, GNAQ and GNA11 has been more difficult than anticipated (Table 1.3).  
Farnesyltransferase inhibitors (FTIs), which are designed to inhibit post-translational 
farnesylation of RAS to block membrane attachment, have been largely ineffective in 
melanoma and other RAS-mutated tumors (92, 93).  Interestingly, NRAS-mutant tumors 
tend to rely on CRAF-mediated MAPK pathway activation over BRAF-mediated MAPK 
pathway activation.  As a result, BRAF inhibition in NRAS-mutant tumors induces wild-
type RAF dimerization and elicits paradoxical activation of MEK1/2 and ERK1/2 (94, 
95).  Single-agent MEK1/2 inhibition downstream of RAS and RAF has also been a 
challenge (96).  The MEK1/2 inhibitor, trametinib, has mainly been studied in BRAF- 
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Table 1.3.  Currently Known Melanoma Drivers and Corresponding Approved 
Therapies 
Gene Nucleotide Change 
Amino Acid 
Change Approved or Potential Targeted Therapies 
BRAF c.1799_1800TG>AT V600D Single-agent use of vemurafenib, dabrafenib or 
trametinib is approved for V600E tumors only.  
Combination trametinib + dabrafenib is approved 
for patiens with V600E/K-mutant tumors.  
Though not specifically evaluated, all other V600 
variants are also thought to confer sensitivity to 
these agents.  Clinical trials are currently 
evaluating novel BRAF inhibitors.  Refer to text. 
c.1799T>A V600E c.1799_1800TG>AA 
c.1799T>G V600G 
c.1798_1799GT>AA V600K 
c.1798G>A V600M 
c.1798_1799GT>AG V500R 
 
NRAS c.35G>C G12A 
The sensitivity of NRAS G12-mutant tumors to 
MEK1/2 inhibitors remains under investigation. 
c.34G>T G12C 
c.35G>A G12D 
c.34G>C G12R 
c.34G>A G12S 
c.35G>T G12V 
   
c.38G>C G13A 
The sensitivity of NRAS G13-mutant tumors to 
MEK1/2 inhibitors remains under investigation. 
c.38G>A G13D 
c.37G>T G13R 
c.38G>T G13V 
   
c.181C>G Q61E 
Clinical trials for the MEK1/2 inhibitor, MEK162, 
demonstrated partial responses in patients with 
NRAS Q61-mutant tumors.  Trametinib only 
seems to have modest efficacy in these tumors.  
Emerging data suggest combined MEK1/2 and 
CDK4/6 inhibition trametinib/MEK162 and 
palbociclib may be effective. 
c.183A>T Q61H c.183A>C 
c.181C>A Q61K 
c.182A>T Q61L c.182_183AA>TG 
c.182A>C Q61P 
c.182A>G Q61R c.182_183AA>GG 
 
KIT c.1669T>C W557R Non D816H KIT-mutant melanomas have been 
shown to confer sensitivity to imatinib, sunitinib, 
and in some cases, dasatinib.  Nilotinib is also 
being evaluated for use in these variants. 
c.1699T>A 
c.1676T>C V559A 
c.1676T>A V559D 
c.1727T>C L576P 
c.1924A>G K642E 
c.2446G>C D816H Confers decreased sensitivity to KIT inhibitors 
 
GNAQ c.626A>T Q209L Currently, there are no GNAQ- or GNA11-
directed therapies.  There is, however, an 
ongoing Phase II study of trametinib (MEK1/2 
inhibitor) alone or in combination with an AKT 
inhibitor in patients with advanced uveal 
melanoma (NCT01979523). 
c.626A>C Q209P 
c.626A>G Q209R 
 
GNA11 c.626A>T Q209L 
c.626A>C Q209P 
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mutant melanoma (97-100) and was just approved in May 2013 for the treatment of 
BRAF V600E/K tumors (101).  Trametinib seems to have only modest efficacy in NRAS-
mutant tumors (97, 102), however, a phase II clinical trial of a different MEK1/2 inhibitor, 
MEK162, elicited partial responses in 20% of patients with NRAS Q61-mutated tumors 
(103).  A phase III trial of MEK162 in NRAS-mutant tumors is currently underway 
(NCT01763164).  Furthermore, interesting pre-clinical data recently demonstrated that 
combined inhibition of MEK1/2 and the cyclin-dependent kinase, CDK4, in NRAS-
mutant allografts, was most effective at attenuating tumor growth (104).  As a result, 
multi-center phase I/II clinical trials investigating the use of trametinib and the CDK4/6 
inhibitor, palbociclib (NCT02065063), or trametinib with a different CDK4/6 inhibitor, 
LEE011 (NCT01781572), are currently underway with promising initial results.   
Although much work remains to determine the best targeted interventions for 
NRAS-mutant tumors, even less progress has been made for GNAQ/GNA11-mutant 
melanomas (Table 1.3).  At present, only case reports of responses to MEK1/2 
inhibition have been observed in GNAQ/GNA11-mutant uveal melanomas (97, 105).  
These patients may be eligible for clinical trials designated for “BRAF wild-type” tumors 
investigating the efficacy of trametinib (NCT02138292) or trametinib in combination with 
the AKT inhibitor GSK2141795 (NCT01941927), however, data are again likely to be 
limited for the GNAQ/GNA11 subset.  Clearly, identifying effective therapeutic agents for 
melanomas harboring mutations in GNAQ and GNA11 is of urgent need.   
“Targeted” immunotherapy is an emerging class of treatment for melanoma and 
many other cancer types.  Instead of targeting proteins altered by driver mutations, 
immunotherapies are designed to block the activity of immune-related proteins to 
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ultimately aid the maturation and activation of T-cells, thus boosting the patient’s own 
tumor immune response (Figure 1.5).  Inhibition of cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4), expressed on the surface of T-cells, was the first immune target 
whose blockade demonstrated responses in melanoma.  CTLA4 inhibits T-cell 
maturation by competing with CD28 on T-cells for binding to CD80 and CD86 receptors 
on antigen-presenting cells (e.g. in cancer, tumor cells) (106).  In a phase III trial, the 
antibody ipilimumab (anti-CTLA4) improved progression-free and overall survival rates 
in patients with metastatic melanoma unselected for genotype (107) and in 2011, was 
approved for use in metastatic melanoma (108).  Additional immunotherapy targets 
include programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) 
expressed on the surface of T-cells or tumor cells, respectively.  Anti-PD1 and anti-PD-
L1 immunotherapies block PD-1 and PD-L1 interaction to attenuate their subsequent 
negative regulatory effects on T-cell maturation (109, 110).  In phase I/II clinical trials, 
anti-PD-1/PD-L1 antibodies significantly improved objective responses in metastatic 
melanomas (111-113), even those that were pre-treated with ipilimumab (112).  
Furthermore, tumors expressing PD-L1 correlated with response to anti-PD-1 agents, 
suggesting that PD-L1 could serve as a useful biomarker in this disease (113).  
Importantly, the anti-PD-1 agent, pembrolizumab, was recently approved for use 
metastatic melanoma (2014) (108).  Anti-CTLA4, PD-1 and PD-L1 immunotherapies 
currently in clinical trials, or approved for use in metastatic melanoma, are listed in 
Table 1.4.  Finally, although it is considered rather toxic, treatment with the cytokine, 
interleukin-2 (IL-2), has also been successful in melanoma.  Interestingly, responses to 
IL-2 therapy may correlate with NRAS mutant status (114).  We are just beginning to 
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 Unlike CD80/86, PD-L1 is selectively expressed on tumor cells and cells within the tumor 
microenvironment in response to inflammatory stimuli.  (C) Clinically-available antibodies 
against CTLA4, PD-1 and PD-L1 block these negative-regulatory interactions to allow T-cells 
to mature and become activated.  See Table 1.4 for a list of these inhibitors. 
Figure 1.5.  Mechanism of 
Action of Melanoma-
Approved 
Immunotherapies.   
(A) Melanoma cells present a 
melanoma-specific antigen 
via an MHC (major 
histocompatibility complex) 
molecule to a T-cell 
expressing a TCR (T-cell 
receptor).  This initiates steps 
toward activation of the T-
cell.  Also on the melanoma 
cell and/or surrounding tumor 
stromal cells, are CD80 and 
CD86 molecules.  These bind 
to the co-stimulatory receptor 
CD-28 on the T-cell.  Along 
with other co-stimulatory 
events, these actions serve 
to activate and mature the T-
cell.  (B) Importantly, 
however, negative-regulatory 
CTLA4 (cytotoxic T-
lymphocyte antigen 4) 
molecules on the T-cell have 
a higher affinity for CD80/86 
than CD28.  By binding up 
the CD80/86, CTLA4 
prevents activation and 
maturation of the T-cells.  
Another mechanism of down-
regulating T-cells is through 
PD-1 (programmed cell death 
protein-1).  PD-1 on T-cells, 
binds PD-L1 (programmed 
cell death protein ligand-1) 
on melanoma cells and also 
serves to down-regulate 
activation of the T-cells. 
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understand the mechanisms of underlying sensitivity or resistance to this class of 
agents, but it is evident that immunotherapy will play an important role in the 
management of metastatic melanoma and may have an expanding role in other disease 
types as well. 
 
Driver-/Pan-Negative Melanoma 
In contrast to the ~70% of melanomas that harbor known driver mutations, the 
remaining ~30% of melanomas have no known driver; we term these tumors “pan-
negative” (Figure 1.2).  Because melanoma is generally refractive to systemic 
chemotherapy and because pan-negative tumors have no identifiable drug target, these 
patients are currently ineligible for treatment with the targeted small molecule inhibitors 
discussed in previous sections.  As described above, tumor responses have been 
observed in patients treated with immunotherapy regardless of genotype, however, 
these responses are not uniform.  Therefore, a major component of the work described 
herein addresses remaining challenges in identifying novel drivers of and novel 
treatment strategies for pan-negative melanoma. 
 
Purpose of Our Melanoma Studies 
Over the past decade, we have seen a remarkable transformation in the way 
malignant melanoma is diagnosed and treated.  Our knowledge of recurrent, somatic 
driver alterations in the genes BRAF, NRAS, KIT, GNAQ and GNA11 has allowed the 
development of rapid and reliable assays by which to identify patients whose tumors
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Table 1.4.  Anti-PD-1, PD-L1, and CTLA4 Immunotherapies Currently Approved or in Clinical Trial Development 
Target Immunotherapy Name Company Cancer Type(s) Evaluated Development/Approval Phase 
PD-1 Pembrolizumab / 
Lambrolizumab (MK-3475) Merck Melanoma, NSCLC 
Approved for advanced melanoma in 
2014 
Pidilizumab CureTech Melanoma, colorectal cancer, DLBCL II 
Nivolumab (BMS-936558) Bristol-Myers Squibb 
Melanoma, RCC, NSCLC, 
HNSCC III 
AMP-224 GlaxoSmithKline Advanced solid tumors I 
AMP-514 (MEDI0680) GlaxoSmithKline Advanced solid tumors I 
 
PD-L1 BMS-936559 Bristol-Myers Squibb Advanced solid tumors I 
MPDL3280A Roche Melanoma, RCC, NSCLC, URO I & II 
MEDI4736 AstraZeneca Advanced Solid Tumors I & II 
MSB0010718C Merck Serono Advanced Solid Tumors / Merkel cell carcinoma I / II* 
 
CTLA4 Ipilimumab (Yervoy) Bristol-Myers Squibb Advanced Solid Tumors 
Approved for advanced melanoma in 
2011 
Tremelimumab / 
Ticilimumab 
Bristol-Myers 
Squibb 
Melanoma, NSCLC, 
HNSCC, HCC, BCL I 
Adapted from ClinicalTrials.gov, Philips & Atkins, International Immunology, 2014 (110) and Mullard, Nature Reviews Drug Discovery, 2013 (109). 
BCL, B-cell lymphoma 
DLBCL, diffuse large B-cell lymphoma 
HCC, hepatocellular carcinoma 
HNSCC, head and neck squamous cell carcinoma 
NSCLC, non-small-cell lung cancer 
RCC, renal cell carcinoma 
URO, urothelial bladder cancer 
*Phase II trials are currently underway only in Merkel cell carcinoma 
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harbor these mutations.  As a result, oncologists are able to assign small molecule 
inhibitors such as vemurafenib (BRAF V600-mutantions) or imatinib (KIT mutations) to 
select patients, which have been enormously successful at delaying tumor progression 
and increasing overall survival times.   
For the patients whose tumors are considered pan-negative, however, treatment 
options are extremely limited.  Therefore, the focus of the melanoma studies outlined 
herein are to identify novel drivers in pan-negative disease that will help direct therapy.  
Specifically, using a variety of NGS techniques, we identified BRAF non-V600 mutations 
(Chapter II) and BRAF fusions (Chapter III) in pan-negative patient tumors from 
Vanderbilt.  Interestingly, these novel alterations can activate the MAPK pathway and 
furthermore, confer sensitivity to MEK1/2 inhibitors both in vitro and in vivo.  We know 
that the well-established melanoma drivers activate the MAPK pathway, and our new 
evidence suggests additional methods of MAPK pathway activation.  Therefore, we took 
our pan-negative studies even further to investigate potential molecular modifiers of 
response to MEK1/2 inhibition in pan-negative melanoma with the hope of identifying 
more effective therapies and/or therapeutic combinations in this disease subset 
(Chapter IV).  Although a large amount of work remains to identify all druggable targets 
in melanoma, a direct result of these studies has been the initiation of multi-center 
clinical trials examining the efficacy of MEK1/2 inhibitors in patients harboring BRAF 
non-V600 mutations and BRAF fusions. 
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PANCREATIC ACINAR CELL CARCINOMA (PACC) 
Pancreatic Cancer Epidemiology and Pathology 
Compared with other cancer types, patients with pancreatic cancer have 
exhibited the least improvement in survival rates over time.  Of the more than 46,000 
predicted 2014 cases in the United States, it is expected that ~85% of patients will die 
from the disease (35).  A contributing factor to these statistics is the relatively late stage 
at which pancreatic tumors are identified, at which time the cancer has extensively 
metastasized (115).  This is likely because early-stage patients rarely have symptoms 
and once symptoms arise, they are rather non-specific (abdominal pain, back pain, 
nausea, jaundice, unexplained weight loss, etc.) (116).  Furthermore, pancreatic cancer 
is a disease of the elderly; rarely is a person under 40 years of age diagnosed with this 
disease (115).  Several risk factors for pancreatic cancer have been identified, the most 
preventable of which is cigarette smoking (117, 118).  Diets high in fats and red meats, 
obesity, and chronic pancreatitis are additional risk factors.  Interestingly, ~10% of 
cases result from a familial pre-disposition, though the contributing genetic factors of 
this predisposition are still largely unknown (115). 
There are several subtypes of pancreatic cancer, generally grouped into exocrine 
and endocrine categories (Table 1.5).  The most common of the exocrine tumors is 
pancreatic ductal adenocarcinoma (PDAC, ~85% of all cases), which, as its name 
suggests, is thought to arise from the pancreatic ductal epithelium (119), though this is 
currently under debate.  New evidence suggests that ductal neoplasias may actually 
arise from pancreatic acinar cells (120, 121).  Regardless, because of its commonality 
and high degree of malignancy, PDAC is the best studied subtype with a well-defined 
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model of progression (Figure 1.6).  Precursor microscopic lesions of PDAC are termed 
pancreatic intraepithelial neoplasias (PanINs), and include PanIN-1A, -1B, -2, and -3.  
Early-stage PanIN-1A and -1B neoplasms are marked by increased mucin production 
and either elongated (-1A) or papillary (-1B) cellular architecture as opposed to a single 
layer of cuboidal epithelium.  PanIN-2 cells begin losing polarity and grow into the ductal 
lumen.  PanIN-3 tumors, also referred to as carcinoma in situ, display high mitotic rates 
and nuclear atypia.  Finally, PDAC is marked by invasive growth (115, 122, 123).  Less 
common, macroscopic/cystic PDAC precursors include intraductal papillary mucinous 
neoplasias (IPMN) and mucinous cystic neoplasias (MCN), which are relatively benign 
(115).   
The origin of pancreatic neuroendocrine tumors (PanNETs), sometimes called islet cell 
tumors, is also controversial.  Originally thought to arise from the hormone-producing 
cells of the Islets of Langerhans, PanNETs are now thought to be derived from 
pleuripotent ductal and/or acinar cells (124).  PanNETs are grouped into functioning and 
non-functioning subcategories, in which functioning PanNETs produce hormones such 
as gastrin, glucagon, insulin, and somatostatin, but non-functioning PanNETs produce 
none of these (Table 1.5) (125). 
A rare subset of pancreatic exocrine tumors is pancreatic acinar cell carcinoma 
(PACC), which comprises fewer than 1% of all diagnoses but affects more males than 
females (126-131).  As its name suggests, PACC is characterized by granulated acinar 
cells that form raspberry-like structures and secrete digestive enzymes (Table 1.5) 
(130).  Because of its rarity, PACC is potentially the least studied subtype of all, with no 
clear driver mutations or treatment options (refer to next section).  In Chapter VI,
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Table 1.5.  Pancreatic Cancer Subtypes and General Characteristics 
Pancreatic Exocrine Tumors Characteristics 
 Pancreatic Ductal Adenocarcinoma (with duct differentiation) Malignant 
 Microscopic Precursors 
 PanIN-1A Pancreatic Intraepithelial Neoplasias (PanINs):   
PanIN-3 is equivalent to carcinoma in situ.  Usually 
metastatic at disease presentation, and not amenable to 
surgical resection.   
PanIN-1B 
PanIN-2 
PanIN-3 
 
Macroscopic / Cystic Precursors) 
 Intraductal Papillary Mucinous Neoplasm (IPMN) Can be benign or malignant at disease presentation, but 
generally more amenable to surgical resection Mucinous Cystic Neoplasm (MCN) 
  
 Other 
 Pancreatic Acinar Cell Carcinoma (PACC) Secrete digestive enzymes: trypsin, chymotrypsin, lipase 
Solid Pseudopapillary Neoplasm Marked by β-catenin (CTNNB1) mutations 
Serous Cystadenoma Benign with no malignant potentials 
 
Pancreatic Neuroendocrine Tumors (with endocrine differentiation) Characteristics 
 Functioning 
 Gastrinoma 
Produce hormones and thus, can be symptomatic 
(changes in blood sugar) which allows for relatively early 
detection 
Glucagonoma 
Insulinoma 
Somatostatinoma 
Vasoactive intestinal polypeptide (VIP)-oma 
  
 Non-functioning Do not produce hormones, no early-stage symptoms 
 
Mixed Pancreatic Tumors (exocrine and endocrine differentiation) Characteristics 
 Mixed acinar cell / neuroendocrine carcinoma Both acinar cell and endocrine differentiation 
 Pancreatoblastoma Majority seen in children 
Table created in collaboration with Chanjuan Shi, MD, Vanderbilt Pathologist. 
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 Figure 1.6.  Pancreas Gross Anatomy and Model of Progression to Pancreatic Ductal Adenocarcinoma (PDAC).   
(A) Gross anatomy of the pancreas and surrounding, associated organs (modified from Bardeesy & DePinho, Nat Rev Cancer, 
2002 (122).  (B) Pancreatic acini surround pancreatic ductal epithelium leading into the pancreatic duct.  Although there is current 
debate as to whether PDAC arises from pancreatic ductal epithelia or acinar cells, here, ductal epithelia are used to illustrate the 
transition from normal epithelia to metastatic PDAC.  Precursor microscopic lesions of PDAC are termed pancreatic intraepithelial 
neoplasias (PanINs), and include PanIN-1A, -1B, -2, and -3.  A full description of progression to PDAC is provided in the text, 
however, in general, PanINs have altered cellular architecture compared to normal epithelia, lose polarity and grow into the ductal 
lumen. PDAC is marked by invasive growth.  Figure modified from Maitra, et al., Mod Pathol, 2003 (23). 
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however, we describe the discovery of novel drivers of PACC which may help guide 
appropriate therapeutic interventions.  Therefore, PACC will be the main point of 
discussion in subsequent introductory sections. 
 
Current Treatment Strategies for Patients with PACC 
Partly due to the infrequency of PACC, there is no standard treatment regimen.  
Patients with local disease or even nearby, well-circumscribed metastases to the liver, 
stomach, spleen or colon can be eligible for surgical resection, which has been shown 
to drastically improve median survival time from 14-16 months to 36-61 months (127, 
128, 132, 133).  Although dismal, these increases in survival time are greater for PACC 
patients than for patients with the most commonly-diagnosed subtype, PDAC (127, 128, 
131-133).  Despite surgery, however, the majority of PACC patients develop recurrent, 
metastatic disease which cannot be managed by additional surgery (128).   
Traditional chemotherapy and/or radiotherapy are other options, but no specific 
chemotherapy agent or method of delivery is preferred over another.  Case reports exist 
in which patients were treated with concurrent capecitabine and radiotherapy (134), 
gemcitabine and radiotherapy (135), or post-operative cisplatin (136).  One case report 
cited the use of neoadjuvant cisplatin plus doxorubicin, and after disease recurrence, 
the FOLFIRINOX regimen (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil), which was 
well-tolerated and led to stable disease (up to 1 year at time of publication) (128, 137).  
Although recent data describe somatic alterations found in PACC (see next section), 
there are currently no targeted therapies approved for patients with this disease. 
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Current Genomic Understanding of PACC 
Parallel to the lack improvement in overall survival in pancreatic cancer 
compared with other cancer types, the genetic landscape of pancreatic tumors is only 
beginning to be elucidated.  We know that a large percentage of ductal 
adenocarcinomas harbor activating mutations in the GTPase KRAS (>90%), the tumor 
suppressive transcription factor p53 (75%), the cell cycle inhibitor CDKN2A/p16 (>90%), 
and the TGFβ-pathway effector SMAD4 (55%) (138).  Deep sequencing studies of 
PDACs, PanNETs and PDAC cystic precursors have identified additional alterations in 
Gα proteins (GNAS) (139) and components of E3 ubiquitin ligases (140), as well as 
alterations in TGFβ/SMAD4 pathway (141) and mTOR pathway proteins(142).  Little 
has been done, however, to determine the absolute significance of these alterations 
toward the disease.  
By contrast, other than rare mutations in KRAS, p53, CDKN2A/p16, and SMAD4, 
little is known about the genetic makeup of PACC.  Various comparative genomic 
hybridization and microsatellite instability efforts have highlighted distinct allelic patterns 
between PACC and other pancreatic tumor types, but these studies did not expand 
upon the potential significance of these differences (143, 144).  These techniques have 
also been combined with polymerase chain reaction (PCR) analyses to identify 
recurrent allelic losses at the APC (adenomatous polyposis coli, Wnt signaling 
suppressor), β-catenin (Wnt signaling pathway effector), CDKN2A/p16 and p53 loci 
(145, 146), as well as truncating mutations in APC and activating mutations in β-catenin 
(126).  The relatively late stage at which PACC is diagnosed makes resections and fine-
needle aspirations for tumor banking purposes, and thus, NGS studies, a challenge 
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(147).  To date, a single whole-exome sequencing (WES) study of 23 surgically 
resected pancreatic carcinomas with acinar differentiation uncovered rare mutations not 
only in p53, SMAD4, and GNAS (Gα protein), but also in the transcriptional repressor 
Rb1, the cytosolic tyrosine kinase JAK1, and BRAF (13%) (129).  Interestingly, all three 
identified BRAF alterations were at codon V600 (one deleted a portion of codon K601 
as well), which, as described above, is commonly mutated in melanoma and can confer 
sensitivity to BRAF inhibitors such as vemurafenib (77) and dabrafenib (79), or to 
MEK1/2 inhibitors such as trametinib (97).  The identification of potentially actionable 
JAK1 and BRAF mutations in PACC is exciting.  However, as will be described in the 
next section, WES has limitations compared with other NGS techniques, suggesting 
that PACC may harbor additional druggable targets (Chapter VI). 
 
Purpose of Our PACC Studies 
As a whole, the diagnosis and treatment of pancreatic cancer has seen perhaps 
the slowest improvements compared with other cancer types.  Progress has been 
delayed particularly for patients with PACC due to late-stage, metastatic diagnosis as 
well as the rarity of this subtype, making large genomic studies difficult.  As described 
above, only one NGS study to-date has assessed PACC (129).  Unfortunately, whole-
exome sequencing is less comprehensive than RNA sequencing or whole-genome 
sequencing techniques, suggesting there is still much to learn about the genetic 
landscape of PACC. 
Therefore, the purpose of the PACC study described herein (Chapter VI) was to 
uncover additional genomic alterations in PACC that may confer sensitivity to targeted 
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therapies.  Interestingly, we identified BRAF fusions similar to those described in 
melanoma (Chapter III), and a RAF1 fusion.  Tumors harboring RAF fusions may be 
sensitive to MEK1/2 inhibition.  Furthermore, we determined that PACCs harboring RAF 
fusions excluded genomic alterations in DNA repair genes found in a subset of the 
remaining PACCs in our cohort.  Such tumors may be sensitive to certain DNA damage-
inducing agents.  Future studies will confirm the importance and frequency of these 
mutations in PACC, as well as evaluate the efficacy of accompanying therapies.  
Regardless, our study is currently the largest NGS-based study of PACC and the first to 
identify actionable mutations in this rare pancreatic cancer subtype. 
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CHAPTER II 
 
BRAF L597 mutations in melanoma are associated with  
sensitivity to MEK inhibitors 
 
 
 
Adapted from:  Kimberly Brown Dahlman*, Junfeng Xia*, Katherine Hutchinson*, 
Charles Ng, Donald Hucks, Peilin Jia, Mohammad Atefi, Zengliu Su, Suzanne Branch, 
Pamela L. Lyle, Donna J. Hicks, Viviana Bozon, John A. Glaspy, Neal Rosen, David 
Solit, James L. Netterville, Cindy L. Vnencak-Jones, Jeffrey Sosman, Antoni Ribas, 
Zhongming Zhao, William Pao. (2012)  BRAF L597 mutations in melanoma are 
associated with sensitivity to MEK inhibitors.  Cancer Discov 2, 791-797.  *co-first 
authors 
 
INTRODUCTION 
 Melanoma is a malignant tumor of melanocytes that caused nearly 9000 deaths 
in the USA in 2011 (148). Recently, the kinase inhibitors vemurafenib and, to a lesser 
extent, imatinib have become standard treatments for patients whose metastatic 
malignant melanomas harbor specific “driver mutations” in BRAF (V600E) (77) or KIT 
(exons 11 and 13) (149), respectively; however only ~40-50% of cases are positive for 
these mutations. Currently, clinical algorithms recommend assessing BRAF status in 
melanomas at only the most common “actionable” mutant site, BRAF V600E 
(c.1799T>A).   
To uncover other potentially targetable mutations, we performed whole-genome 
sequencing (WGS) of a tumor/normal pair from a patient with a highly aggressive BRAF 
(V600) and KIT (W557, V559, L576, K642, D816) wildtype (WT) melanoma. Among the 
many mutations identified, we focused on the biological and clinical significance of a 
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confirmed somatic mutation at the BRAF L597 codon. Our findings have direct 
therapeutic implications for patients with metastatic melanoma. 
 
RESULTS 
Identification of a BRAF L597R Mutation by Whole-Genome Sequencing 
A 75-year old white man presented with an ulcerated right ear melanoma which 
was widely excised with uninvolved sentinel lymph nodes. Four months later, he 
developed local recurrence and underwent additional surgery as well as post-operative 
radiation. This specimen was negative for the BRAF V600E (c.1799T>A) mutation using 
an allele‐specific PCR assay, and negative for KIT exons 9, 11, 13, 17 and 18 mutations 
by PCR‐based methods. Twelve months later the patient developed widespread 
metastasis, and required a palliative thyroidectomy. He died 13 days later with both 
cardiac and brain involvement.   
To identify potential driver mutations in his tumor using an unbiased genome-
wide approach, we performed WGS of DNA from his metastatic thyroid lesion, along 
with DNA from matched blood. A subset of the single nucleotide polymorphisms 
(SNPs), insertions, and deletions were validated (Figure 2.1a; Appendix Tables A2.1-
A2.6; Appendix Figures A2.1-A2.6; see also Excel file Supplementary Tables S3, 
S5, S6 & S8 from (150)). The validated somatic SNP with the combined highest depth 
of coverage (DP) and quality (qual) scores was BRAF L597R (c.1790T>G) (Figure 2.1; 
see also Excel file Supplementary Table S8 from (150)). The high depth of coverage 
for this SNP was in part due to concurrent amplification of the BRAF locus on 
chromosome 7 (Appendix Figure A2.6; see also Excel file Supplementary Table S5
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 Figure 2.1. Detection and Validation of the BRAF L597R Mutation. (A) Validation of 128 somatic SNPs by direct sequencing. 
Seventy putative somatic missense or nonsense SNPs identified by WGS were initially selected for validation by direct sequencing using 
DNA from the metastatic melanoma and matched blood. Depth of coverage (DP > 21) and quality (Qual > 37) score cutoff values were 
established (represented by the shaded areas) so that the SNPs that were not detected in the tumor (red diamonds) in the initial 70 
SNPs selected fell below the cutoff. Based on these cutoff scores, we reanalyzed the WGS data and identified an additional 58 somatic 
nonsynonymous SNPs to validate by direct sequencing. In total, 119/128 (93%) SNPs were detected in the tumor but not in the germline 
by direct sequencing (blue diamonds). (B) Sequencing chromatograms show presence of a heterozygous BRAF L597 mutation in the 
tumor but not in the matched blood. Arrows indicate the position of the mutant or WT peaks. (C) Alignment of next-generation sequence 
reads displaying the BRAF L597R mutation compared to the reference human genome. The region shown represents base pairs 
140,453,089-140,453,201 on chromosome 7. Seventy-two reads overlap the mutant position (chr7:140,453,145), including 47 reverse 
(in red) and 25 forward (in blue) strands, respectively. 
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from (150)). Screening of an earlier biopsy confirmed that this mutation was present 
prior to radiation therapy (data not shown), suggesting that it occurred early in the 
pathogenesis of the patient’s disease. 
 
Frequency of BRAF L597 and Other Exon 15 Mutations in “BRAF Wild-type” 
Melanoma 
Both BRAF L597 and V600 are encoded by exon 15. To determine how many 
exon 15 mutations might be overlooked by assessing only the V600 position, we 
analyzed the mutational status of the entire coding exon in 49 additional tumor samples 
negative for mutations at V600 as well as for recurrent mutations in NRAS (G12/13, 
Q61), KIT (W557, V559, L576, K642, D816), GNAQ (Q209) and GNA11 (Q209) (30). 
Two (4%) additional tumors had BRAF L597 mutations (c.1790 T>A, p. L597Q; 
c.1789_1790 CT>TC, p. L597S). A third tumor harbored a BRAF K601E mutation 
(c.1801 A>G), while a fourth had a D594N mutation (1780G>A) (Table 2.1). The BRAF 
c.1789_1790 CT>TC mutation was confirmed to be in cis by cloning and sequencing of 
the PCR product (data not shown). Thus, 8% of “pan-negative” cases harbored 
additional non-V600 BRAF exon 15 mutations. 
Signaling Induced by BRAF L597 and K601E Mutants is Suppressed by a MEK1/2 
Inhibitor 
BRAF L597 and K601 are located in the activation segment of the kinase domain 
and are adjacent to V600. Since V600 mutants are sensitive to specific BRAF and MEK 
inhibitors, we studied whether signaling induced by L597 and K601 mutants in 293H 
cells was inhibited by the BRAF mutant inhibitor, vemurafenib, and the MEK inhibitor, 
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Table 2.1. Mutations Detected in BRAF Exon 15 in 49 SNaPshot Screen “Pan-Negative” 
Melanomas 
Samplea Nucleotide Amino acid 
1 c.1801A>G p.K601E 
2 c.1790T>A p.L597Q 
3 c.1789_1790CT>TC p.L597S 
4 c.1780G>A p.D594N 
aSamples considered melanoma SNaPshot screen “pan-negative” were those that did not have mutations in BRAF 
(V600), NRAS (G12/13, Q61), KIT (W557, V559, L576, K642, D816), CTNNB1 (S37/45), GNAQ (Q209) and GNA11 
(Q209). 
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GSK1120212. We chose to study L597R/Q/S and K601E mutations because they have 
been reported to occur in melanoma by the Catalogue of Somatic Mutations in Cancer 
(COSMIC) (151) and we identified these mutations in our “pan-negative” samples 
(Table 2.1). We did not study endogenous melanoma cell lines, because to our 
knowledge, none harbor and are dependent upon an L597 or K601E mutation for 
survival. We did not further investigate the sensitivity of the D594N mutation because it 
has been reported that D594 mutations results in an inactive kinase (152). Compared to 
a vector control, ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated 
phospho-MEK and -ERK levels (Figure 2.2a), although the L597R/Q mutants did so to 
a lesser extent, consistent with studies on an analogous L597V mutant (42). 
Vemurafenib treatment of all of the BRAF mutant-expressing cells led to a decrease in 
phospho-MEK and -ERK protein levels, while treatment with the MEK inhibitor led to a 
more dramatic decrease in phospho-ERK signaling (Figure 2.2). These data suggest 
that patients whose tumors harbor BRAF L597 and K601 mutations could benefit from 
treatment with MEK inhibitors. 
 
Objective Radiographic Response to MEK1/2 Inhibitor Therapy in a Patient with a 
Metastatic Melanoma with a BRAF L597 Mutation 
A 69-year old patient with a metastatic melanoma who had previously received 
therapy with dacarbazine chemotherapy was enrolled in a phase I trial testing the 
allosteric MEK inhibitor TAK-733 (153). After 2 cycles of therapy, the patient was noted 
to have a partial radiographic response with a decrease of 31% in the sum of maximum 
diameters of target metastatic lesions in the liver and spleen and as of this submission
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 Figure 2.2. MAPK Pathway Signaling Induced by BRAF L597R/S/Q and K601E is Sensitive to RAF and MEK1/2 Inhibition.  
(A) Immunoblotting of lysates from 293H cells transfected with empty vector (vector) or plasmids encoding BRAF V600E-FLAG, 
BRAF L597R-FLAG, BRAF L597Q-FLAG, BRAF L597S-FLAG, and BRAF K601E-FLAG demonstrate that BRAF L597R/Q 
activate the MAPK pathway signaling to a lesser degree than BRAF V600E, L597S, and K601E.  Immunoblotting of lysates from 
293H cells transfected with plasmids encoding BRAF V600E-FLAG, BRAF L597R-FLAG, BRAF L597Q-FLAG, BRAF L597S-
FLAG or BRAF K601E-FLAG demonstrate that MAPK pathway signaling can be inhibited by increasing doses (0, 0.1 M, 0.5 M, 
1 m, 5 M) of (B) the BRAF inhibitor vemurafenib or (C) the MEK1/2 inhibitor GSK1120212, 2 hr post-inhibitor treatment. 
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remains progression-free at >24 weeks (Figure 2.3). Follow-up sequencing analysis of 
DNA from the patient’s tumor revealed a somatic BRAF L597S (c.1789_1790CT>TC) 
mutation (Figure 2.3c). These data validate the notion that BRAF L597S mutated 
melanomas are sensitive to MEK inhibitors in patients. 
 
DISCUSSION 
Inhibitors of mutant BRAF and the MAPK pathway are either FDA approved or being 
developed for melanomas that harbor recurrent genetic alterations involving BRAF 
V600E (c.1799T>A) (77, 98). Here, WGS of a tumor-normal pair revealed that a BRAF 
“wildtype” tumor harbored an unexpected BRAF L597 mutation occurring in exon 15. 
Through analysis of additional tumors negative for recurrent mutations in BRAF 
(V600E/K/M/R/D) as well as NRAS (G12/13, Q61), KIT (W557, V559, L576, K642, 
D816), GNAQ (Q209) and GNA11 (Q209) (30), we show that BRAF exon 15 mutations 
not involving the V600 codon are relatively common (4 of 49 samples (8%), including 
two L597 mutations), consistent with other studies in melanoma (154). We further 
demonstrate in vitro that signaling induced by ectopic expression of BRAF L597 and 
K601 mutants is suppressed by MEK inhibition. Finally, we report a case of a patient 
whose BRAF L597S mutant-metastatic melanoma responded radiographically to the 
MEK inhibitor, TAK-733.  Collectively, these data suggest that tumor cells harboring 
BRAF L597 and possibly K601E mutants may be dependent upon ERK-signaling and 
therefore susceptible to treatment with MEK inhibitors.  Although prior studies have 
shown that BRAF L597 mutations are activating (42), to our knowledge, this is the first 
report on the sensitivity of such mutations in vitro and in patients to MEK inhibitors. 
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 Figure 2.3. Computed Tomography Images from a Patient with BRAF L597S Mutant 
Metastatic Melanoma Responding to Therapy with the MEK1/2 Inhibitor, TAK-733. 
Arrows indicate the tumor in the liver (left) and spleen (right) at baseline (A) and after 4 
cycles of treatment (B).  (C) Table listing the target lesion measurements at baseline and 
after two cycles of TAK-733 administration.  (D) Tumor and blood DNA from a 69 year old 
patient with a metastatic melanoma treated with TAK-733 was extracted and subject to direct 
sequencing. The arrows indicate the positions of the mutated peaks in the tumor DNA that 
are absent in the blood DNA. Forward and reverse indicate the use of forward and reverse 
primers to generate the sequences, respectively. 
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Whether MEK inhibitors will be clinically better than mutant BRAF inhibitors for 
BRAF L597 and K601E mutants cannot be determined by the in vitro experiments 
performed in this study.  Cells expressing BRAF K601E have been previously shown to 
be moderately inhibited by vemurafenib (155); however, the few patients whose 
melanomas harbored this mutation did not display responses to another BRAF inhibitor, 
GSK2118436 (dabrafenib) (79, 156). There is 1 patient with a K601E mutation in BRAF 
that did respond to GSK1120212 (trametinib) (100). Additional in vivo and human 
studies will need to be performed to address which class of agents is the most 
appropriate.  
The choice of tumor mutations to be interrogated in the clinic requires a balance 
among feasibility, cost, and comprehensiveness. Single mutation testing (i.e. BRAF 
V600E (c.1799T>A)), is relatively cost-effective but will clearly overlook other actionable 
mutations, as demonstrated here. Whole genome sequencing is comprehensive, but 
currently prohibitively expensive for routine clinical use. Presently, an intermediate 
solution involves use of multiplex tests which can interrogate a limited number of known 
mutations in selected genes that may act as targets for drug therapy. For example, 
tumors from patients with malignant melanomas at Vanderbilt are routinely screened for 
recurrent mutations that occur with at least greater than or equal to 1% frequency in the 
disease (i.e. BRAF (V600E/K/M/R/D), NRAS (G12/13, Q61), KIT (W557, V559, L576, 
K642, D816), GNAQ (Q209) and GNA11 (Q209)), using a SNaPshot-based assay (30). 
Such screening results in 33% of cases having a “pan-negative” status (Figure 2.4). 
Non-V600 mutations in BRAF were not originally chosen for examination, as these were 
observed to occur in COSMIC at a frequency of less than 1% (151). The observations 
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Figure 2.4. Mutation Spectrum of Melanomas Tested in the Vanderbilt Clinical Lab. 
From July 1, 2010 to December 31, 2011, 538 melanomas were interrogated by our 
melanoma SNaPshot assay in Vanderbilt’s CLIA-certified molecular diagnostics laboratory. 
This assay queries mutations in BRAF (V600), NRAS (G12/13, Q61), KIT (W557, V559, 
L576, K642, D816), CTNNB1 (S37/45), GNAQ (Q209) and GNA11 (Q209). 
Pan-
Negative
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NRAS
19%
KIT
3%
GNAQ
2%
GNA11
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that L597 and K601 mutations may occur at a frequency of 4% and 2%, respectively, in 
“pan-negative” cases and that patients harboring tumors with these mutations may be 
sensitive to MAPK pathway inhibitors suggest that such tumors should subsequently 
undergo BRAF exon 15 mutational analyses to exclude the possibility of rare but 
potentially actionable BRAF mutations. 
WGS of the tumor/normal pair also revealed a number of other somatic 
mutations potentially relevant to melanoma biology (see Excel file Supplementary 
Table S8 in (150)). For example, we validated three mutations in the glutamate receptor 
encoded by GRIN2A (c.3395C>T, p.P1132L; c.3103G>A, p.D1035N; and c.C154T, 
p.R52X). GRIN2A mutations were recently reported to occur in up to 33% of 
melanomas (157). The role of this mutation in melanoma is currently unknown. We also 
identified a tumor-specific non-canonical KRAS mutation (c.466T>C; p.F156L) that has 
not been previously reported in cancer but has been described as a germline mutation 
in patients with Noonan or cardio-facio-cutaneous syndromes (158, 159). Interestingly, 
this mutant protein accumulates in the active conformation, similar to KRAS G12D, and 
expression of an analogous HRAS F156L mutation in NIH3T3 cells is transforming 
(159-161). RAS mutations have been reported to co-occur with BRAF mutations 
involving codons other than BRAF 600 or 601 (162). In addition, we validated other 
somatic mutations in genes of which the importance in melanoma are unspecified but 
are recognized to have important functions in other tumor types, such as APC, BRCA2, 
NOTCH1, PTEN, and NF1. Future studies will need to be performed to determine if 
these alterations are passenger or driver mutations and how they would affect 
responses to MEK inhibition.  
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MATERIALS AND METHODS 
Patient sample used for whole genome sequencing 
The patient was a 75-year-old white male who presented with a 2.3mm ulcerated 
melanoma of the right ear with a satellite lesion; lymph nodes were free of disease (T3b 
N2c, AJCC stage IIIC). Four months later, disease recurred, and he underwent local 
wide excision followed by a neck dissection and 3000Gy to a limited portion of ear and 
right neck. Approximately 12 months following his regional recurrence, he developed 
widely metastatic disease. He underwent a partial thyroidectomy for palliation. 
Melanoma from the thyroid was utilized for whole genome sequencing. The patient 
passed away 13 days after surgery with brain and cardiac metastases. He lived for 
slightly less than 17 months following his initial diagnosis. The patient’s case and 
biological samples were analyzed with informed consent (IRB# 030220). 
 
DNA extraction from patient samples 
Genomic DNA (gDNA) was extracted from a flash-frozen melanoma thyroid 
metastasis (90% tumor content) using standard proteinase K digestion and phenol 
extraction. gDNA from matched patient blood was extracted using the Gentra Puregene 
Blood Kit (QIAGEN). Identity testing was performed to confirm that tumor and blood 
gDNA originated from the same individual (Applied Biosystems). For examining BRAF 
exon 15 from the 49 patient samples, DNA from formalin-fixed paraffin embedded 
(FFPE) tissue was extracted using the QIAGEN DNA FFPE Tissue Kit. All patient 
samples were analyzed with informed consent on an IRB-approved protocol (IRB 
#030220 and IRB #100178). 
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Whole genome sequencing 
Paired-end sequencing of tumor and matched blood gDNA was performed on an 
Illumina Genome Analyzer IIx platform. Average coverage was 55.7x and 47.8x for the 
tumor and matched blood samples, respectively. The 100 bp reads were aligned to the 
Human Genome (UCSC hg19) using ELAND (Version 2) (163). FastQC (Version 0.9.1, 
(164)) was used to perform a quality control check of the raw data. See below Methods 
for single nucleotide polymorphism (SNP), insertion/deletion, structural variant, and 
copy number variation detection and validation details. 
 
Direct dideoxynucleotide-based sequencing 
Somatic SNPs and structural variants (SVs) were validated by direct sequencing 
of gDNA from the tumor and matched blood (Appendix Table A2.5 and Appendix 
Table A2.6). To determine the frequency of BRAF exon 15 mutations, we performed 
direct sequencing using gDNA extracted from 49 FFPE samples that were pan-negative 
for 43 driver mutations in BRAF, NRAS, KIT, CTNNB1, GNAQ, and GNA11 (30) (see 
Appendix Table A2.5 for BRAF PCR primers). Sequences were analyzed using 
Mutation Surveyor DNA Variant Analysis Software (SoftGenetics) and manual 
inspection of the sequence traces. 
 
Cloning BRAF exon 15 
Exon 15 of BRAF was PCR amplified using HotStarTaq Master Mix (QIAGEN) 
(Appendix Table A2.5). If two mutations were detected in exon 15, the PCR products 
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were cloned using the TOPO TA Cloning Kit (Invitrogen) to determine if the mutations 
were in cis or trans. Sequences were analyzed using BioEdit v.7.0.5.3. 
 
Transfections and drug treatment 
WT BRAF and BRAF V600E plasmids were described previously (95). The 
BRAF L597R, L597Q, L597S, and K601E mutations were introduced into the WT BRAF 
plasmid using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies). Direct sequencing of entire cDNAs was performed to confirm 
introduction of the mutation and no other mutations. 293H cells (Invitrogen) were 
transfected using Lipofectamine 2000 (Invitrogen) and 80 ng DNA; cells serum-starved 
for 6h were treated with vehicle (DMSO), PLX4032/vemurafenib (Chemietek), or 
GSK1120212 (Chemietek) at 0, 0.1 M, 0.5 M, 1 m, 5 M for 2 h. The 293H cells 
were passaged in the laboratory for no more than 6 months after receipt. Cells were 
tested for identity by isozyme and karyotype analysis by Invitrogen. 
 
Western blotting 
Cells were lysed using standard RIPA buffer supplemented with protease and 
phosphatase inhibitors. Lysates were quantified and subjected to SDS-PAGE and 
western blot analysis using the following antibodies:  phospho-MEK1/2 (Ser217/221), 
total-MEK1/2, phospho-ERK1/2 (Thr202/Tyr204), total-ERK1/2, FLAG, and BRAF. All 
antibodies were purchased from Cell Signaling except for anti-FLAG (Sigma-Aldrich) 
and BRAF (Santa Cruz). 
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Patient treatment 
Subject 58005-514 was treated with oral daily dosing with TAK-733 (Millennium 
Pharmaceuticals Inc., Cambridge, MA) at 16 mg on days 1–21 of 28-day cycles within 
an ongoing phase 1 clinical trial. Objective response was assessed by CT scans 
performed every 2 months according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) guideline (version 1.1) (165). This study is registered with 
ClinicalTrials.gov (NCT00948467) and full information about this clinical trial will be 
provided elsewhere when completed. 
 
Single nucleotide polymorphism detection 
Single nucleotide polymorphisms (SNPs) were called by SAMtools (166) (Version 
0.1.12a, http://samtools.sourceforge.net/) with the default parameters and filtered to 
coordinates with ≥ 3x coverage and a Phred-like consensus quality of ≥ 20. Repeats, 
duplications, and the reads that failed the platform/vendor quality check we removed by 
using SAMtools and Picard (Version 1.38, http://picard.sourceforge.net/index.shtml). 
False SNP calls were reduced using Base Alignment Quality (BAQ) (167). Novel, tumor-
specific somatic SNPs were identified by filtering out known SNPs in dbSNP131 and the 
1000 Genomes Project (November 2010). Functional annotations of SNPs were 
assessed using ANNOVAR (Appendix Figure A2.1) (168). 
 
Insertion and deletion detection 
Indels were called using Pindel (Version 0.2.3) with the default parameters (169). 
Somatic indels were further filtered to require a minimum 3 supporting tumor reads. 
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Structural variant detection 
CREST was used to detect somatic structural variants (SVs) (170). Germline 
SVs were filtered out in the paired analysis. For each predicted SV, the soft-clipped 
reads were manually checked by reviewing the multiple alignments for the breakpoint. 
 
Copy number variation determination  
FREEC was used to identify copy number variations (CNVs) (171). The BAM 
files were converted to SAM files using SAMtools and were then used as the input data 
for FREEC. 
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CHAPTER III 
 
BRAF fusions define a distinct molecular subset of melanomas with potential 
sensitivity to MEK1/2 inhibition 
 
 
 
Adapted from:  Hutchinson, K.E., Lipson, D., Stephens, P.J., Otto, G., Lehmann, B.D., 
Lyle, P.L., Vnencak-Jones, C.L., Ross, J.S., Pietenpol, J.A., Sosman, J.A., Puzanov, I., 
Miller, V.A., Pao, W. (2013). BRAF Fusions Define a Distinct Molecular Subset of 
Melanomas with Potential Sensitivity to MEK Inhibition. Clin Cancer Res 19, 6696-6702. 
 
 
INTRODUCTION 
Melanoma is a malignant tumor of melanocytes and is expected to account for 
more than 9,000 deaths in the United States in 2013 (172).  In the past, melanoma was 
classified according to clinical and pathological characteristics such as histology (depth, 
Clark level, and ulceration) and anatomic site of origin. This classification system has 
since evolved to further stratify melanoma into molecular subsets based on 
constitutively activating “driver” mutations identified in the serine-threonine kinase 
encoded by BRAF (V600), the GTPase encoded by NRAS (G12/13, Q61), the tyrosine 
kinase encoded by KIT (W557, V559, L576, K642, D816), and the GTPases encoded 
by GNAQ (Q209) and GNA11 (Q209) (40-44). These driver mutations are present in 60-
70% of malignant melanomas, primarily activate the mitogen-activated protein kinase 
(MAPK) pathway, and are clinically targetable with highly specific inhibitors. For 
example, melanomas harboring the most common driver mutation, BRAF V600E 
(c.1799T>A, ~40% frequency) are sensitive to the mutant-specific BRAF inhibitors, 
vemurafenib (77) and dabrafenib (173) or the MEK inhibitor, trametinib (98), while KIT-
59 
 
mutant melanomas are targetable with the KIT inhibitors, imatinib or nilotinib (83, 89). 
Because of these important clinical implications, we automatically screen melanomas at 
the Vanderbilt-Ingram Cancer Center for these specific mutations as part of routine care 
(30).  We also recently found that another 3% of melanomas harbor non-V600 exon 15 
BRAF mutations (i.e. D594, L597 and K601) with potential sensitivity to MEK inhibitors 
(150).  Unfortunately, the remaining one-third of melanomas contain no known drivers; 
we describe these as “pan-negative”.  At present, treatment options for these patients 
are limited to emerging immune therapies such as ipilimumab (107) and anti-PD1/PD-
L1 (111, 113), but even these therapies are not uniformly effective.  
Here, we identified two novel fusions involving the BRAF kinase domain, the 
sulfurylase kinase PAPSS1, and the transcriptional co-activator TRIM24, by targeted 
next-generation sequencing (NGS) in two malignant melanomas that were “pan-
negative” for known melanoma driver mutations.  Although oncogenic BRAF fusions 
have been described previously in cancer (174-181), to our knowledge, BRAF fusions 
have not yet been reported in melanoma.  We characterized signaling properties 
induced by the fusions and ascertained the frequency of BRAF fusions in a cohort of 
melanomas enriched for wild-type BRAF status.  Collectively, our results have 
therapeutic implications for patients with melanoma. 
 
RESULTS 
Identification of a PAPSS1-BRAF Fusion in a “Pan-Negative” Melanoma 
A 2.2 cm thick (Clark Level V), focally ulcerated, malignant melanoma from the left 
shoulder of a 27-year-old Caucasian female was screened for common melanoma 
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driver mutations in BRAF, NRAS, KIT, GNAQ and GNA11 by the Vanderbilt melanoma 
SNaPshot assay (30) and determined to be “pan-negative”.  Axillary dissection revealed 
metastatic involvement of 21 of 25 axillary lymph nodes (initial tumor staging: pT4bN3 = 
Stage IIIC), and the area was subsequently irradiated.  Unfortunately, she developed 
local recurrence and lung metastasis.  She was subsequently treated with experimental 
and standard immunotherapies. The patient’s disease progressed rapidly and she died 
nine months later (11 months after initial diagnosis).  During the course of treatment, the 
primary shoulder lesion was sent to Foundation Medicine (Cambridge, MA) for 
comprehensive genomic profiling with the FoundationOneTM assay (182).  This test 
involves targeted NGS of 3,320 exons in 182 cancer-related genes and 37 introns in 14 
genes recurrently rearranged in cancer and simultaneously detects single nucleotide 
variants, insertions, deletions, copy number changes, and select rearrangements (see 
Supplementary Methods).  Profiling revealed the presence of a large genomic deletion 
of approximately 350 kilobase pairs between BRAF intron 8 and an intragenic region of 
chromosome 7, suggesting a possible gene fusion event.  Subsequent targeted RNA 
sequencing of tumor cDNA identified a novel, in-frame fusion between exon 5 of the 
sulfurylase kinase PAPSS1 (3’-phosphoadenosine 5’-phosphosulfate synthetase-1) and 
exon 9 of BRAF generated by a t(4;7)(q24;q34) translocation (Figure 3.1).   
 
Signaling Induced by the PAPSS1-BRAF Fusion is Abrogated by MEK1/2 
Inhibitors but not BRAF Inhibitors 
To determine the effect of the PAPSS1-BRAF fusion on MAPK signaling in cells, 
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 Figure 3.1.  Detection of the PAPSS1-BRAF Fusion.  Three representative spanning sequence reads from targeted RNA 
sequencing of the “pan-negative” melanoma case shows alignment of PAPSS1 (red text) to chromosome 4 and of BRAF (dark 
blue text) to chromosome 7.  The break-point occurs in-frame between exon 5 of PAPSS1 and exon 9 of BRAF.  Below are 
schematics of wild-type BRAF (blue), wild-type PAPSS1 (red), and the fused PAPSS1-BRAF proteins.  The APS kinase domain 
of PAPSS1 and the serine-threonine (S/T) kinase domain of BRAF remain intact in the fused protein.  APS, adenosine 
phosphosulfate; ATP, adenosine 5’-triphosphate; CRD, cysteine-rich domain; ex, exon; RBD, Ras-binding domain; RKTR, Arg-
Lys-Thr-Arg dimerization domain; WT, wild-type. 
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we expressed cDNAs encoding FLAG-tagged WT BRAF, mutant BRAF (V600E), WT 
PAPSS1 or the fusion in 293H cells. Corresponding lysates were probed by 
immunoblotting with antibodies against phosphorylated and total forms of MEK1/2 and 
ERK1/2, as well as against PAPSS1, FLAG and BRAF.  Ectopic expression of PAPSS1-
BRAF in 293H cells led to increased levels of phosphorylated MEK1/2 and ERK1/2, 
similar to levels induced by BRAF V600E  (Figure 3.2a).  WT PAPSS1 did not induce 
MAPK pathway activation (Appendix Figure A3.1).  These data confirm that the 
PAPSS1-BRAF fusion activates the MAPK signaling cascade. 
Activation of MAPK signaling by BRAF V600E is sensitive to inhibition by both 
vemurafenib (a BRAF mutant-specific inhibitor) and trametinib (a MEK inhibitor) (98).  
To determine if signaling induced by the BRAF fusion was inhibited by these agents, we 
transfected 293H cells with the V600E or PAPSS1-BRAF cDNAs and treated them with 
vehicle control or increasing concentrations of vemurafenib or trametinib for 2 hours.  
Immunoblotting studies with the corresponding lysates showed that BRAF V600E-
induced MEK1/2 phosphorylation was effectively reduced by vemurafenib, but MEK1/2 
phosphorylation induced by PAPSS1-BRAF was not.  Trametinib, however, was 
effective at reducing ERK1/2 phosphorylation in both V600E- and PAPSS1-BRAF-
expressing cells (Figure 3.2b). These results suggest that downstream signaling 
induced by the PAPSS1-BRAF fusion could be abrogated by MEK but not mutant-
specific BRAF inhibitors. 
 
Frequency of BRAF Fusions in Melanoma  
To determine whether BRAF fusions are recurrent in melanoma, we interrogated 
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Figure 3.2.  Signaling Induced by PAPSS1-BRAF is More Sensitive to MEK1/2 
Inhibition than BRAF Inhibition.  (A)  Immunoblotting of lysates from 293H cells 
transfected with vector (empty vector) or plasmids encoding BRAF V600E-FLAG or 
PAPSS1-BRAF-FLAG demonstrate that the BRAF fusion activates MAPK pathway signaling 
similarly to BRAF V600E. (B) While MAPK pathway signaling induced by expression of 
BRAF V600E is sensitive to increasing doses (0, 0.1, 0.5, 1, and 5 μmol/L) of the BRAF 
inhibitor vemurafenib (vem) or the MEK1/2 inhibitor trametinib (tra), signaling induced by 
PAPSS1-BRAF is more sensitive to trametinib than vemurafenib. kDa, kilodalton. 
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51 additional melanomas from various institutions genotyped with the FoundationOneTM 
assay. This cohort was enriched with cases negative for BRAF mutations (both V600 
and non-V600), likely due to referral bias.  Only 8 of 52 (15%) tumors harbored V600 
changes, at least less than half the expected percent in unbiased cohorts (30), and 8 of 
52 (15.4%) harbored non-V600 (D594, L597, K601, etc.) changes (Figure 3.3).  In 
addition to the PAPSS1-BRAF fusion, we identified another BRAF fusion, this time 
involving tripartite motif-containing 24 (TRIM24-BRAF; inv(7)(q32-34q34)) (Table 3.1, 
Figure 3.4a).  This tumor was also “pan-negative” for other known “driver” mutations 
(Figure 3.3, Table 3.2).  Similar to PAPSS1-BRAF, ectopic expression of TRIM24-
BRAF led to activation of the MAPK pathway which was sensitive to MEK, but not 
BRAF, inhibition (Figure 3.4b).  Thus, in this cohort, BRAF fusions were present in 8% 
[2 of 24, 95% confidence interval (C.I.) of 1.2%-27.0%] of “pan-negative” melanomas 
(Figure 3.3, Table 3.2).   
To extend these findings, we also analyzed RNA, whole genome and whole 
exome sequencing data on an independent dataset available from The Cancer Genome 
Atlas (TCGA) skin cutaneous melanoma (SKCM) dataset.  In two of 49 (4.1%) “pan-
negative” cases, we identified sequence reads indicative of potential BRAF fusions, 
involving CDC27 and TAX1BP1 as 5’ partners (Figure 3.5).  Consistent with these 
findings, TCGA reverse phase protein array (RPPA) data comparing levels of 
phosphorylated MEK1/2 in the tumors harboring fusions versus those with BRAF, 
NRAS, KIT, GNAQ or GNA11 mutations revealed that the fusion cases harbor 
phosphorylated MEK1/2 levels similar to, or greater than, levels observed in BRAF or 
NRAS-mutant melanomas (Figure 3.5c).  Collectively, these data suggest that BRAF
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Figure 3.3.  52 Melanomas Genotyped on the FoundationOneTM Assay.  Schematic of the mutation distribution in 52 patient 
melanomas genotyped by the FoundationOneTM assay.  Each column of boxes indicates a single patient, where green boxes 
indicate the presence of a mutation in BRAF, NRAS, KIT, GNAQ, and/or GNA11 and grey boxes indicate lack of mutation(s).  
Cases with V600E/K BRAF mutations, non-V600 BRAF mutations, BRAF fusions and certain NRAS mutations are indicated.  
Specific mutations for each case can be found in Supplementary Table S1.  No KIT mutations were identified.  Note the difference 
in the percent of cases positive for BRAF V600 mutations in this cohort versus those genotyped in Figure 3.4, demonstrating that 
this cohort was enriched for cases lacking BRAF V600 alterations. 
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Table 3.1.  BRAF Rearrangements in “Pan-Negative” Melanomas 
Sample Detection Method BRAF Exon Break 
5’ Partner,  
Exon Break 
Spanning 
Pairs (n) 
Split 
Reads (n) 
FM-Mel29 FoundationOneTM exon 9 TRIM24, exon 9 200 37 
FM-Mel30 FoundationOneTM, RNA Kinome Seq exon 9 PAPSS1, exon 5 15 5 
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 Figure 3.4.  Detection of a TRIM24-BRAF Fusion and Abrogation of Resultant Signaling.  
(A) Four representative spanning sequence reads from genotyping of a second “pan-negative” 
melanoma with the FoundationOneTM assay shows the alignment of TRIM24 (purple text) to 
chromosome 7q32-24 and of BRAF (dark blue text) to chromosome 7q34.  The reads specifically 
align to intron 9 of TRIM24 and to intron 8 of BRAF, which indicates a coding sequence break 
between TRIM24 exon 9 and BRAF exon 9.  Below are schematics of wild-type BRAF (blue), 
wild-type TRIM24 (purple), and the fused TRIM24-BRAF proteins.  The RING-finger, B-box types 
1 and 2, and coiled-coil domains of TRIM24 and the serine/threonine (S/T) kinase domain of 
BRAF remain intact in the fused protein. (B) Immunoblotting of lysates from 293H cells 
transfected with BRAF V600E-FLAG or TRIM24-BRAF-FLAG show that TRIM24-BRAF activates 
the MAPK pathway, which can be inhibited by the MEK inhibitor, trametininb (tra), but not the 
BRAF inhibitor, vemurafenib (vem).  Drug dosing:  (DMSO vehicle control), 0.1, 0.5, 1 and 5 
μmol/L. kDa, kilodalton. B-box types 1 & 2 are zinc-finger-like domains; BROMO, bromodomain, 
binds acetylated lysines on histones; CRD, cysteine-rich domain; ex, exon; PHD, Plant Homeo 
Domain, binds tri-methylated lysines on histone H3; RBD, Ras-binding domain; RING, Really 
Interesting New Gene, RING-finger domains play key roles in the ubiquitylation pathway; RKTR, 
Arg-Lys-Thr-Arg dimerization domain; WT, wild-type.
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Table 3.2.  52 Melanomas from Various Institutions Genotyped by FoundationOneTM 
  Sample Information Commonly Mutated Genes 
  
Name Gender Age Stage Site           (if not skin) 
Median 
Sequencing 
Deptha 
BRAF NRAS KIT GNAQ GNA11 
D
r
i
v
e
r
-
P
o
s
i
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 
FM-Mel1 M 46 IV   589 V600E Q61L       
FM-Mel2 M 85 IV   1012 V600E         
FM-Mel3 F 51 III   1155 V600E         
FM-Mel4 M 48 IV   1341 V600E         
FM-Mel5 F 43 IV   1550 V600E         
FM-Mel6 M 62 III   1833 V600E         
FM-Mel7 F 74 III   1102 V600K         
FM-Mel8 M 56 IV   1255 V600K         
FM-Mel9 F 35 IV   1360   Q61K       
FM-Mel10 M  83 IV   1684   Q61K       
FM-Mel11 F 76 III   1054   Q61L       
FM-Mel12 M 65 III   1623   Q61L       
FM-Mel13 M 56 IV   1276   Q61R       
FM-Mel14 M 71 IV   1012   Q61R       
FM-Mel15 M 42 IV   924   Q61R       
FM-Mel16 F 71 n/a   1445   Q61R       
FM-Mel17 F 57 IV   673   Q61R       
FM-Mel18 M 65 IV Uveal/Occular 956       Q209P   
FM-Mel19 M 40 IV Uveal/Occular 1703       Q209P   
FM-Mel20 M 71 IV   743         Q209L 
FM-Mel21 F 44 IV Uveal/CNS 808         Q209L 
FM-Mel22 F 32 IV   1416 D594N         
FM-Mel23 M 78 IV   1809 G469S         
FM-Mel24 M 63 IV   1104 G469V         
FM-Mel25 F 55 IV   1023 K601E/amp         
FM-Mel26 M n/a III   872 L597Q         
FM-Mel27 M 71 IV   1602 L597R         
FM-Mel28 M 83 IV   1779 T599_V600insT         
P
a
n
-
N
e
g
a
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 FM-Mel29 F 59 IV   775 TRIM24-BRAF         
FM-Mel30b F 27 III   1207 PAPSS1-BRAF         
FM-Mel31 n/a n/a n/a   1417           
FM-Mel32 F 54 IV   1568           
FM-Mel33 M n/a IV   1116           
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P
a
n
-
N
e
g
a
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 
FM-Mel34 M 73 IV   1232           
FM-Mel35 F 50 IV   961           
FM-Mel36 M 62 IV   1240           
FM-Mel37 M 54 IV   1032           
FM-Mel38 F 44 IV   1477           
FM-Mel39b F 22 n/a   1364           
FM-Mel40 F 68 IV   793           
FM-Mel41 F 41 IV   1547           
FM-Mel42 M 46 III   220           
FM-Mel43 F 54 IV   966           
FM-Mel44 F 70 III  254           
FM-Mel45 F 55 IV   1196           
FM-Mel46 M 52 IV   1342           
FM-Mel47 M 44 IV   1665           
FM-Mel48 M 61 IV Anal 1128           
FM-Mel49 F 50 IV   1463           
FM-Mel50 M 38 IV   1396           
FM-Mel51 F 67 IV   807           
FM-Mel52b M 58 IV Uveal/Occular 1226           
aMedian Sequencing Depth refers to the median number of unique reads covering each base in the targeted genomic regions. 
bCases from Vanderbilt-Ingram Cancer Center 
n/a – not available 
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Figure 3.5.  Potential TAX1BP1-BRAF and CDC27-BRAF Fusions Identified in Data 
from The Cancer Genome Atlas.  Representative RNA sequencing reads from TCGA skin 
cutaneous melanoma dataset (SKCM) demonstrate the alignment of paired-end reads 
mapping to (A) exon 11 of BRAF (blue text) and exon 8 of TAX1BP1 (green text), both on 
chromosome 7 or (B) to exon 10 of BRAF (blue text) on chromosome 7 and exon 16 of 
CDC27 (orange text) on chromosome 17.  (Legend continued on next page) 
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Figure 3.5 Legend continued:  Below each alignment schematic are diagrams of WT BRAF 
(blue) and the TAX1BP1-BRAF (A) or CDC27-BRAF (B) fusion proteins.  (C) Box and 
whisker plots based on RPPA data distributions for total (left panel) or phosphorylated (right 
panel) MEK1/2 protein levels.  Samples are divided based on SNaPshot mutation status into 
“pan-negative” (NEG), BRAF-mutant (includes the non-V600 BRAF alterations listed in Table 
S1 as well as BRAF N581T, S467L and G466E), NRAS-mutant, KIT-mutant, or GNAQ/11-
status.  The last two data points in each graph represent the “pan-negative” samples 
harboring CDC27-BRAF and TAX1BP1-BRAF.  Differences in total MEK1/2 protein levels 
(left panel) are not statistically significant between any of the sample groups, however, the 
phosphorylated MEK1/2 levels between “pan-negative” and BRAF-mutant or NRAS-mutant 
samples are statistically significant (right panel, p<0.0001, Student’s t-test).  Although 
statistical analyses cannot be performed on single samples, the phosphorylated MEK1/2 
levels of the “pan-negative” cases harboring CDC27-BRAF and TAX1BP1-BRAF are similar 
to, or greater than, the levels observed in BRAF- or NRAS-mutant cases. CRD, cysteine-rich 
domain; ex, exon; RBD, Ras-binding domain; RKTR, Arg-Lys-Thr-Arg dimerization domain; 
WT, wild-type. 
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fusions exist in 4-8% of “pan-negative” melanomas (Figure 3.6).   
 
DISCUSSION 
The classification and treatment of melanomas by known recurrent single-
nucleotide driver mutation status in BRAF (V600), NRAS (G12/13, Q61), KIT (W557, 
V559, L576, K642, D816), GNAQ (Q209) and GNA11 (Q209) (30) has changed 
standard treatment practice by enabling rationally guided treatment.  However, in our 
experience at Vanderbilt, using an established SNaPshot-based assay in the clinic (30), 
approximately one-third of melanomas are still “pan-negative” for these mutations.  We 
recently determined that approximately 8% of cases negative for these drivers harbor 
other activating mutations in BRAF exon 15 (D594E/G/H/N/V, L597R/S/Q/V and 
K601E/I/N) rather than the better-known V600E/K/M/R/D alterations (150), and we 
showed in a patient harboring a BRAF L597 mutation that tumor regression could be 
induced by a MEK inhibitor (150).  Here, we have identified another subset of potentially 
clinically relevant “pan-negative” melanomas defined by BRAF fusions.  Specifically, we 
found two novel BRAF fusions (PAPSS1-BRAF and TRIM24-BRAF) in 2 of 24 (8%) 
“pan-negative” melanomas genotyped on an assay that examines that status of 182 
cancer-related genes and 37 introns in 14 genes recurrently rearranged in cancer.  
Ectopic expression of either fusion activates the MAPK pathway (Figure 3.2a, Figure 
3.4b), and induced signaling is readily diminished by treatment with the MEK inhibitor, 
trametinib (Figure 3.2b, Figure 3.4b).  Through mining TCGA skin cutaneous 
melanoma dataset, we also identified two potential BRAF fusions in another 49 “pan-
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Figure 3.6.  Molecular Subsets of Melanoma.  Pie chart demonstrating the percentage 
distribution of genes with clinically-relevant and recurrent driver mutations in individuals with 
melanoma, including non-V600 BRAF alterations (left), interrogated on the Vanderbilt 
melanoma SNaPshot assay (Lovly et al., PLoS ONE, 2012 (30)).  In this study, we have 
demonstrated that BRAF fusions occur in approximately 4-8% “pan-negative” cases (right). 
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negative” cases, indicating a frequency of 4.1% in an independent cohort (Figure 3.5).  
PAPSS1 is a bifunctional sulfurylase kinase, with an N-terminal adenosine-5’-
phosphosulfate kinase domain and a C-terminal ATP sulfurylase domain (183).  Only 
the adenylylsulfate kinase domain of PAPSS1 remains intact in the PAPSS1-BRAF 
fusion described herein.  TRIM24 is a transcriptional co-regulator of nuclear receptors 
such as the retinoic acid receptor-α (RARα) (184) and is known to facilitate 
ubiquitination of p53 for proteasomal degradation (185).  Interestingly, a version of 
TRIM24-BRAF fusion was identified in the early 1990s in a cDNA library derived from a 
model of mouse hepatocellular carcinoma (184, 186), but not identified in humans until 
now.  In addition to BRAF, TRIM24 is also fused to the kinase domains of FGFR1 in a 
myeloproliferative disorder case (8p11 myeloproliferative syndrome) (187) and of RET 
in a case of papillary thyroid cancer (188).  Like PAPSS1-BRAF, we show that 
expression of TRIM24-BRAF leads to activation of the MAPK pathway which is sensitive 
to MEK inhibition (Figure 3.4b). 
Although BRAF fusions have been found in other cancers (pilocytic astrocytoma, 
gastric adenocarcinoma, thyroid cancer, prostate cancer, and melanocytic nevi) (Figure 
3.7) (174-181), to our knowledge, BRAF fusions have not yet been functionally 
characterized in malignant melanoma.  A BRAF rearrangement was identified 
previously by break-apart fluorescence in situ hybridization (FISH) in a single malignant 
melanoma in 2010, however, insufficient sample remained for follow-up analyses that 
might have identified the fusion partner and allowed for its characterization (181).  
Additionally, a FCHSD1-BRAF fusion was identified in a large congenital melanocytic 
nevus (LCMN) (176).  If left untreated/unresected, LCMN can be a precursor to 
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Figure 3.7.  BRAF Fusions Identified in Melanoma and Other Cancer Types.  
Schematics of wild-type BRAF (top) and all currently known BRAF fusions including those 
identified in this study (PAPSS1-BRAF and TRIM24-BRAF).  All BRAF fusions break 
between exons 8 through 11, thus leaving the serine-threonine (S/T) kinase domain of BRAF 
intact. CRD, cysteine-rich domain; ex, exon; RBD, Ras-binding domain; RKTR, Arg-Lys-Thr-
Arg dimerization domain; WT, wild-type. 
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melanoma, but this is thought to occur in fewer than 5% of LCMN cases (189).  Notably, 
every BRAF fusion characterized to date activates MAPK pathway signaling (174-179, 
181) and when interrogated, had transforming abilities (174, 175, 178, 181).  Because 
PAPSS1-BRAF and TRIM24-BRAF are structured similarly to all other BRAF fusions 
(Figure 3.7), and because we show that both PAPSS1-BRAF and TRIM24-BRAF 
activate MAPK pathway signaling (Figure 3.2, Figure 3.4), we expect these melanoma 
BRAF fusions will also be transforming.  Additional biological studies outside the scope 
of this manuscript are ongoing. 
In protein fusions involving receptor tyrosine kinases (RTKs), the 5’ partners 
usually encode coiled-coil domains which enable dimerization necessary for kinase 
activity (190).  In the case of BRAF fusions, AKAP9 (174) and TRIM24 are the only 5’ 
partners that contain coiled-coil domains.  BRAF harbors its own small dimerization 
motif (Arg-Lys-Thr-Arg, RKTR, amino acids 506-509) spanning exons 12 and 13 (49), 
which is intact in all currently-known BRAF fusions (Figure 3.7); therefore, the need for 
5’ partners with dimerization ability may not be necessary for BRAF fusion function.  In 
full-length wild-type BRAF, modulation of the RAS-binding domain (RBD) by activated 
RAS leads to BRAF homo-/hetero-dimerization and activation (191).  This negative-
regulatory RBD has been replaced by the various 5’ partners in all known BRAF fusions 
(Figure 3.7).  Similarly, the recently-discovered BRAF V600E splice variants which 
induce vemurafenib resistance harbor N-terminal exons and mutant kinase domain 
exons, but RBD exons are spliced out, allowing for constitutive dimerization at the 
RKTR dimerization interface (191).  Recently, Sievert, et al., demonstrated that 
KIAA1549-BRAF fusion variants can homodimerize with one another; introduction of a 
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dimer interface mutant (R509H) disrupts this interaction (192).  Future studies should 
ascertain the dimerization properties of the various BRAF fusions. 
 In summary, through NGS analysis of a “pan-negative” melanoma, we 
identified a novel PAPSS1-BRAF fusion.  The fusion protein activates the MAPK 
pathway, and the induced downstream signaling is sensitive to MEK inhibition.  
Subsequent analysis of 51 additional melanomas (24 of which were “pan-negative”) 
revealed a second fusion, TRIM24-BRAF, that also activates MEK1/2 and ERK1/2.  We 
also identified two candidate BRAF fusions in the TCGA skin cutaneous melanoma 
dataset.  Thus, BRAF fusions may occur in 4-8% of the “pan-negative” melanoma 
population (Figure 3.6).  Coupled with knowledge that the transforming ability of 
multiple BRAF fusions has already been established (174, 175, 178, 181), we believe 
enough evidence exists to raise awareness that BRAF fusions are present in this “pan-
negative” population and have implications for MAPK pathway-targeted therapies 
currently in clinical trials.  Their presence may explain an unexpected clinical response 
to MEK inhibitor therapy or assist in selecting patients for MEK-directed therapy.  
Collectively, these biochemical and genetic data define an additional molecular subset 
of melanoma that should be routinely screened for in the clinic, and knowledge about 
BRAF fusions in melanoma may provide insight into the mechanism of responses to 
treatment with an expanding list of available kinase inhibitors. 
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MATERIALS AND METHODS 
Case histories of patients with BRAF fusions. 
Patient 1 (PAPSS1-BRAF):  A 2.2 cm thick (Clark Level V), focally ulcerated, 
malignant melanoma from the left shoulder of a 27-year-old Caucasian female was 
screened for common melanoma driver mutations by the Vanderbilt melanoma 
SNaPshot assay (30) and determined to be “pan-negative”.  Axillary dissection revealed 
metastatic involvement of 21 of 25 axillary lymph nodes (initial tumor staging: pT4bN3 = 
Stage IIIC), and the area was subsequently irradiated.  Unfortunately, she developed 
local recurrence and lung metastasis.  She was subsequently treated with experimental 
and standard immunotherapies. The patient’s disease progressed rapidly and she died 
nine months later (11 months after initial diagnosis).  During the course of treatment, the 
primary shoulder lesion was sent to Foundation Medicine (Cambridge, MA) for 
comprehensive genomic profiling with the FoundationOneTM assay (182).  The patient 
was consented on VICCMEL09109.    
Patient 2 (TRIM24-BRAF):  A 60-year old female with a history of breast cancer 
presented with a 4 mm-thick (Clark level III), ulcerated, primary malignant melanoma 
located over her right scapula. Immunohistochemical studies with appropriate controls 
demonstrated tumor expression of S-100 and Melan-A, supporting the diagnosis of 
melanoma and not breast cancer.  The FoundationOneTM assay was performed on the 
primary tumor. The patient was consented in Israel; further clinical treatment data are 
not available. 
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FoundationOneTM Assay and Data Analysis 
Formalin-fixed, paraffin-embedded (FFPE) blocks with a minimum 20% tumor content 
were sent to Foundation Medicine for the FoundationOneTM assay.  DNA was extracted 
from 40μm of FFPE tissue using the Promega Maxwell 16 FFPE Plus LEV DNA 
Purification Kit according to manufacturer’s instructions.  DNA was quantified using a 
standardized PicoGreen fluorescence assay (Invitrogen).  Molecular barcode-indexed 
ligation-based sequencing libraries were constructed using standard methods (193) 
from at least 50ng and up to 200ng of sheared DNA depending upon how much DNA 
was available from a sample.  Briefly, genomic DNA extracted from FFPE tissue 
sections was sheared to ~100-400bp by sonication before end-repair, dA addition and 
ligation of indexed, Illumina sequencing adaptors.  Solution-based hybrid capture (193) 
with a custom Agilent SureSelect biotinylated RNA bait set was used to enrich all 3,320 
exons of 182 cancer-related genes and 37 introns from 14 genes recurrently rearranged 
in cancer representing approximately 1.1 Mb of the human genome.  The selected 
libraries were sequenced on an Illumina HiSeq 2000 platform using 49x49 paired-end 
reads. 
Genomic DNA sequences were mapped to the reference human genome (hg19) 
using the Burrows-Wheeler Aligner (87) and processed using the publicly-available 
SAMtools (166), Picard, and Genome Analysis Toolkit (194). Genomic base 
substitutions were detected using a Bayesian methodology, which allows for the 
detection of novel somatic mutations at low mutant allele frequency (MAF) through the 
incorporation of tissue-specific prior expectations.  The probability that a mutation is 
present in the data is evaluated using empirically observed error rates, and mutation 
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candidates are issued if p(mut / data)>99%.  Short insertions and deletions are detected 
by local assembly of data from each exon using the de-Bruijn approach, where 
candidate mutations with maximal number of supporting reads are retained.  Mutations 
were filtered for strand bias (Fisher’s test, p<1e^(-6)), and read location bias (KS test, 
p<1e^(-6)), the presence in 2 or more normal controls or verified in dbSNP v.135 (195), 
and subsequently annotated for known and likely somatic mutations using the 
Catalogue of Somatic Mutations in Cancer (COSMIC) (196). Copy number alterations 
were detected by comparing targeted genomic DNA sequence coverage at all exons 
with a process-matched normal control sample as well as allele frequencies of ~1,800 
genome-wide SNPs, and fitting data to a model of absolute copy numbers and tumor 
purity.  Focal amplifications are called at segments with ≥6 copies and homozygous 
deletions at 0 copies, in samples with purity >20%.  Genomic rearrangements were 
detected by clustering chimeric reads mapped to targeted introns. 
 
Targeted RNA Sequencing and Data Analysis 
Total RNA was extracted from 40μm of FFPE tissue (same block used for DNA 
extraction) using a prototype kit for the Promega Maxwell according to the 
manufacturer’s instructions and was quantified using a standardized RiboGreen 
fluorescence assay (Invitrogen).  Total RNA was reverse transcribed with random 
hexamer primers by the SuperScript® III First-Strand Synthesis System (Invitrogen) to 
make cDNA.  Double-stranded cDNA was made with the NEBNext® mRNA Second 
Strand Synthesis Module (New England Biolabs) (197) and used as input to library 
construction.  Molecular barcode-indexed ligation-based sequencing libraries were 
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constructed using standard methods (193) from double-stranded cDNA starting with 
end-repair and followed by dA addition and ligation of indexed, Illumina sequencing 
adaptors.  Solution-based hybrid capture (193) with the Agilent SureSelect Kinome Kit 
was performed according to the protocol in Levin et al, 2009 (198) and the selected 
libraries were sequenced on an Illumina HiSeq 2000 platform using 49x49 paired-end 
reads. 
cDNA sequences were mapped to the reference human genome (hg19) and 
transcriptome (RefSeq) using the Burrows-Wheeler Aligner (87) and processed using 
the publicly available SAMtools (166), Picard, and Genome Analysis Toolkit (194). Gene 
fusions were detected by clustering chimeric reads mapping to separate genes. 
 
cDNA Constructs 
The BRAF V600E FLAG-tagged plasmid was described previously (95).  Using 
Herculase II Fusion Polymerase (Agilent), full-length wildtype (WT) PAPSS1 was cloned 
from 293H cell line cDNA.  To create the FLAG-tagged PAPSS1-BRAF construct, exons 
1-5 of PAPSS1 were cloned from 293H cell line cDNA, and exons 9-18 of WT BRAF 
were cloned from a WT BRAF FLAG-tagged construct.  Primers capturing exon 5 of 
PAPSS1 and exon 9 of BRAF contained BRAF and PAPSS1 sequence, respectively, 
such that PAPSS1 and BRAF could be spliced together through a subsequent PCR 
reaction, a process termed Gene SOE-ing (Gene Splicing by Overlap Extension) (199).  
Similarly, exons 1-9 of TRIM24 were cloned from 293H cell line DNA and “SOE-n” to 
exons 9-18 of WT BRAF(-FLAG).  PCR products were then cut with restriction enzymes 
and ligated into the pcDNA3.1+ vector (Invitrogen).  C-terminal FLAG tags were added 
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to the WT PAPSS1 sequence by PCR.  Direct sequencing of the WT PAPSS1(-FLAG), 
PAPSS1-BRAF(-FLAG) and TRIM24-BRAF(-FLAG) constructs was performed to 
confirm the sequences and to ensure no other mutations were introduced during the 
cloning process.  Primers are listed in Table 3.3.  
 
Transfections, Drug Treatment and Immunoblotting 
293H cells (Invitrogen) were transfected using Lipofectamine 2000 (Invitrogen).  
After 24hr (BRAF V600E, PAPSS1, PAPSS1-BRAF) or 48hr (TRIM24-BRAF), cells 
were serum-starved for 6hr then treated with vehicle (DMSO), PLX4032/vemurafenib 
(Chemietek), or GSK1120212/trametinib (Chemietek) for 2hr.  Cells were then lysed 
using standard RIPA buffer supplemented with protease and phosphatase inhibitors. 
Lysates were quantified and subjected to SDS-PAGE and immunoblot analysis using 
antibodies against the following targets:  phospho-MEK1/2 (Ser217/221), total-MEK1/2, 
phospho-ERK1/2 (Thr202/Tyr204), total-ERK1/2, BRAF and FLAG. All antibodies were 
purchased from Cell Signaling except for anti-BRAF (C-terminal, SantaCruz) and anti-
FLAG (Sigma-Aldrich). 
 
BRAF Fusion Detection and Reverse Phase Protein Array (RPPA) Analysis from 
TCGA Data 
Raw RNA, whole genome, and whole exome sequencing files from TCGA 
(n=266, skin cutaneous melanoma dataset) were downloaded and raw reads spanning 
exon 7 (chr7:140500162-140500281) through exon 12 (chr7:140477791-140477875) of 
BRAF were extracted from indexed .bam files (SAMtools, (166)).  Upon manual 
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Table 3.3.  Cloning Primers 
Primer Name: # Bases: Sequences (5'-->3') 
EcoRI-PAPSS1_Fwd 45 GCCGCCGAATTCGCCGCCACCATGGAGATCCCCGGGAGCCTGTGC 
EcoRI_PAPSS1_Rev 37 CGGCGGGAATTCCTAAGCTTTCTCCAAGGATTTGTAG 
EcoRI-
PAPSS1_FLAG_Rev 72 
CGGCGGGAATTCCTACTTGTCATCGTCGTCCTTGTAGTCAGCTTTCTCCAAGGATTTGTAGTATTCTG
TCAG 
PAPSS1-BRAF_Fwd 45 CTTCTACAGGAACGGGACTTGATTAGAGACCAAGGATTTCGTGGT 
PAPSS1-BRAF_Rev 45 GTCTCTAATCAAGTCCCGTTCCTGTAGAAGTTCCACAACTTGCTG 
EcoRI-BRAF_Rev 40 CGGCGGGAATTCTCACTTGTCATCGTCGTCCTTGTAGTCG 
NheI-TRIM24_Fwd 45 GCCGCCGCTAGCGCCGCCACCATGGAGGTGGCGGTGGAGAAGGCG 
TRIM24-BRAF_Fwd 45 TCCATCTCTCATCAGGACTTGATTAGAGACCAAGGATTTCGTGGT 
TRIM24-BRAF_Rev 45 GTCTCTAATCAAGTCCTGATGAGAGATGGAAGGTTGCTGGATGGG 
NotI-BRAF_Rev 42 CGGCGGGCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCG 
Text Color Code: 
Black = Restriction enzyme “landing pad” 
Purple = Restriction enzyme sequence 
Red = PAPSS1 sequence 
Blue = BRAF sequence 
Green = Kozak or FLAG sequence 
Orange = TRIM24 sequence 
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inspection, two potential BRAF fusions in SNaPshot “pan-negative” patients were 
identified (TAX1BP1-BRAF and CDC27-BRAF, Figure 3.5a&b).  Level 3 processed 
RPPA and mutation data were accessed via the Broad Institute TCGA Genome Data 
Analysis Center (2013), skin cutaneous melanoma (primary and metastatic solid tumor 
cohort).  Samples evaluated for both mutation and RPPA (N=200), were merged and 
plotted (beeswarm, R package) according to mutation status (Figure 3.5c). 
 
Nomenclature 
Exon numbering was determined using the following transcripts for each protein:  
BRAF: NM_004333; PAPSS1: NM_005443; TRIM24: NM_015905. 
 
 
 
 
 
 
 
 
 
 
85 
 
CHAPTER IV 
 
ERBB activation modulates sensitivity to MEK1/2 inhibition 
in a subset of driver-negative melanomas 
 
 
 
Adapted from:  Hutchinson, K.E., Johnson, D.B., Johnson, A.S., Sanchez, V., Kuba, M., 
Lu, P., Chen, X., Kelley, M., Wang, Q., Zhao, Z., Sosman, J.A., Pao, W. (2014) ERBB 
activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative 
melanomas.  Manuscript in preparation. 
 
 
INTRODUCTION 
Malignant melanoma is comprised of molecular subsets characterized by 
constitutively activating “driver” mutations in the serine-threonine kinase BRAF (codon 
V600), the GTPase NRAS (G12, G13, and Q61), the receptor tyrosine kinase KIT 
(W557, V559, L576, K642, and D816), and the Gα GTPases GNAQ (Q209) and GNA11 
(Q209) (40-44).  Importantly, all of these mutations have been shown to activate the 
mitogen-activated protein kinase (MAPK) signaling pathway.  Some of these drivers, 
notably BRAF V600E and KIT kinase domain mutations, are associated with high 
sensitivity to targeted BRAF (vemurafenib, dabrafenib) or KIT (neratinib, imatinib) small-
molecule inhibition, respectively (77-81, 83, 89).  In addition to BRAF-specific inhibition 
with vemurafenib and dabrafenib, the MEK1/2 inhibitor trametinib was also approved in 
2013 for BRAF V600-mutant melanoma (97, 98, 100, 101).  The optimum treatment for 
other subsets, including NRAS-, GNAQ- or GNA11-mutant melanomas, remains to be 
determined.  
Despite the exciting advances in targeted treatment for melanoma, up to one- 
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third of tumors are negative for any of these driver mutations, herein called “pan-
negative”.  Because they have no identifiable drug target, treatment options for these 
patients are extremely limited.  Apart from standard chemotherapy, “targeted” 
immunotherapies such as ipilimumab (anti-cytotoxic T-lymphocyte antigen-4 / anti-
CTLA-4) and anti-programmed death-1 / programmed death 1-ligand 1 (anti-PD-1 / PD-
L1), are an emerging treatment for both driver-positive and –negative melanomas.  
While promising, efficacy is not uniform (107, 111, 113).  More recently, in melanomas 
previously considered pan-negative for common driver mutations, we identified non-
V600 BRAF mutations at codons L597 and K601 (150), and BRAF fusions (200).  
Importantly, both alterations activate the MAPK pathway and the induced signaling 
confers sensitivity to MEK1/2 inhibition.  As a result of these studies, MEK1/2 inhibitors 
are being evaluated for use in the BRAF non-V600-mutant and BRAF fusion subsets 
through an ongoing, multicenter Phase II clinical trial (NCT02296112).  Taken together, 
these data suggest that the majority of melanoma signaling processes involve the 
MAPK pathway.   
Current evidence suggests that many pan-negative melanoma cell lines are 
sensitive to MEK1/2 inhibitors without a known molecular basis (201, 202). Based on 
these observations, and because the majority of currently known driver mutations in 
melanoma revolve around MAPK pathway activation, an open question is whether all 
pan-negative melanomas could be treated with MEK1/2 inhibitors.  Here, we 
investigated this issue by examining the sensitivity of a panel of 16 pan-negative 
melanoma cell lines to trametinib. Collectively, our study is the first to investigate varied 
responses to MEK1/2 inhibition in pan-negative melanoma and suggests that 
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differences in ERBB activation and DUSP4 expression in this subset may modulate 
responses.  In the future, these studies may lead to novel clinical trials involving 
pharmacological inhibition of ERBB family members in combination with established 
MEK1/2 inhibitors in otherwise untreatable melanoma. 
 
RESULTS 
Pan-Negative Melanomas Display Differential Sensitivity to MEK1/2 Inhibition 
To determine whether there are differences in sensitivity of pan-negative 
melanomas to MEK1/2 inhibition, we treated an initial collection of six pan-negative 
melanoma cell lines (Appendix Table A4.1) with the clinically-available MEK1/2 
inhibitor, trametinib, and determined the average IC50 for each in comparison to a well-
described BRAF V600E-mutant melanoma line, SK-Mel-28.  Interestingly, we observed 
two distinct responses. Three pan-negative lines were highly sensitive to trametinib with 
IC50’s relatively similar to SK-Mel-28 and well below the Cmax for trametinib (36.1nM, 
(99)).  The other three pan-negative lines exhibited IC50’s at or above the Cmax of 
trametinib (Figure 4.1a).  When we investigated MAPK pathway signaling in these six 
cell lines following treatment with trametinib, the lines less sensitive to trametinib 
displayed paradoxical activation of MEK1/2 (Figure 4.1b and Appendix Figure A4.1).  
To distinguish between the two groups, we herein termed the two MEK1/2-inhibitor 
response groups as Class I and Class II, respectively.   
Paradoxical MEK1/2 activation following treatment with a MEK1/2 inhibitor has 
been reported previously in the setting of a RAS mutation (203, 204), a BRAF V600 
mutation and concurrent MEK1 mutation (205) or BRAF amplification and MEK2 
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Figure 4.1. Pan-Negative Melanomas Display Differential Sensitivity to MEK1/2 
Inhibition.  (A) IC50s for a panel of 6 pan-negative melanoma lines and one BRAF V600E 
line to trametinib were determined by standard growth inhibition assays with increasing 
concentrations of drug.  Class I cells display IC50’s well below the trametinib Cmax and 
similar to that of the V600-mutant line; Class II lines exhibit IC50s above the trametinib 
Cmax.  (B) Paradoxical activation of MEK1/2 is observed in Class II cells upon trametinib 
treatment. nM, nanomolar; tra, trametinib; p, phosphorylated.  The p-value was calculated 
using Student’s T-test, assuming unequal variance. 
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mutation (206, 207) (Appendix Table A4.2).  Targeted next-generation sequencing 
(Vanderbilt Cancer Panel for MiSeq, refer to Appendix 4 Materials and Methods 
and Appendix Table A4.3) did not detect any RAS mutations (NRAS, KRAS or HRAS) 
or MEK1 and 2 mutations in the six pan-negative melanoma cell lines (Appendix Table 
A4.4).  Moreover, although RAS activity in both classes was slightly less than that of an 
NRAS-mutant cell line, we observed no significant difference in RAS activity between 
the two pan-negative groups of cells (Appendix Figure A4.2).   
 
Class II Pan-Negative Melanoma Lines Exhibit Active ERBB Receptors 
A previous study of cancer cells not specific to melanoma reported paradoxical 
activation of MEK1/2 upon MEK1/2 inhibition in a BRAF-/NRAS-wild-type setting, citing 
that signaling in these cells is regulated by receptor tyrosine kinases (RTKs) (208) 
(Appendix Table A4.2).  Therefore, we investigated the RTK status of Class I and II 
lines by commercial phosphorylated RTK array and immunoblotting analysis.  The 
phospho-RTK array indicated that all lines exhibited some degree of low-level EGFR 
activity (Appendix Figure A4.3a), but only Class II lines displayed activation of 
HER2/ERBB2 and HER3/ERBB3 receptors.  Subsequent immunoblotting analysis 
confirmed that only Class II lines exhibit endogenous levels of phosphorylated EGFR, 
HER2 and HER3 receptors (Figure 4.2a).  There were no stark differences in 
expression of total EGFR, HER2 and HER3 between Class I and II cells, though Class II 
cells may harbor slightly increased levels of these proteins (Appendix Figure 4.3b). 
ERBB-phosphorylated Class II lines also displayed elevated levels of phosphorylated 
AKT, suggesting that Class II cells may be dependent on not only MAPK pathway 
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 Figure 4.2.  Class II Pan-Negative Melanoma Lines Exhibit Active ERBB Receptors and 
are Sensitive to ERBB Kinase Inhibition.  (A)  Immunoblotting analysis reveals that only 
Class II pan-negative cells express endogenously phosphorylated EGFR, HER2 and HER3, 
in addition to phospho-AKT.  All cells were cultured in the presence of serum.  (B)  After 6 
days of proliferation in vehicle (DMSO), 50nM trametinib, 50nM afatinib, or the combination, 
only the Class II lines are sensitive to single-agent afatinib.  Additionally, the combination is 
more effective at inhibiting proliferation of Class II cells than either single agent.  (C) 
Immunoblotting analysis of Class I and II cells following treatment with DMSO, 50nM 
trametinib, 50nM afatinib or the combination shows that phosphorylation of EGFR, HER2, 
HER3 and AKT is diminished upon afatinib treatment, but only the combination abolishes 
signaling of both AKT and ERK1/2 in these lines. afat, afatinib; nM, nanomolar; p, 
phosphorylated; tra, trametinib. 
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signaling, but also the PI3K/AKT pathway. 
 
Class II Pan-Negative Melanoma Lines are Sensitive to EGFR Small-Molecule 
Inhibition 
Because Class II lines demonstrated active EGFR, HER2 and HER3, we 
examined their potential sensitivity to the ERBB-targeting small molecule inhibitors, 
afatinib (irreversible, inhibits EGFR>HER2>HER3) and lapatinib (reversible, inhibits 
HER2>EGFR). Cell viability and proliferation analyses confirmed that only Class II lines 
were sensitive to afatinib and lapatinib administration, whereas Class I cells were 
resistant to either agent (afatinib, Figure 4.2b, Appendix Figures 4.4a, 4.4b; 
lapatinib, data not shown).  Additionally, treatment with single-agent afatinib ablated 
AKT phosphorylation in Class II lines (Figure 4.2c).     
To determine whether Class II cells would be more sensitive to combined 
inhibition of the ERBBs and MEK1/2, we administered both afatinib and trametinib to the 
Class II cells.  While a minimal added effect was observed on cell viability (Appendix 
Figures 4.4a, 4.4b), the combination enhanced inhibition of proliferation in Class II 
cells, while no added effect was observed in Class I cell proliferation (Figure 4.2b).  
Furthermore, combined inhibition of ERBBs and MEK1/2 attenuated both AKT and 
ERK1/2 phosphorylation, causing a slight increase in levels of the pro-apoptotic protein, 
BIM, in Class II cells (Figure 4.2c). 
   
ERBB and AKT Activation Status May Predict Sensitivity to MEK1/2 Inhibition  
To determine the frequency of ERBB activation in pan-negative melanomas, we 
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expanded our cohort to 10 additional pan-negative lines (16 total) from various 
institutions (Appendix Table A4.1).  Interrogating the phospho-ERBB status of these 10 
lines by immunoblot analysis revealed one additional line (WM3918) with clearly active 
EGFR, HER2 and HER3 (Figure 4.3a).  None of the additional lines were sensitive to 
afatinib (Figure 4.3b).  Five of the added lines (WM-Mel-36, WM3928F, M375, D35, 
MM329) displayed a Class I phenotype in that they were highly sensitive to trametinib 
(IC50 << trametinib Cmax) but exquisitely resistant to afatinib, indicating that 8 of 16 
(50%) of pan-negative melanomas were Class I-like.  Clustering of the cells analyzing 
expression of phosphorylated ERBBs 1, 2, and 3 and phosphorylated AKT as observed 
by immunoblot across the 16 cell lines (Figure 4.3c) revealed that Class I-like lines with 
high sensitivity to MEK1/2 inhibition displayed very little to no phosphorylated ERBBs or 
AKT. For Class II-like lines (i.e. considered less sensitive to MEK1/2 inhibition), the 
three lines that display definite ERBB phosphorylation as well as AKT phosphorylation 
(CHL-1, HMCB, MeWo) were the only lines that were sensitive to afatinib.  In contrast, 
the high phospho-EGFR-expressing line, WM3918, which did not respond to afatnib, did 
not display activated AKT, suggesting that Class II-like cells depend on ERBB-activated 
signaling not exclusive to the MAPK pathway.  The other Class II-like lines (WM1382, 
VP-Mel-20, VP-Mel-21) exhibited no phospho-ERBBs but had high or intermediate 
activation of AKT.  Notably, two lines (VP-Mel-20 and WM3681) were susceptible to 
neither ERBB nor MEK1/2 inhibition, indicating that these lines may be dependent on 
other, as yet undetermined, signaling pathways and may represent an additional subset 
of pan-negative melanoma.  In summary, 8 of 16 (50%) of cell lines displayed a Class I 
phenotype.  Of the lines with decreased sensitivity to MEK1/2 inhibition (Class II
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Figure 4.3. ERBB and AKT Activation Status May Predict Sensitivity to MEK1/2 Inhibition.  (A) Immunoblotting analysis of 
10 additional pan-negative melanoma lines reveals that phosphorylated ERBB and AKT status is variable, with one additional line 
(WM3918) exhibiting obvious ERBB activity.  (B) Summary of growth inhibition assay-derived IC50’s for the 16 pan-negative 
melanoma lines (including Class I and II lines) and a BRAF V600-mutant line (SK-Mel-28, for comparison) to afatinib and 
trametinib.  (C) A clustering analysis of the expression of phospho-EGFR/HER2/HER3 (pERBB) and phospho-AKT by immunoblot 
in (A) reveals differences between Class I-like and Class II-like pan-negative melanomas. afat, afatinib; nM, nanomolar; p, 
phosphorylated; tra, trametinib. 
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phenotype), ERBB activity was observed in 4 of these 16 lines (25%), and 3 (18.8% of 
total) were sensitive to afatinib.  Because ~30% of melanomas are currently considered 
pan-negative, one could extrapolate that ~6% of all melanomas are Class II-like. 
 
Lack of DUSP4 is a Potential Mechanism for ERBB Activation in Class II 
Melanomas 
RTK-activated cancers, unlike BRAF V600E-activated cancers, may harbor lower 
levels of the ERK1/2 phosphatase, DUSP4 (208).  To determine whether this was the 
case in Class II pan-negative melanomas, we analyzed the six original Class I & II cells 
by immunoblot analysis and observed DUSP4 expression existed primarily in Class I 
cells, whereas Class II cells harbored little to no DUSP4 expression (Figure 4.4a).  
Immunohistochemical analysis of BRAF-mutant, NRAS-mutant and pan-negative 
patient melanomas revealed a wide distribution of DUSP4 expression in each subtype, 
but a trend toward lower overall DUSP4 expression in the pan-negative subset (Figure 
4.4b).  RNA sequencing analysis of DUSP4, EGFR, HER2 and HER3 expression in 
pan-negative melanomas genotyped through The Cancer Genome Atlas (TCGA) 
revealed an inverse relationship between DUSP4 and EGFR expression (Appendix 
Figure A4.5).  Interestingly, when DUSP4 was restored in Class II cells, EGFR and 
HER3 activation was diminished by 48 hours (Figure 4.4c).   
Once activated, ERK1/2 can serve as a transcriptional co-regulator of various 
proteins, including ERBB ligands (209).  Since DUSP4 negatively regulates ERK1/2 
activity, ERK1/2-mediated transcription of ERBB ligands may be altered between Class 
I and II cell lines.  Therefore, we examined whether Class II cells secreted higher levels
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 Figure 4.4. Lack of DUSP4 is a Potential Mechanism for ERBB Activation in Class II Melanomas.  (A) Immunoblot analysis of 
DUSP4 expression in Class I and II pan-negative melanomas reveals that Class II melanomas express little or no DUSP4 compared 
with Class I melanomas.  (B) Plot of H-scores for immunohistochemistry against DUSP4 in 15 BRAF-mutant, 17 NRAS-mutant and 42 
pan-negative melanomas on a patient tissue microarray (TMA) reveals a wide distribution of DUSP4 expression in all three subsets, but 
a trend toward lower overall DUSP4 expression in the pan-negative group.  (C) Restoring DUSP4 expression in Class II melanoma lines 
by adenovirus infection leads to a reduction in active EGFR and HER3.  (D) By protein array, amphiregulin (AREG) levels are higher in 
Class II melanomas compared with Class I melanomas, which was confirmed by ELISA, shown here.  Serum-free media and 
conditioned media from HCT116 cells were used as negative and positive controls, respectively.  The p-value was calculated by 
Student’s T-test assuming unequal variances.  (E) Restoring DUSP4 in Class II cells decreases the expression of AREG in MeWo and 
HMCB Class II cell lines.  The p-value was calculated by Student’s T-test assuming equal variances. adv, adenovirus; ctrl, control; p, 
phosphorylated; SF media serum-free media
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of ERBB ligands compared to Class I cells.  Analysis of conditioned media for four of 
seven ERBB ligands (epidermal growth factor, EGF; heparin-binding epidermal growth 
factor, HB-EGF; heregulin / neuregulin β1, HRG / NRGβ1; amphiregulin, AREG) by 
protein array revealed potentially higher levels of HB-EGF and AREG in Class II cells 
(Appendix Figure 4.6a, 4.6b).  Subsequent enzyme-linked immunosorbent assays 
(ELISAs) for HB-EGF and AREG confirmed upregulation of AREG while no clear 
difference in HB-EGF expression was revealed (Figure 4.4d, Appendix Figure 4.6c).  
In addition to suppressing ERBB activity, DUSP4 restoration in Class II cells decreased 
AREG expression in two of the three Class II cell lines (Figure 4.4e).  These data 
suggest that a potential mechanism of constitutive ERBB activation in Class II cells may 
be associated with lower levels of DUSP4, which allows for ERK1/2-mediated 
transcription of ERBB ligands. 
 
DISCUSSION 
The identification of MAPK-pathway activating driver mutations in BRAF, NRAS, 
KIT, GNAQ and GNA11 in melanoma has revolutionized the treatment of this disease 
beyond standard chemotherapy to include targeted, small-molecule inhibitors such as 
vemurafenib, dabrafenib, imatinib, nilotinib and trametinib.  Unfortunately, only two-
thirds of patients harbor these drivers leaving the remaining one-third of “pan-negative” 
patients with no targeted treatment option.  Since melanoma is widely considered to be 
dependent on MAPK pathway signaling for its growth and survival, we set out to 
determine if there are subsets of pan-negative melanoma that display differential 
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sensitivities to MAPK pathway inhibition in order to ultimately identify novel molecular 
targets.   
We ascertained that there are two possible MEK1/2-inhibitor response “classes” 
within pan-negative melanomas (Table 4.1, Figure 4.5):  Class I pan-negative 
responders behave like BRAF V600-mutant cells in that they are highly sensitive to 
MEK1/2 inhibition and downregulation of phosphorylated MEK1/2 and ERK1/2 is 
observed.  Class II pan-negative responders, however, are less sensitive to MEK1/2 
inhibition and display paradoxical activation of MEK1/2 upon treatment.  These pan-
negative melanomas did not harbor mutations in MEK1 or 2 (205-207), nor did they 
display increased RAS activity (203, 204), both of which are implicated in previous 
citings of paradoxical MEK1/2 activation upon MEK1/2 inhibition, specifically in the 
BRAF V600-mutant setting (Appendix Table A4.2).  Another study, however, alluded 
that tumors driven by receptor tyrosine kinases (RTKs) would exhibit paradoxical 
MEK1/2 activation after MEK1/2 inhibition (208).  Interestingly, only the less MEK1/2-
inhibitor sensitive Class II pan-negative responders displayed basal activation of EGFR, 
HER2 and HER3 (Figure 4.2).  Importantly, we show that Class II cells respond well to 
the EGFR>HER3>HER2 inhibitor, afatinib, and combining afatinib with trametinib elicits 
even greater effects on proliferation and signaling than either single agent (Figure 
4.2b,c).  We also reveal that a potential mechanism of heightened ERBB activity in 
Class II pan-negative melanomas is the relative lack of DUSP4 expression, a negative 
regulator of ERK1/2 (Figure 4.4).  By restoring expression of DUSP4 in these cells, 
both amphiregulin (AREG) expression and ERBB activity is diminished (Figure 4.4c, 
4.4e).  Consistent with our in vitro data, analysis of tissue microarrays and RNA 
98 
 
Table 4.1.  Summary of BRAF V600-mutant and Pan-Negative 
(PN)Class I and II Phenotypes 
Trametinib Response Class BRAF V600E
PN 
Class I
PN 
Class II 
Immuno- 
Blot 
pMEK1/2 ↓ ↓ ↑ 
pERK1/2 ↓ ↓ ↓ 
Growth 
Inhibition 
Assay 
vemurafenib S R R 
trametinib S S I 
ERBB Activation No No Yes 
ERBBi Sensitivity No No Yes 
DUSP Expression Yes Yes No 
% of Pan-Negatives n/a 50% 18.8% 
% of all melanomas ~40% ~15% ~6% 
↓, decrease in activity; ↑, increase in activity; S, sensitive; R, resistant; I, 
intermediate sensitivity; ERBBi, ERBB inhibitor 
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 Figure 4.5.  Summary of Class I and Class II Pan-Negative Melanomas.  (A) Class I pan-negative melanomas are primarily driven by 
the MAPK pathway and express generally robust levels of the ERK1/2 phosphatase, DUSP4, but have no endogenously active ERBB 
receptors.  Class I melanomas behave similarly to BRAF V600-mutant melanomas in that they are highly sensitive to MEK1/2 inhibition. 
(B) Class II pan-negative melanomas are activated by ERBB receptors, which activate both MAPK and PI3K/AKT signaling, making 
them less susceptible to MEK1/2 inhibition than Class I melanomas, but more susceptible to combined inhibition of ERBBs and MEK1/2.  
A potential mechanism for the ERBB activity in Class II’s is the relative lack of DUSP4 expression, presumably allowing ERK1/2-
mediated transcription of ERBB ligands such as amphiregulin (AREG).  (C) This pie chart displays the breakdown of driver events that 
sustain melanoma.  Our study has shown that 4 pan-negative melanomas display ERBB activation (25%), but only 3 of those (18.8%) 
were sensitive to ERBB inhibition which can be extrapolated to ~6% of all melanomas.  Studies are ongoing to determine the exact 
driver of these tumors. 
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sequencing expression data from The Cancer Genome Atlas (TCGA) revealed a wide 
distribution of DUSP4 expression in pan-negative samples (Figure 4.4b) and an inverse 
relationship between DUSP4 and EGFR expression (Appendix Figure A4.5).   
Interrogation of a larger panel of pan-negative melanoma cell lines revealed the 
potential for other mechanisms of MEK1/2 inhibitor response and non-response (Figure 
4.3).  In addition to our original group of three Class II cell lines, we identified another 
Class II-like line with ERBB activation, WM3918.  Although WM3918 is Class II-like in its 
response to trametinib, unlike the other Class II lines with ERBB activity, WM3918 did 
not respond to afatinib.  This indicates that WM3918 may be dependent on other, as yet 
unidentified, signaling pathways in addition to the MAPK pathway.  Furthermore, the 
pan-negative lines VP-Mel-20 and WM3681 were resistant to both MEK1/2 and ERBB 
inhibition, once again suggesting the existence of additional subsets of melanoma 
dependent on other signaling pathways.  Studies are ongoing to determine the 
pathway(s) and mechanism(s) that distinguish these melanomas from our proposed 
Class I / Class II model.   
Activation of receptor tyrosine kinases (RTKs) through mutation (15-17, 210-213) 
or amplification/overexpression (187, 214-217) represent major hallmarks of cancers 
such as lung and breast, but are not considered an intrinsic characteristic of melanoma.  
Generally, upregulation of RTKs has been cited as the cause of acquired resistance to 
RAF inhibitors in BRAF V600-mutant melanoma (218-222). Therefore, our study is the 
first to define a potential role for ERBB activity in pan-negative melanoma and how that 
activity might modulate therapeutic responses, specifically to MEK1/2 inhibitors, in this 
subset.  Our data reveal, unsurprisingly, that not all melanomas are equally sensitive to 
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MEK1/2 inhibition.  Clinically, it is possible that the less sensitive tumors (i.e. Class II) 
would either not respond to MEK1/2 inhibition, or have a shortened duration of 
response.  Our observation of endogenous ERBB activity and resultant sensitivity to 
ERBB inhibition in 3 of 4 Class II-like pan-negative lines advocates for the use of ERBB 
inhibitors in this disease, potentially in combination with MEK1/2 inhibitors.   
In 2011, Patel and colleagues published the results of a Phase II trial 
investigating the use of gefitinib, an EGFR TKI, on an unselected melanoma population 
of 48 patients (223).  Although the median progression-free and overall survival figures 
were 1.4 and 9.7 months, respectively, there were two partial responders (4%) with a 
medium duration of response of 10.9 months.  For comparison, the median progression-
free survival of BRAF V600-mutant patients on vemurafenib is 6.8 months (78).  
Therefore, it is possible that these two “exceptional responders” were Class II-like, 
harboring activated EGFR and possibly, active AKT.  In the future, by selecting the right 
patients for ERBB inhibitor therapy, not only may the response and survival rates 
improve, but we may also define further mechanisms for ERBB activation and inhibitor 
response or resistance in melanomas currently considered as pan-negative.   
In line with these endeavors, it will be important to determine the appropriate 
clinical test by which to identify Class II patients.  Because this phenotype is not 
represented by a single driver mutation (point mutation, insertion, deletion, etc), it is 
necessary to identify an assay that detects changes in protein levels between tumor and 
normal.  Next-generation whole-genome or RNA sequencing analyses are certainly 
capable, however, are not only time-consuming but also costly, especially if only 
investigating for one or two targets.  Immunohistochemical (IHC) methods, both 
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traditional and quantitative (224), may be more suitable.  Because an inverse 
relationship between total EGFR and DUSP4 expression was observed in TCGA RNA 
sequencing data (Appendix Figure A4.5) samples could be analyzed for total levels of 
EGFR and DUSP4.  Our in vitro data, however, demonstrated clear differences between 
phosphorylated ERBBs and DUSP4, while differences between Class I and II total 
levels of EGFR/HER2/HER3 were relatively inconclusive (Appendix Figure 4.3b). 
Unfortunately, IHC for phosphorylated proteins is unreliable.  Mass cytometry (a.k.a. 
CyTOF) alternatively has several advantages over traditional IHC methods.  Not only 
does mass cytometry allow for highly quantitative, single-cell analyses of either a few or 
several targets, but it is also useful for phospho-protein analyses (225). Furthermore, 
mass cytometry has the ability to analyze live, single-cell suspensions as well as image 
whole fixed tissues.  Ideally, CyTOF could be used to compare the levels of 
phosphorylated ERBBs, phosphorylated AKT, and total DUSP4 levels in tumor and 
matched normal samples from each patient.   
In summary, we have identified a subset of pan-negative melanoma with reduced 
sensitivity to MEK1/2 inhibition that is mediated by an ERBB activation / DUSP4 
expression axis supported by patient tissue microarray and RNA sequencing analyses 
for DUSP4 and EGFR.  Interrogating a large number of pan-negative melanoma cell 
lines for ERBB activity and sensitivity to trametinib or afatinib revealed that this Class II 
phenotype potentially represents 18.8% of pan-negative melanomas, or ~6% of all 
melanomas.  Studies are ongoing to determine additional mechanisms of modified 
response to MEK1/2 and ERBB inhibition in pan-negative melanoma. 
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MATERIALS AND METHODS 
Cell Lines 
The sources and culturing conditions of all 16 pan-negative melanoma lines are 
listed in Supplementary Table S1.  Fetal bovine serum (FBS) was heat-inactivated 
(Atlanta Biologicals) and the penicillin-streptomycin solution was at a final concentration 
of 100U/mL penicillin and 100μg/mL streptomycin (Mediatech).  RPMI-1640 (Mediatech 
#MT10040CV), DMEM (Gibco/Life Technologies #11965). SK-Mel-28 was provided 
through MTA with Christine Pratilas (Memorial Sloan-Kettering Cancer Center) to 
Kimberly Dahlman (Vanderbilt) and cultured in DMEM + 10% FBS + 1% pen/strep.  
Wistar Institute cell lines were cultured in a solution of 4 parts MCDB-153 media 
(Sigma, #M7403) to 1 part Leibovitz’s L-15 medium (Gibco/Life Technologies, #11415-
064) and also containing 2% FBS, 1% pen/strep, 5ug/mL bovine insulin (Sigma # 
I5500), and 1.68 mM calcium chloride (VWR #97062-586).  The HCT116 colorectal 
cancer cell line was kindly provided by Robert Coffey (Vanderbilt) and cultured in RPMI 
+ 10% FBS + 1% pen/strep.  VP-Mel cell lines were derived from patient melanomas; 
patients gave consent for the use of their tissue under VICC-MEL0287.  All cells were 
tested in-house for mycoplasma contamination and confirmed to be negative.  
Additionally, all melanoma cell lines were subjected to the Vanderbilt SNaPshot assay 
for melanoma, described previously (30) and updated to include BRAF L597Q 
(c.1790T>A), R (c.1790T>G), and S (c.1789_1790CT>TC) and BRAF K601E 
(c.1801A>G), to confirm genotype. 
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Antibodies 
Phospho-EGFR (Y1068) was from Abcam (ab40815).  Total-EGFR was from BD 
Biosciences (#610017).  Actin was from Sigma (#A2066).  The following antibodies 
were from Cell Signaling:  Phospho-antibodies against EGFR Y845 (#2231), HER2 
Y1248 (#2247), HER2 Y1221/1222 (#2243), HER3 Y1197 (#4561), HER3 Y1289 
(#4791), MEK1/2 S217/221 (#9154), AKT S473 (#4060), ERK1/2 T202/Y204 (#9101); 
total antibodies against DUSP4 (#5149), Bim (#2819), HER2 (#2242), HER3 (#4754), 
MEK1/2 (#9126), AKT (#9272), ERK1/2 (#9102). 
 
Drugs / Adenovirus / siRNA 
Trametinib (GSK1120212) was from Chemietek.  Afatinib was synthesized by the 
Organic Synthesis Core Facility at Memorial Sloan-Kettering Cancer Center under the 
direction of Ouathek Ouerfelli.  DUSP4 adenovirus was described previously (226) and 
kindly provided by Justin Balko (Vanderbilt). Pooled small interfering RNA’s against 
HER3 (SMARTpool: ON-TARGETplus ERBB3 siRNA) and a pooled scrambled control 
(On-TARGET plus non-targeting siRNA pool) were from Dharmacon (L-003127-00-0005 
and D-001810-10-05, respectively). 
 
Growth Inhibition Assays 
Cells were seeded at 3,000 cells per well of a 96-well plate.  Following 4- or 5- 
day treatment with DMSO or increasing doses of drug in sextuplicate, Cell Titer Blue 
reagent (Promega) was added to each well and fluorescence was measured as per 
manufacturer’s instructions on a BioTek microplate reader. 
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Immunoblotting 
All cells were lysed on ice using standard RIPA buffer (50mM Tris-HCl, pH 7.5; 
150mM NaCl; 1% IGEPAL/NP-40 substitute; 0.1% SDS) and supplemented with 
protease and phosphatase inhibitors (Roche Complete Mini Protease Inhibitor cocktail 
tablet, EDTA-free, used as per manufacturer’s instructions; 40mM sodium fluoride; 1mM 
sodium orthovanadate; 1μM okadaic acid). Cells were not allowed to reach >85-90% 
confluence before harvesting.  Lysates were quantified by Bradford assay and 
subjected to SDS-PAGE on 4-12% Bis-Tris gels (Invitrogen/Life Technologies).  
Following transfer to PVDF membranes, immunoblot analysis was performed using 
antibodies against the indicated targets.  Membranes were incubated in 
chemiluminescent reagents (Perkin Elmer) and exposed to film for signal detection. 
 
DUSP4 adenovirus infection 
Cells were plated evenly into 6-cm dishes in serum-containing media.  The 
following day, media was replaced with a solution of 1.5μL of a control GFP adenovirus 
or DUSP4-containing adenovirus, 500μL of serum-free media, and 50uL of 1M HEPES 
solution (25mM final concentration).  Plates were rocked every 15 minutes for 1 hr.  
Finally, 1.5 mL serum-containing media was added to each plate (total volume ~2mL).  
24 hr after adenovirus infection, cells were treated with DMSO or 50nM trametinib for 24 
hr.  Cells were harvested for immunoblotting or serum-free conditioned media was 
harvested for ELISAs as described in other sections.   
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Enzyme-linked immunosorbent assays (ELISAs) 
One day following even seeding into 6-cm dishes, serum-containing culture 
media was replaced with serum-free culture media.  After 48hr, the conditioned media 
was harvested, spun at 4˚C to pellet loose cells/debris, and used as per manufacturer’s 
instructions for the HB-EGF and AREG ELISAs (Abcam, ab100531 and ab99975, 
respectively). 
 
Tissue Microarray (TMA) Immunohistochemistry for DUSP4 
The melanoma TMA was created using formalin-fixed, paraffin-embedded tissues from 
17 BRAF-mutant (14 V600E, 3 V600K), 17 NRAS (15 Q61, 1 G12 and 1 G13) and 49 
pan-negative melanoma patients seen at Vanderbilt.  All patient tissues were reviewed 
for ≥50% tumor content and assessed using the Vanderbilt melanoma SNaPshot assay 
(30) to confirm mutation status.  Immunohistochemistry was performed for DUSP4 (Cell 
Signaling #5149) as described previously (226) according to the following parameters: 
antigen retrieval using citrate buffer, pH 6.0 (decloaking chamber); dilution of 1:400; 
overnight incubation at 4 °C; and the Envision Visualization System from Dako. Tumor 
regions stained for nuclear DUSP4 were assessed using a four value intensity scale (0 
to 3) and percentage extent (0 to 100%). The H-score was calculated by summing the 
products of both parameters (range 0-300).  The Wilcoxon Rank Sum Test was used to 
compare H-scores among the three genotypic groups. 
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CHAPTER V 
 
Conclusions and Future Directions in Pan-Negative Melanoma 
 
INTRODUCTION 
 Recurrent, activating driver mutations in BRAF, NRAS, KIT, GNAQ and GNA11 
are present in ~70% of all melanomas and primarily activate the mitogen-activated 
protein kinase (MAPK) pathway (40-44).  Furthermore, a number of these drivers confer 
sensitivity to small-molecules such as vemurafenib (BRAF V600 mutations) (77, 78) or 
imatinib (KIT mutations) (84).  Unfortunately, however, ~30% of patient tumors harbor 
none of these well-defined driver alterations and are ineligible for targeted inhibition 
strategies.  Therefore, the objectives of the work described in Chapters II-IV were to 
identify novel candidates for targeted inhibition in pan-negative melanoma as well as 
modifiers of response to MEK1/2 inhibition in this disease subset.   
 
Atypical BRAF Mutations Summary and Future Directions 
In Chapter II, through whole-genome sequencing (WGS) of a tumor-normal pair 
from a patient with metastatic melanoma, we identified a BRAF L597R mutation.  
Because codon L597 is only three amino acids away from the highly activating driver 
mutation, BRAF V600E(/K/M/R/D), and a variant of L597R (L597V) was previously 
shown to elicit BRAF kinase activity (42), we hypothesized that the BRAF L597R 
mutation would activate the MAPK pathway and confer sensitivity to RAF or MEK1/2 
inhibitors.  In vitro characterization of BRAF L597R confirmed that this mutation indeed 
activates the MAPK pathway, however, signaling induced by the mutation is more 
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responsive to MEK1/2 inhibition (trametinib) than BRAF inhibition (vemurafenib).  Our 
data are supported by a clinical case in which a patient with an analogous BRAF L597S 
mutation responded readily to the MEK1/2 inhibitor, TAK-733.  BRAF exon 15 
sequencing of an additional cohort of pan-negative melanomas revealed that non-V600 
BRAF exon 15 mutations may comprise 8% of the pan-negative subset (150). 
As a direct result of this study, a multicenter phase II clinical trial has been 
initiated to evaluate the efficacy of the MEK1/2 inhibitor, trametinib, in metastatic 
melanomas expressing these non-V600 BRAF exon 15 alterations (NCT02296112). It is 
too early to provide preliminary results at this time, however, this study should allow for 
determination of the sensitivity of such alterations to MEK1/2 inhibitors in patients. 
 
BRAF Fusions in Melanoma Summary and Future Directions 
 In Chapter III, targeted next-generation sequencing analysis using the 
FoundationOneTM assay (Foundation Medicine, Incorporated (Cambridge, 
Massachusetts)) identified a BRAF fusion (PAPSS1-BRAF) in a second patient with 
pan-negative disease.  Analysis of additional pan-negative samples and RNA 
sequencing data from The Cancer Genome Atlas (TCGA) revealed the existence of 
three additional BRAF fusions, suggesting a potential frequency of 4-8% in the pan-
negative population.  Like BRAF fusions identified in other cancer types, the serine-
threonine kinase domain of BRAF remains intact, while the negative-regulatory RAS-
binding domain is lost.  Like non-V600 BRAF exon 15 mutations, we showed that the 
BRAF fusions we identified can activate the MAPK pathway and that signaling induced 
by the fusions is responsive to MEK1/2 inhibition (200).  Furthermore, our data provide 
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evidence of the need to expand the capabilities of current clinical genotyping platforms 
to include fusion detection.  Since the publication of our manuscript (200), the list of 
novel BRAF fusions in this cancer type has grown.  Table 5.1 details 10 additional 
BRAF fusions identified in pan-negative melanomas genotyped by Foundation 
Medicine, Inc. platforms.  In 2013, Botton and colleagues identified 7 additional BRAF 
fusions in melanocytic tumors (227); in 2014, Wiesner, et al., not only reported 
additional BRAF fusions, but also identified fusions involving the kinases ROS1, ALK, 
NTRK1 and RET (228).  Only a few of these fusions harbored the same 5’-fusion 
partner (AGK-BRAF).  In all cases, the negative-regulatory RAS-binding domain (RBD) 
of BRAF is removed, leaving an intact serine-threonine kinase domain.  However, in our 
studies, we observed that not all of the fusions were expressed equally, nor did they 
elicit the same level of MAPK pathway activity.  This suggests 5’ fusion partners may 
differentially influence expression, possibly through their transcriptional promoters.  
These differences may also influence response to MEK1/2 inhibition.  These are 
important basic biological details that should be the focus of future studies. 
 Botton, Wiesner, and colleagues also observed that the majority of BRAF fusions 
occur in tumors displaying Spitzoid morphology (227, 228).  Pathological review of the 
two BRAF fusions in our study (PAPSS1-BRAF and TRIM24-BRAF) as well as the 
more-recently identified BRAF fusion tumors listed in Table 5.1, revealed that BRAF 
fusions do appear to be enriched in tumors with Spitzoid morphology (personal 
communication with Jeffrey S. Ross, Medical Director, Foundation Medicine, Inc.).  
Based on these findings, perhaps prioritizing tumors that are morphologically Spitzoid 
for comprehensive fusion genotyping would be a more efficient approach to identify
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Table 5.1.  Twelve Additional Melanomas Genotyped by Foundation Medicine, Inc., Harboring BRAF Fusions   
Sample Histology Fusion BRAF exons Depth of Coverage 
1 Unknown primary melanoma AGAP3-BRAF 9-18 23 
2 Skin melanoma AGK-BRAF* 8-18 40 
3 Unknown primary melanoma AGK-BRAF* 8-18 12 
4 Unknown primary melanoma AKAP9-BRAF** 10-18 49 
5 Unknown primary melanoma CUX1-BRAF 9-18 1027 
6 Skin melanoma DYNC1I2-BRAF 10-18 6 
7 Unknown primary melanoma MZT1-BRAF 11-18 168 
8 Skin melanoma PAPSS1-BRAF*** 9-18 15 
9 Unknown primary melanoma SLC12A7-BRAF 11-18 79 
10 Skin melanoma TRIM24-BRAF*** 9-18 200 
11 Unknown primary melanoma ZKSCAN1-BRAF 10-18 167 
12 Unknown primary, melanoma ZNF767-BRAF 11-18 216 
Courtesy of Jeffrey S. Ross, Medical Director at Foundation Medicine, Inc. 
*AGK-BRAF previously cited in a case of Spitzoid melanoma (Botton, et al., Pigment Cell Melanoma Res, 2013 (227)) 
**AKAP9-BRAF was cited in a case of thyroid cancer (Ciampi, et al., J Clin Invest, 2005 (174)) 
***Reported in our publication, Hutchinson et al., Clinical Cancer Res, 2013 (200) 
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likely BRAF fusion candidates. 
Finally, in addition to the non-V600 BRAF exon 15 alterations, tumors harboring 
BRAF fusions will also be evaluated for sensitivity to trametinib in the phase II clinical 
trial (NCT02296112).  As described above, future pre-clinical studies should attempt to 
address the significance of the various BRAF 5’ fusion partners toward each fusion’s 
ability to induce MAPK pathway signaling; clinically, the trial data may provide 
correlative evidence of each partner’s ability to impact tumor sensitivity to trametinib. 
 
ERBB Activation in Pan-Negative Melanoma Summary and Future Directions 
Finally, because the majority of well-known melanoma drivers and the BRAF 
mutations and fusions we identified herein all activate the MAPK pathway, in Chapter IV 
we investigated potential modifiers of response to MEK1/2 inhibition in pan-negative 
melanoma.  We identified two classes of MEK1/2-inhibitor responders, which we have 
termed Class I and Class II.  Class I pan-negatives are highly sensitive to MEK1/2 
inhibition, and Class II pan-negative responders are less sensitive to MEK1/2 inhibition.  
Subsequent analyses evaluating phosphorylated receptors revealed that Class II pan-
negative cell lines harbor baseline activation of the ERBB receptors EGFR, HER2 and 
HER3, making these cells reliant on ERBB-mediated signaling.  Furthermore, these 
cells are sensitive to ERBB inhibition, which can be enhanced upon combination with a 
MEK1/2 inhibitor.  A potential mechanism of ERBB activation in Class II cells could be 
the relative lack of the ERK1/2 inhibitor, DUSP4, compared with Class I cells.  We show 
that a lack of DUSP4 may allow for ERK1/2-mediated transcription of ERBB ligands 
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such as amphiregulin and restoring DUSP4 in Class II cells decreases amphiregulin 
expression. 
Our results also revealed that pan-negative melanomas may be driven by other 
pathways as well.  Specifically, one cell line (WM3918), although it displayed activated 
EGFR, HER2 and HER3, was unresponsive to ERBB inhibition.  Unlike the Class I 
MEK1/2 inhibitor responders CHL-1, MeWo and HMCB, AKT was not activated in this 
cell line.  Further investigation will be needed to identify the pathway upon which this 
cell line is primarily dependent.  Additionally, unlike all other pan-negative cell lines we 
assayed, and uncharacteristic of melanoma, two cell lines were exquisitely resistant to 
MEK1/2 inhibition (VP-Mel-20 and WM3681).  Again, further investigation is required to 
uncover the pathway or pathways driving melanomas like these. 
 Melanoma is generally not thought to be driven by receptor kinases other than 
KIT.  However, our findings provide rationale for the clinical use of ERBB inhibitors in 
this disease.  As mentioned in Chapter IV, a phase II trial of the EGFR inhibitor, 
gefitinib, was largely unsuccessful, likely because the study was conducted in a 
population unselected for a particular genotype.  Two patients, however, exhibited a 
durable response (223).  Therefore, these two studies support the idea that tumors 
should be screened to identify patients with elevated levels of ERBBs to appropriately 
assign therapy, as we already do with established driver mutations and respective 
targeted agents.   
As described in Chapter IV, next-generation sequencing (NGS) or 
immunohistochemical (IHC) methods might be useful to screen for “Class II” tumors, 
however, NGS is prohibitively expensive if only screening for a handful of targets and 
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IHC is unreliable when assaying for phosphorylated proteins.  In this case, the most 
appropriate screening technique may be mass cytometry, or, CyTOF.  Not only can 
CyTOF assess phosphorylation, but this method can also assess live cells.  This 
capability would be ideal for rapid clinical analysis.   
 
The Future of Research in Pan-Negative Melanoma 
Collectively, our findings have advanced the understanding of potential drivers 
and inhibition strategies in pan-negative melanoma.  Regardless, nearly one-third of 
melanoma patients are still pan-negative with no known druggable target (Figure 5.1).  
To uncover other potential targets, we performed a cross-analysis of 241 tumor-normal 
pairs from recent next-generation sequencing efforts in melanoma (229).  The genes 
that were mutated in >10% of pan-negative tumors included a number of kinases (ALK, 
STK31, EPHA4 and 7, ERBB4, KDR/VEGFR2), a GTPase (RAC1) and a tumor 
suppressor (NF1).  ALK (anaplastic lymphoma kinase) rearrangements are common in 
non-small-cell lung cancer (NSCLC) and confer sensitivity to inhibitors such as crizotinib 
(20, 230).  None of the alterations identified in these tumors were rearrangements; 
however, a handful of ALK kinase domain mutations (R1212H, E1197K, G1286K) are 
predicted to have a high functional impact ((231) mutationassessor.org) and may result 
in constitutive kinase activity.  Although a number of studies have identified 
overexpression of or alterations in STK31 (serine-threonine kinase 31) (232-235), 
EPHA4 (ephrin receptor A4) (236, 237), EPHA7 (ephrin receptor A7) (238, 239), a clear 
role for these proteins and their variants is currently poorly understood.  KDR/VEGFR2 
is rarely overexpressed in melanoma (240), however, the kinase domain alterations 
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Figure 5.1.  Molecular Subsets of Melanoma Before and After Our Studies.  These pie 
charts represent the percentage distribution of known melanoma driver alterations in all 
anatomical subsets prior to (A) and after (B) the studies outlined in this work. 
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identified in our analysis may lead to increased angiogenesis.  Recurrent ERBB4 (241) 
and RAC1 (242, 243) alterations have been previously cited in melanoma.  In both 
cases, these mutations elicited constitutive kinase (ERBB4) or GTPase (RAC1) activity 
and increased proliferation in transduced melanoma lines. 
As addressed in the primary Introduction section of this work, NF1 loss or 
deleterious truncation and splice mutations have been recently associated with 
resistance to RAF inhibition in BRAF V600-mutant melanoma (71-73).  According to 
TCGA, NF1 mutations occur in a significant 13% of melanomas, not only overlapping 
with BRAF alterations, but also co-occurring with NRAS drivers or occurring in pan-
negative melanomas (cBio Portal for Cancer Genomics / TCGA).  In the cohort of 52 
melanomas genotyped by Foundation Medicine, Inc. (see Chapter III), we determined 
that NF1 mutations are actually enriched in pan-negative tumors or tumors with non-
V600 BRAF exon 15 mutations (Figure 5.2, Table 5.2).  Notably, retrospective analysis 
of the BRAF L597R patient in Chapter II (150) revealed that this patient’s tumor 
additionally harbored two NF1 alterations (L79X and E2409X).  In our experience, these 
atypical BRAF alterations are often less activating than BRAF V600E (42, 150).  
Therefore, we hypothesize that added loss of NF1 function is necessary to elicit full 
RAS-mediated activity of the MAPK and PI3K/AKT pathways in these tumors.  Similarly, 
we do not yet know the biological impact of a single NF1 mutation in a pan-negative 
tumor.  Likely, these mutations overlap with as-yet unidentified, mutated signaling 
molecules.  These hypotheses should therefore be the focus of future studies. 
The role of immunotherapy in pan-negative melanoma should also be addressed.  
Because these tumors have no identifiable small-molecule drug target, standard
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Figure 5.2.  52 Melanomas Genotyped by FoundationOneTM Including NF1 Alterations.  Schematic of the mutation 
distribution in 52 patient melanomas genotyped by the FoundationOneTM assay.  Each column of boxes indicates a single patient, 
where green boxes indicate the presence of a mutation in BRAF, NRAS, KIT, GNAQ, GNA11, and/or NF1 and grey boxes indicate 
lack of mutation(s).  Cases with V600E/K BRAF mutations, non-V600 BRAF mutations, BRAF fusions and certain NRAS 
mutations are indicated.  Specific mutations for each case can be found in Table 5.2. 
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Table 5.2.  52 Melanomas from Various Institutions Genotyped by FoundationOneTM, Including NF1 Alterations 
  Sample Information Commonly Mutated Genes Other 
  
Name Gender Age Stage Site          (if not skin) 
Median 
Sequencing 
Deptha 
BRAF NRAS KIT GNAQ GNA11 NF1 
D
r
i
v
e
r
-
P
o
s
i
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 
FM-Mel1 M 46 IV   589 V600E Q61L         
FM-Mel2 M 85 IV   1012 V600E           
FM-Mel3 F 51 III   1155 V600E           
FM-Mel4 M 48 IV   1341 V600E           
FM-Mel5 F 43 IV   1550 V600E           
FM-Mel6 M 62 III   1833 V600E           
FM-Mel7 F 74 III   1102 V600K           
FM-Mel8 M 56 IV   1255 V600K         V2050_G2052del 
FM-Mel9 F 35 IV   1360   Q61K         
FM-Mel10 M  83 IV   1684   Q61K         
FM-Mel11 F 76 III   1054   Q61L         
FM-Mel12 M 65 III   1623   Q61L         
FM-Mel13 M 56 IV   1276   Q61R         
FM-Mel14 M 71 IV   1012   Q61R         
FM-Mel15 M 42 IV   924   Q61R         
FM-Mel16 F 71 n/a   1445   Q61R         
FM-Mel17 F 57 IV   673   Q61R         
FM-Mel18 M 65 IV Uveal/Occular 956       Q209P     
FM-Mel19 M 40 IV Uveal/Occular 1703       Q209P     
FM-Mel20 M 71 IV   743         Q209L   
FM-Mel21 F 44 IV Uveal/CNS 808         Q209L   
FM-Mel22 F 32 IV   1416 D594N         E1790* 
FM-Mel23 M 78 IV   1809 G469S           
FM-Mel24 M 63 IV   1104 G469V         Q1070* 
FM-Mel25 F 55 IV   1023 K601E/amp           
FM-Mel26 M n/a III   872 L597Q         Q2239* 
FM-Mel27 M 71 IV   1602 L597R         Q2239* 
FM-Mel28 M 83 IV   1779 T599_V600insT           
P
a
n
-
N
e
g
a
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 FM-Mel29 F 59 IV   775 TRIM24-BRAF           
FM-Mel30b F 27 III   1207 PAPSS1-BRAF           
FM-Mel31 n/a n/a n/a   1417           E1192*/V34fs*4 
FM-Mel32 F 54 IV   1568           H2261fs*4 
FM-Mel33 M n/a IV   1116           loss 
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P
a
n
-
N
e
g
a
t
i
v
e
 
M
e
l
a
n
o
m
a
s
 
FM-Mel34 M 73 IV   1232           loss 
FM-Mel35 F 50 IV   961           Q1341*/Y1422fs*1 
FM-Mel36 M 62 IV   1240           Q2531*/Q803* 
FM-Mel37 M 54 IV   1032           Q684* 
FM-Mel38 F 44 IV   1477             
FM-Mel39b F 22 n/a   1364             
FM-Mel40 F 68 IV   793             
FM-Mel41 F 41 IV   1547             
FM-Mel42 M 46 III   220             
FM-Mel43 F 54 IV   966             
FM-Mel44 F 70 III  254             
FM-Mel45 F 55 IV   1196             
FM-Mel46 M 52 IV   1342             
FM-Mel47 M 44 IV   1665             
FM-Mel48 M 61 IV Anal 1128             
FM-Mel49 F 50 IV   1463             
FM-Mel50 M 38 IV   1396             
FM-Mel51 F 67 IV   807             
FM-Mel52b M 58 IV Uveal/Occular 1226             
aMedian Sequencing Depth refers to the median number of unique reads covering each base in the targeted genomic regions. 
bCases from Vanderbilt-Ingram Cancer Center 
n/a – not available 
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chemotherapy and immunotherapy are the only viable treatment options in such 
patients.  However, responses are not uniform (107, 111, 113).  In a phase I study of 
the anti-PD-1 antibody, BMS-036558, Topalian and colleagues performed 
immunohistochemistry for PD-L1 on 18 melanomas.  Of the 15 melanomas that stained 
positive for PD-L1 expression, 5 patients exhibited partial response to therapy and one 
had a complete response (40%).  Although this is not a perfect correlation, not one of 
the patients with PD-L1 negative tumors displayed clinical responses (113).  
Importantly, patients were unselected for genotype in this study.  Thus, it is likely that 
several of these tumors harbored canonical driver alterations which may have 
attenuated immunotherapy response.  Along these lines, an ongoing phase I trial will 
evaluate combination dabrafenib and ipilimumab, with or without trametinib, in 
metastatic BRAF V600-mutant melanomas (NCT01767454).  Since we have shown that 
melanoma is generally MAPK-pathway driven, for pan-negative melanomas, MEK1/2 
inhibition combined with immunotherapy may be a rational treatment option in future 
investigations.  Additional clinical trials are currently evaluating anti-CTLA4 and anti-PD-
L1/PD-1 immunotherapies as a concurrent combination or sequentially in both BRAF 
V600-mutant and unselected melanoma populations (NCT01024231, NCT01783938).  
Future studies should evaluate targeted therapy/immunotherapy and 
immunotherapy/immunotherapy combinations specifically in pan-negative melanoma.   
An alternative method to identify factors that may correlate with sensitivity to 
immunotherapy would be to perform genome-wide studies on tumors from exceptional 
responders to this class of therapy.  For example, a recent study in the New England 
Journal of Medicine performed whole-exome sequencing (WES) on melanomas from 
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patients treated with ipilimumab or tremelimumab (anti-CTLA4 agents) to assess for 
somatic neoantigens.  Importantly, patients that benefitted from anti-CTLA4 therapy 
displayed a distinct neoantigen signature compared with patients that did not respond 
these therapies (244).  Although additional studies are required to validate these results, 
this same approach could be applied to patient tumors receiving anti-PD-1/PD-L1 
therapies.  Eventually, these signatures could be used to predict which patients would 
likely benefit from immunotherapy. 
 
SUMMARY 
 Collectively, we have identified novel drivers of melanoma that predict response 
to targeted therapies such as MEK1/2 inhibitors (atypical BRAF mutations and BRAF 
fusions).  Similarly, we have also identified modifiers of response to MEK1/2 inhibition 
(ERBB activation), that confer sensitivity instead to other targeted agents.  These 
studies have led to novel clinical trials in this disease, but despite our efforts, a large 
proportion of melanoma patients are still considered pan-negative without a druggable 
target.  Two areas of further investigation in pan-negative disease are to delineate the 
significance of deleterious NF1 alterations in pan-negative melanomas and to further 
ascertain a role for immunotherapy in this subset, either as a single agent, or in 
combination with other targeted therapies and/or immunotherapies. 
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CHAPTER VI 
 
Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies 
recurrent RAF fusions and frequent inactivation of DNA repair genes 
 
 
 
Adapted from:  Chmielecki, J.*, Hutchinson, K.E.*, Frampton, G.M., Chalmers, Z.R., 
Johnson, A., Shi, C., Elvin, J., Ali, S.M., Ross, J.S., Basturk, O., Balasubramanism, S., 
Lipson, D., Yelensky, R., Pao, W., Miller, V.A., Klimstra, D.S., Stephens, P.J. (2014) 
Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies 
recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov. 
*co-first authors 
 
 
 
INTRODUCTION 
Compared to pancreatic ductal adenocarcinoma (PDAC), pancreatic acinar cell 
carcinomas (PACCs) tend to occur at a younger age, affect a disproportionate number 
of males, and exhibit distinct morphologic and immunohistochemical properties (126, 
131, 245). Median overall survival (14-38 months) is improved with surgical resection, 
but few patients achieve durable responses from chemotherapy and/or radiation (128, 
131). Unlike other solid tumors in which targeted therapies against matched molecular 
aberrations have proven superior to chemotherapy (26), few such targets have been 
identified in PACC. Studies investigating the genomics of  PACC have observed 
activation of the β-catenin pathway, broad chromosomal gains and losses 
encompassing multiple genes, and somatic inactivation of tumor suppressor genes (e.g. 
SMAD4, RB1, BRCA2 and TP53) (126, 129, 144, 146).  Whole exome sequencing 
(WES) identified rare mutations in BRAF, GNAS, and JAK1, suggesting that a subset of 
PACCs may be driven by well-characterized oncogenic events.  However, these 
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alterations occur in a small proportion of tumors, and overarching genomic themes have 
yet to be elucidated. 
Therefore, to identify potentially actionable mutations in PACC, we herein 
performed comprehensive genomic profiling of the largest series of PACCs to-date 
(n=44).  From this effort, we identified recurrent rearrangements involving BRAF and 
RAF1 (CRAF) in ~23% of tumors and inactivation genomic alterations (GAs) in DNA 
repair genes (45%) in non-fusion tumors.  These alterations have been associated with 
sensitivity to MEK1/2 inhibitors and DNA damaging agents, respectively, in other cancer 
types.  Collectively, these results provide a rationale for using personalized therapies in 
this disease. 
 
RESULTS 
Identification of RAF Fusions in Pancreatic Acinar Cell Carcinomas 
We performed comprehensive genomic profiling of 44 PACCs, including closely 
related mixed acinar carcinomas (16 pure PACC, 14 mixed acinar/neuroendocrine, 6 
mixed acinar/ductal, 2 mixed acinar/neuroendocrine/ductal, and 6 samples with 
incomplete histological analysis), using next-generation sequencing (NGS)-based 
platforms (32, 33). DNA was analyzed for base substitutions, insertions/deletions, copy 
number alterations, and select rearrangements (Appendix Tables A6.1 and A6.2); 
eleven samples had sufficient material for broad fusion detection using targeted RNA-
sequencing (Table 6.1, Appendix Table A6.2). The resulting analysis identified 
rearrangements involving BRAF or RAF1 in 10 samples of mixed and pure histology 
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Sample DNA or DNA/RNA
pERK 
IHC BRAF RAF1 BRCA1 BRCA2 ATM MSH2 MLH1 RAD50 BRIP1 FANCA PALB2 NRAS KRAS EGFR STK11 MET NF1 PTEN TSC2 RPTOR CTNNB1 APC TP53 SMAD4 CDKN2A CDKN2B RB1 PRKAR1A
1 DNA Focal V600_K601>E - - - - - - - - - - - - - - - - - - - - - - - deletion deletion - -
2 DNA Focal fusion: SND1 (ex 1-9) + BRAF (ex 9-18) - - - - - - - - - - - - - - - - - - - - - G262V - deletion deletion - -
3 DNA Pos fusion: SND1 (ex 1-14) + BRAF (ex 11-18) - - - - - - - - - - - - - - - - - - - - - - - deletion deletion - -
4 DNA Pos fusion: GATM (ex 1-2) + BRAF (ex 11-18) - - - - - - - - - - - - - - - - - - - - - - R361H deletion deletion - -
5 DNA n/a fusion: SND1 (ex 1-10) + BRAF (ex 9-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
6 DNA Pos fusion: SND1 (ex 1-10) + BRAF (ex 11-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
7 DNA n/a fusion: SND1 (ex 1-10) + BRAF (ex 9-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
8 DNA n/a fusion: SND1 (ex 1-14) + BRAF (ex 9-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
9 DNA/RNA Pos fusion: HERPUD1 (ex 1-4) + BRAF (ex 7-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
10 DNA/RNA Pos fusion: ZSCAN30 (ex 1-3) + BRAF (ex 10-18) - - - - - - - - - - - - - - - - - - - - - - - - - - -
11 DNA/RNA Pos - fusion: HACL1 (ex 1-16) + RAF1 (ex 8-17) - - - - - - - - - - - - - - - - - - - - - - - - - -
12 DNA Neg - - splice - - - - - - - - - - - - - splice, x2 - - - - - H214R - - - - -
13 DNA Neg - - E1250fs*8 - - - - - - - - - - - - - - - - - - - S90fs*30 - - - - -
14 DNA/RNA Neg - - E23fs*17 - - - - - - - - - - - - - - - - - - - - - - - - -
15 DNA Neg - - W1508* - - - - - - - - - - - - - - - - - - - - - - - - -
16 DNA/RNA Pos - - - R1512H - - splice K722fs*14 - - - Q61R - - - - - - - - - - P152fs*18 - - - - -
17 DNA/RNA Neg - - - R3128* - - - - - - - - - - - - - - - amplification G34E - - - - - - -
18 DNA n/a - - - S1982fs*22, Q1987fs*7 - - - - - - - - - - - - - - - - - - - - - - splice -
19 DNA Neg - - - N1706fs*5 - - - - - - - - - - - - - - - - - - - L364* - - - -
20 DNA n/a - - - R645fs*15 - - - - - - - - - - - - - - - - - - - splice, truncation - - - -
21 DNA/RNA Neg - - - S1951fs*11 - - - - - T266M - - - - - - - - - - - - - - - - - -
22 DNA Focal - - - N433fs*18 - - - - - - - - - - - - - - - - - - - - - - R251* -
23 DNA n/a - - - R645fs*15, L659fs*6 - - - - - - - - - - - - - - - - - - Y220H - - - - -
24 DNA Neg - - - W563fs*10 - - - - - - - - - V765M - - - - - - - - - - - - - -
25 DNA Neg - - - - R309fs*8 - - - - - - - - - - - - - - - - - R110H E538* deletion deletion - deletion
26 DNA Neg - - - - E2139* - - - - - - - - - - - - S229* - - - - - - - - - M331fs*14
27 DNA n/a - - - - R189K - - - - - - - - - - - splice - - - - - - - - - I244fs*6 E272*
28 DNA/RNA Neg - - - - - R680* - - - - - - - - - T263M - - D359fs*28 - - - R213* - - - A74fs*4 -
29 DNA Neg - - - - - deletion - - - - - - - - - - - - - - - - - - - - H483fs*12 -
30 DNA/RNA Neg - - - - - - - - N196S - - - - - - - - - - - - R213fs*39 G108_F109>V - - - - -
31 DNA Pos - - - - - - - - - - S254fs*3 - - - - - - - - - - - - L201fs*38 deletion deletion - -
32 DNA Pos - - - - - - - - - - - Q61R - - - - - - - - - - - - - - - -
33 DNA/RNA Pos - - - - - - - - - - - - G12D - - - - - - - - - - - - - - -
34 DNA Neg - - - - - - - - - - - - - - S216F - - - - - - - - - - - - -
35 DNA Neg - - - - - - - - - - - - - - E165* - - - - - - - - - - - - -
36 DNA Neg - - - - - - - - - - - - - - - - deletion - - - - - - - - - - deletion
37 DNA Neg - - - - - - - - - - - - - - - - - L318fs*6 - - - - C135F - - - - -
38 DNA Neg - - - - - - - - - - - - - - - - - M35V, G36V - - - - - - - - - -
39 DNA Neg - - - - - - - - - - - - - - - - - - - - - - - - - - - -
40 DNA n/a - - - - - - - - - - - - - - - - - - - - G34R - - - - - - -
41 DNA n/a - - - - - - - - - - - - - - - - - - - - D32Y - - Q249fs*87 - - - -
42 DNA Neg - - - - - - - - - - - - - - - - - - - - - - L330fs*15 - - - - -
43 DNA Neg - - - - - - - - - - - - - - - - - - - - - - - - - - - -
44 DNA/RNA Neg - - - - - - - - - - - - - - - - - - - - - - - - - - - splice
Table 6.1.  Genomic alterations across selected targets. See Figure 6.5 for additional details.
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(23%) that were mutually exclusive with activation of other known oncogenes. The 
structure of these fusions closely resembled that of published RAF fusions in other 
cancers (178, 181, 200). Six variants of a recurrent SND1-BRAF fusion were observed 
in 5 unique samples resulting from an inversion on chromosome 7 that juxtaposed the 5’ 
region of SND1 to the complete kinase domain of BRAF  (Figure 6.1a). In all variants, 
intact highly twisted thermonuclease domains within SND1 are predicted to faciliate 
dimerization and activation of the downstream BRAF kinase domain (246).  A survey of 
our internal database of ~15,000 samples identifed this fusion in only one carcinoma of 
unknown primary origin, suggesting that SND1-BRAF is highly enriched in PACC. Rare 
SND1-BRAF fusions have been reported in lung adenocarcinomas (n=3), and as a 
mechanism of acquired resistance to MET inhibition in a single gastric cancer cell line 
(179, 247).  We also identified in our PACCs 3 similar, but non-recurrent, novel BRAF 
fusions resulting from translocations between BRAF (chr7) and HERPUD1 
(homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain 
member 1 protein) (chr16), ZSCAN30 (zinc finger and SCAN domain containing protien 
30) (chr19) or GATM (Glycine amidinotransferase) (chr15) (Figure 6.1b). Finally, a 
chromosome 3 inversion produced an HACL1 (2-hydroxyacyl-CoA lyase 1)-RAF1 fusion 
that harbored an intact RAF1 kinase domain (Figure 6.1c). RNA-seq confirmed 
expression of the novel HERPUD1-BRAF, ZSCAN30-BRAF, and HACL1-RAF1 fusion 
transcripts; all the observed RAF fusions were in-frame and predicted to result in 
functional protein products. While RAF fusions have been reported in multiple other 
diseases (178, 181, 200), to our knowledge, this is the first report of their role in 
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Figure 6.1.  Structure of BRAF and RAF1 Fusions. (A) SND1-BRAF results from a 
chromosome 7 inversion encompassing ~12.6Mb that juxtaposes the 5’ end of SND1 with the 
3’ end of BRAF (top).  Arrows indicate the direction of transcription for each gene.  Five 
variants of SND1-BRAF were identified in six pancreatic acinar cell carcinomas (bottom); 
SND1 exons 1-10 fused to BRAF exons 9-18 was observed in two independent samples.  (B) 
Three BRAF fusions involving translocations between chromosome 7 and chromosomes 16, 
19, and 15 were identified in three independent samples.  (C) A RAF1 fusion resulting from a 
chromosome 3 inversion was observed in a single sample.  Complementary DNA (cDNA) 
sequences surrounding the breakpoints are highlighted below each fusion; corresponding 
protein translations are annotated using single letter abbreviations.  Protein diagrams are 
drawn to scale. ex, exon; TN-thermonuclease domain. 
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pancreatic cancer. Furthermore, these fusions represent a highly recurrent GA in 
PACC. 
 
Biological Activity of RAF Fusions 
 To understand better the oncogenic potential of the SND1-BRAF fusion, we 
engineered cells expressing the recurrent variant of this fusion protein (SND1 exons 1-
10; BRAF exons 9-18). Analysis of protein lysates from these 293H transfectants 
confirmed constitutive activation of the MAPK pathway, as evidenced by 
phosphorylation of MEK1/2 and ERK1/2 at key signaling residues (Figure 6.2a). This 
activity was similar in degree to that induced by BRAF V600E, a hyperactive version of 
this protein. MAPK pathway activation could be abrogated by treatment of these cells 
with the MEK1/2 inhibitor trametinib, to a lesser a degree by the pan-RAF inhibitor TAK-
632, and minimally by the multi-kinase inhibitor sorafenib (Figure 6.2b). Oncogenic 
potential of the fusion was assessed using Ba/F3 cells, which are dependent on 
interleukin-3 (IL-3) for survival unless transformed by an oncogene. Similar to other 
kinase fusions, expression of SND1-BRAF in Ba/F3 cells was transforming and 
conferred IL-3 independence (Figure 6.2c). Consistent with the biochemical 
characterization, treatment of SND1-BRAF transformed Ba/F3 cells with trametinib 
resulted in marked growth inhibitory effects whereas TAK-632 inhibited growth to a 
lesser extent, and sorafenib had no effect (Figure 6.2d). These biochemical and growth 
inhibitory findings were confirmed in an independent gastric cell line (GTL.16.903.R1) 
harboring an acquired SND1-BRAF fusion (Figure 6.3) (179). 
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 Figure 6.2.  Biochemical Properties of SND1-BRAF.  (A) Immunoblotting of lysates from 293H cells transfected with empty 
vector or plasmids encoding BRAF V600E or SND1-BRAF demonstrate that the BRAF fusion activates the MAPK pathway.  (B) 
MAPK pathway activity induced by BRAF V600E or SND1-BRAF can be inhibited most potently by MEK inhibition (trametinib), 
and to a lesser degree by RAF inhibition (TAK-632 or sorafenib).  Cells were treated with 0, 0.1, 0.5, 1, and 5 μmol/L of each drug 
for 2 hours.  (C) Ba/F3 cells stably transfected with BRAF V600E or SND1-BRAF display IL-3 independence and sustained 
proliferation.  (D) Growth of SND1-BRAF-dependent Ba/F3 cells is inhibited by the MEK inhibitor, trametinib (tra), and to a lesser 
degree by TAK-632 (TAK); growth was uninhibited by treatment with sorafenib (sor). Par-parental, vec-vector, wt-wildtype. 
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Figure 6.3.  MET-Inhibitor Resistant, SND1-BRAF Fusion-Containing GTL16 Cells are Sensitive to Trametinib.  (A) 
Immunoblotting of lysates from GTL16.903.R1 cells following 10 hours of treatment with DMSO, the MET inhibitor crizotinib (criz), 
the RAF inhibitors sorafenib (sor) and TAK-632 (TAK), or the MEK1/2 inhibitor trametinib (tra) confirm resistance to MET inhibition 
and demonstrate dimunition of MAPK pathway activity upon treatment with trametinib.  (B) Similarly, GTL16.903.R1 cell growth is 
inhibited by trametinib.  GTL16.903.R1 represents GTL16 gastric adenocarcinoma cells derived to be resistant to the MET 
inhibitor PF-04217903, resistant clone 1; kDa, kilodalton; sor and soraf, sorafenib. 
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 We next performed immunohistochemical (IHC) staining for phosphorylated ERK 
(pERK), a readout for MAPK pathway activation, on 35 samples for which additional 
material was available (Table 6.1). Of the fusion positive samples (n=10), 7 had 
sufficient material for IHC analyses. Six of these samples (86%) stained strongly 
positive for pERK; one sample (14%) showed focal staining (Figure 6.4). Of the 28 
fusion negative samples with material available for IHC, 4 samples stained positive for 
pERK, and 2 showed focal staining. Activating events in the MAPK pathway (NRAS 
Q61R x2, KRAS G12D, and BRAF V600_K601>E) were likely responsible for this result 
in 4 samples.  In two positive cases, the mechanism for positive or focal pERK staining 
could not be explained by the genomic alterations (GAs) identified. The remaining 22 
cases were negative for pERK staining. 
 
Additional Genomic Alterations in Signaling Proteins 
Broad analysis of recurrent cancer-related GAs in PACC revealed a unique 
genomic landscape compared to other subtypes of pancreatic cancer (Figure 6.5 and 
Figure 6.6).  Whereas over 90% of PDACs harbor activating mutations in KRAS, we 
observed only a single KRAS mutation in a mixed acinar/neuroendocrine tumor (Figure 
6.5b). Compared to PDACs, we observed  a lower frequency of tumors with GAs in 
SMAD4 (14% versus  55%),  CDKN2A (14% versus 90%), and TP53 (23% versus 
75%), but a higher frequency of BRCA2 mutations (20% versus 7-10%) in PACCs 
(Figure 6.5b) (142, 248). PACCs can display neuroendocrine features; we observed a 
lower frequency of MEN1 mutations (7% versus 44%), and similar frequencies of NF1 
alterations (7% versus 6%)  compared to pancreatic neuroendocrine tumors (142, 249). 
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Figure 6.4.  Representative Immunohistochemical Staining for Phosporylated ERK1/2.  
(A) Representative phosphorylated ERK1/2 (pERK1/2)-negative sample with no staining 
observed in neoplastic cells; positive nuclear and cytoplasmic labeling (left) is observed in 
reactive myofibroblasts and adjacent stroma.  (B) Representative pERK1/2-positive sample 
with the majority of neoplastic cells displaying intense nuclear and cytoplasmic labeling.  
Scale bar, 300μm. 
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Figure 6.5. Genomic Landscape of PACC.  (A) Long tail plot across 31 genes that were 
recurrently altered in this sample set.  (B) See next page for figure.   Co-occurrence of 
select genomic alterations and pathway deregulation across all tumors (n=44).  Each vertical 
column represents one tumor.  Colors correspond to the different mechanisms through which 
the DNA sequence was affected.  Samples with mixed components are denoted in type.  
Tumors characterized as “unknown” denote cases where complete histological work-up was 
unavailable and the presence of a mixed phenotype was unclear from the limited 
pathological information (see Materials and Methods).  See also, Table 6.1. 
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 Figure 6.5 (B) Figure legend on previous page. 
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 Figure 6.6.  Non-Fusion Genomic Alterations in PACC.  Diagrams of select DNA repair 
(BRCA1, BRCA2), Wnt pathway signaling (CTNNB1), MAPK pathway signaling (STK11) 
proteins and other tumor-suppressors and oncogenes (TP53, PRKAR1A, RB1, SMAD4) 
altered in PACC.  Important functional domains are indicated in the legend for each protein 
and mutations are denoted in vertical black text.  Diagrams are continued on the following 
page. 
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 Figure 6.6.  Continued from previous page. 
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Rare mutations in GNAS were also identified (5%; n=2) in pure acinar samples, and 
have been implicated previously in pancreatic intraductal papillary mucinous neoplasms 
(250). Infrequent alterations in Wnt/β-catenin pathway genes (CTNNB1 and APC, 10%), 
RB1 (11%), and mutations in BRAF (2%) have been described previously in small 
cohorts of PACCs (126, 129).  Loss-of-function alterations in PRKAR1A  were observed 
in  11% of cases, including mixed and pure histologies. Germline mutations in in 
PRKAR1A  are associated with Carney complex and an increased lifetime risk of acinar 
neoplasms (251); however, clinical data available for 4 of 5 patients whose tumors 
harbored these alterations confirmed the absence of this syndrome. Therefore, germline 
or somatic PRKAR1A alterations may contribute to tumorigenesis of PACCs.  
 
Inactivating Genomic Alterations in DNA Repair Genes 
Inactivating GAs (i.e. truncations, homozygous deletions, and known deleterious 
point mutations) in DNA repair genes were observed in 45% of PACCs, including mixed 
and pure histologies (Figure 6.5b and Figure 6.6). These alterations were significantly 
enriched in “fusion negative” tumors, and were mutually exclusive with RAF GAs 
(p=1.2x10-8, Fisher’s exact test). Although BRCA1/2 alterations have been linked to an 
increased risk of PDAC, they have been described only rarely in PACC (252). 
Alterations in BRCA1, ATM, MSH2, BRIP1, and PALB2 were mutually exclusive with 
other GAs in this pathway. Regardless of their germline or somatic status, deficiencies 
in DNA repair contribute to tumorigenesis in almost half of PACCs. We also identified 
alterations in multiple other signaling pathways that overlapped heavily with DNA repair 
defects and/or RAF alterations (Figure 6.5b). Alterations in MAPK, Wnt, and PI3K 
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pathways were mutually exclusive with RAF alterations, however, they overlapped with 
samples harboring DNA repair deficiencies. 
 
DISCUSSION 
The findings presented herein have immediate clinical impact for PACC patients 
with the potential to significantly influence treatment of this disease. While no specific 
inhibitors exist for BRAF fusions, anecdotal clinical data have shown anti-tumor effects 
of sorafenib in combination with either chemotherapy or bevacizumab plus temsirolimus 
against similar BRAF fusions in solid tumors (253, 254). Our in vitro data suggest that 
trametinib is superior to either TAK-632 or sorafenib against SND1-BRAF-harboring 
cells (Figure 6.2 and Figure 6.3) and may be a better treatment option for patients. 
DNA repair deficiencies are associated with sensitivity to platinum-based therapies and 
may also predict susceptibility to PARP inhibitors currently in late-stage clinical 
development (255). Collectively, these data suggest that approximately two-thirds of  
PACC patients could derive potential clinical benefit from these molecularly matched 
therapies.  
 The treatment of many solid tumors has shifted towards a “personalized 
approach” where tumor-specific molecular abnormalities are targeted with appropriately 
matched pharmacological inhibitors (26). However, to identify clinically relevant 
molecular targets, one must use appropriate profiling techniques. Of note, prior WES 
that focused on identification of somatic mutations failed to identify oncogenic RAF 
fusions and identified a low frequency of BRCA2 and ATM mutations (129). The 
diversity of BRAF breakpoints and fusion partners suggest that a single test looking for 
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the frequent SND1-BRAF fusion would only identify a fraction of patients whose tumors 
are dependent on rearrangement-induced activation of this gene. IHC analysis for 
pERK, a surrogate marker for MAPK pathway activation, was strongly or focally positive 
in all fusion positive cases as well as in cases that harbored additional activating events 
in the MAPK pathway (e.g. NRAS, BRAF, and KRAS). However, in our hands, 
successful staining was largely dependent on fixation quality with more intense staining 
observed around the periphery of the tumors, and on a high quality phospho-specific 
antibody that had been validated against proper controls.  
 It also appears essential in this disease to investigate the multiple mechanisms 
through which tumor suppressor genes can be inactivated, as loss of function in DNA 
repair genes occurred via base substitutions, insertions/deletions, and copy number 
alterations. Thus, a comprehensive analysis of tumor alterations is ideal for PACCs and 
appears superior to individual gene tests, WES, and analyses that assess only a single 
class of alterations. This approach could potentially identify clinically actionable events 
in the majority of patients and result in stratification of patients to “personalized 
therapies” with the maximum likelihood of efficacy.  
 In conclusion, genomic analysis of pure PACCs and related mixed acinar 
carcinomas revealed recurrent fusions in BRAF and RAF1 (23%). The recurrent SND1-
BRAF fusion was oncogenic and cells harboring this fusion were sensitive to treatment 
with the MEK1/2 inhibitor, trametinib. “Fusion negative” tumors were significantly 
enriched for deficiencies in DNA repair genes (45%). These results confirm that 
comprehensive molecular profiling to interrogate diverse alterations is essential to 
optimally identify treatment options for patients with PACC. The data further suggest 
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multiple potential therapeutic options for a tumor in which standard chemotherapeutic 
approaches have proven futile. 
 
MATERIALS AND METHODS 
Histologic Assessment of PACCs   
The tumor histology in all cases was confirmed by independent pathology review 
by a single pathologist (D. Klimstra).  Immunohistochemical staining was incorporated, 
when available.  The tumor histology in all cases revealed morphologic evidence of 
acinar differentiation, include a solid, nested or acinar architectural pattern, cytologic 
monotony, paucity of stroma, and cytoplasmic granularity.  The presence of acinar 
differentiation was confirmed using immunohistochemical labeling for pancreatic 
exocrine enzymes (trypsin and chymotrypsin), which were expressed in all cases in 
>25% of the neoplastic cells.  Additionally, there was immunolabeling for 
neuroendocrine markers (chromogranin or synaptophysin) in >25% of cells, qualifying 
for a diagnosis of mixed acinar neuroendocrine carcinoma (256), in 12 cases.  Finally, 5 
cases showed morphological and/or immunohistochemical evidence of ductal 
differentiation and were diagnosed as mixed acinar ductal carcinoma (257).  Tumors 
characterized as unknown denote (purity) cases where representative images were 
consistent with acinar cell carcinoma, but complete histological work-up was unavailable 
and the presence of a mixed phenotype was unclear from the limited pathological 
information.   
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Comprehensive Genomic Profiling 
Local site permissions to use clinical samples were obtained for this study. All 
samples were submitted to a CLIA-certified CAP-accredited laboratory (Foundation 
Medicine, Cambridge MA) for next-generation sequencing (NGS)-based genomic 
profiling. The pathologic diagnosis of each case was confirmed on routine hematoxylin 
and eosin (H&E) stained slides and all samples forwarded for DNA extraction contained 
a minimum of 20% tumor cells. DNA was extracted from 4 formalin-fixed, paraffin-
embedded (FFPE) 10 micron sections.  DNA was adaptor-ligated and capture was 
performed for all coding exons of 236 or 405 cancer related genes and 47 introns of 19 
genes frequently rearranged in cancer.  Samples for which RNA was available 
underwent targeted RNA-sequencing for rearrangement analysis in 265 genes 
(Appendix Tables A6.1 & A6.2) (32, 33). Sequencing of captured libraries was 
performed using an Illumina HiSeq 2000 or Illumina HiSeq 2500 to a median exon 
coverage depth of >600x, and resultant sequences were analyzed for base 
substitutions, insertions, deletions, copy number alterations (focal amplifications and 
homozygous deletions) and select gene fusions, as previously described (32). Natural 
germline variants from the 1000 Genomes Project (dbSNP135) were removed, and 
known confirmed somatic alterations deposited in the Catalog of Somatic Mutations in 
Cancer (COSMIC v62) were highlighted as biologically significant (151). All inactivating 
events (i.e. truncations and deletions) in known tumor suppressor genes were also 
called as significant. To maximize mutation-detection accuracy (sensitivity and 
specificity) in impure clinical specimens, the test was previously optimized and validated 
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to detect base substitutions at a ≥5% mutant allele frequency (MAF) and indels with a 
≥10% MAF with ≥99% accuracy (32). 
 
cDNA constructs 
The BRAF V600E FLAG-tagged pcDNA3.1+ plasmid was described previously 
(95).  Using Q5® High-Fidelity DNA Polymerase (New England Biolabs), full-length wild-
type (WT) SND1 was cloned from 293H cell line cDNA.  To create the FLAG-tagged 
SND1-BRAF construct, exons 1-10 of SND1 were cloned from 293H cell line cDNA, and 
exons 9-18 of WT BRAF were cloned from a WT BRAF FLAG-tagged construct.  
Primers capturing exon 10 of SND1 and exon 9 of BRAF contained BRAF and SND1 
sequence, respectively, such that SND1 and BRAF could be spliced together through a 
subsequent PCR reaction, a process termed Gene SOE-ing (Gene Splicing by Overlap 
Extension) (199).  PCR products were then cut with restriction enzymes and ligated into 
the pcDNA3.1+ vector (Invitrogen) and the pMXs-puro retroviral vector (Cell Biolabs).  
C-terminal FLAG tags were added to the WT SND1 sequence by PCR prior to vector 
ligation.  The WT BRAF FLAG and BRAF V600E FLAG sequences were also subcloned 
into pMXs-puro after modifying the restriction sites by PCR.  Direct sequencing of all 
pcDNA3.1+ and pMXs-puro constructs was performed to confirm the sequences and to 
ensure no other mutations were introduced during the cloning process. Primers are 
listed in Table 6.2.  
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Cell Culture 
293H cells (Invitrogen/Life Technologies) were grown in DMEM (Gibco/Life 
Technologies), supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Atlanta Biologicals) and 1% pen-strep solution (Mediatech, final concentration 100U/mL 
penicillin, 100µg/mL streptomycin).  Ba/F3 cells (a gift from Christine Lovly, Vanderbilt)  
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Table 6.2.  Cloning Primers 
Primer Name: # Bases: Sequences (5'-->3') 
EcoRI-SND1_Fwd 45 GCCGCCGAATTCGCCGCCACCATGGCGTCCTCCGCGCAGAGCGGC 
NotI-SND1_Rev 38 CGGCGGGCGGCCGCTTAGCGGCTGTAGCCAAATTCGTC 
SND1-BRAF_Fwd 45 GGGGAGAACAACCAGGACTTGATTAGAGACCAAGGATTTCGTGGT 
SND1-BRAF_Rev 45 GTCTCTAATCAAGTCCTGGGTGTTCTCCCCCTCCAGCCTCGGTGG 
NotI-SND1_FLAG_Rev 73 GGCGGGCGGCCGCTTACTTGTCATCGTCGTCCTTGTAGTCGCGGCTGTAGCCAAATTCGTCTGCATC
ATCAGC 
PacI-BRAF_Fwd 38 GCCGCCTTAATTAAGCCGCCACCATGGCGGCGCTGAGC 
NotI-BRAF_Rev 42 CGGCGGGCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCG 
Text Color Code: 
Black = restriction enzyme “landing pad” 
Purple = restriction enzyme sequence 
Red = SND1 sequence 
Blue = BRAF sequence 
Green = Kozak or FLAG sequence 
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were cultured in RPMI (Mediatech) supplemented with 10% FBS, 1% pen-strep 
solution, and 1ng/μL mouse IL-3 (Gibco/Life Technologies).  GTL16.903.R1 cells (kindly 
provided through MTA with Keith Ching of Pfizer) were described previously (179) and 
cultured in RPMI (Mediatech) supplemented with 10% FBS and 1% pen-strep solution.  
 
Cell Viability and Growth Inhibition Assays 
Cells were seeded at 3,000 cells per well (GTL16.903.R1 drug treatments in 
triplicate or Ba/F3 IL-3 independence assays in decuplicate) or 4,000 cells per well 
(Ba/F3 drug treatments in triplicate) of a 96-well plate.  Following 3-day (GTL16.903.R1) 
or 5-day (Ba/F3) treatment with DMSO or increasing doses of drug in triplicate, Cell 
Titer Blue reagent (Promega) was added to each well and fluorescence was measured 
as per manufacturer’s instructions on a BioTek microplate reader.  Ba/F3 cells were 
always washed three times in PBS before resuspension in media with or without IL-3 
and seeding. 
 
Ba/F3 Retroviral Transduction 
The empty pMXs-puro retroviral plasmid or pMXs-puro vector encoding WT 
BRAF, BRAF V600E, WT SND1 or SND1-BRAF (all FLAG-tagged) were transfected 
along with pCMV-VSVG (vesicular stomatitis virus surface protein envelope plasmid) 
into HEKgpIRES cells (HEK293 cells stably harboring a gag-pol internal ribosome entry 
site).  At 24 and 48hr, viral media was harvested, filtered, and the virus pelleted at 4˚C.  
Each virus was resuspended in RPMI/FBS/pen-strep/IL-3 media plus 2μg/mL final 
concentration polybrene and added to the target Ba/F3 cells.  2μg/mL puromycin 
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selection began 48hr following infection for 2 weeks, changing media and puromycin 
each day. All described assays were performed at least two independent times. 
 
Drugs 
Sorafenib, TAK-632, and trametinib were from Chemietek.  Crizotinib was from 
Selleck Chemicals. 
 
Immunoblotting 
All cells (293H, Ba/F3, GTL16.903.R1) were lysed on ice using standard RIPA 
buffer (50mM Tris-HCl, pH 7.5; 150mM NaCl; 1% IGEPAL/NP-40 substitute; 0.1% SDS) 
and supplemented with protease and phosphatase inhibitors (Roche Complete Mini 
Protease Inhibitor cocktail tablet, EDTA-free, used as per manufacturer’s instructions; 
40mM sodium fluoride; 1mM sodium orthovanadate; 1μM okadaic acid). Lysates were 
quantified by Bradford assay and subjected to SDS-PAGE on 4-12% Bis-Tris gels 
(Invitrogen/Life Technologies).  Following transfer to PVDF membranes, immunoblot 
analysis was performed using antibodies against the following targets:  phospho-
MEK1/2 (Ser217/Ser221) (Cell Signaling #9154), total-MEK1/2 (Cell Signaling #9126), 
phospho-ERK1/2 (Thr202/Tyr204) (Cell Signaling #9101), total-ERK1/2 (Cell Signaling 
#9102), phospho-MET (Tyr1234/Tyr1235) (Cell Signaling #3077), BRAF (Santa Cruz N-
terminal sc-55522, C-terminal sc-166) and FLAG (Sigma-Aldrich A8592).  Membranes 
were incubated in chemiluminescent reagents (Perkin Elmer) and exposed to film for 
signal detection. 
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293H Transfections 
293H cells (Invitrogen/Life Technologies) were transfected with 80 ng plasmid 
DNA using Lipofectamine 2000 (Invitrogen/Life Technologies) as per the manufacturer’s 
protocol.  After 24hr cells were serum-starved for 6hr then treated with vehicle (DMSO), 
sorafenib, TAK-632 or trametinib for 2hr.  Cells were then lysed and subjected to 
immunoblotting as described above. 
 
Immunohistochemistry (IHC) 
 Immunolabeling for phosphorylated ERK1/2 was performed on tissue sections of 
each tumor using a rabbit monoclonal antibody (Cell Signaling Technology), phospho-
p44/42MAPK (202Y284).  Tissue sections containing the tumor and surrounding non-
neoplastic tissues were deparaffinized and pre-treated in CC1 solution, mild regime.  
The primary antibody was applied at a dilution of 1:1000 with an incubation time of 60 
minutes.  The secondary biotinylated anti-rabbit antibody was applied at a dilution of 
1:200 for 60 minutes, and diamino benzidine was used as the chromagen.  Staining was 
performed using the Ventana Discovery XT automated IHC staining platform.  The 
immunolabeled slides were scored semiquantitatively as positive (labeling >25% of 
nuclei and cytoplasm), focal (labeling <25% of nuclei and cytoplasm), or negative (no 
labeling) based on examination of the best preserved regions of the tissue sections.  
Because of the relatively better fixation of the tissue at the periphery of the sections, 
these regions most commonly displayed positive labeling, and most cases scored as 
positive showed labeling of >75% of the cells in these regions.  Peripheral nerves and 
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activated myofibroblasts also showed immunolabeling for phosphorylated ERK1/2, 
serving as positive internal controls for the staining. 
 
Nomenclature 
Exon numbering was determined using the following transcripts for each protein: 
SND1: NM_014390, BRAF: NM_004333, GATM: NM_001482, ZSCAN30: 
NM_001112734, HERPUD1: NM_014685, RAF1: NM_002880, HACL1: NM_012260. 
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CHAPTER VII 
 
Conclusions and Future Directions in Pancreatic Acinar Cell Carcinoma 
 
INTRODUCTION 
 Unlike other cancer types, the landscape of genomic alterations in pancreatic 
acinar cell carcinoma (PACC) is poorly understood and driver mutations have not yet 
been discovered.  The rarity of this disease (<1%) compared with more prevalent 
subtypes such as pancreatic ductal adenocarcinoma (PDAC), has made it difficult to 
perform large-scale sequencing studies (128).  Prior to our investigation, one study 
performed whole-exome sequencing (WES) on a cohort of PACCs and uncovered 
potentially relevant alterations in BRAF, GNAS and JAK1 (129).  Because WES is less 
comprehensive than RNA or whole-genome sequencing (WGS) techniques, there may 
still be much to learn about the genomic landscape of PACC.  Therefore, the objective 
of the work described in Chapter VI was to identify oncogenic and actionable drivers in 
the largest cohort of PACCs to date (n=44).  To do so, we collaborated with Foundation 
Medicine, Incorporated (Cambridge, Massachusetts) to perform targeted, yet 
comprehensive, next-generation sequencing (NGS) in this cohort. 
 
RAF Fusions in PACC Summary and Future Directions 
 From our sequencing analysis, we identified six variants of a recurrent SND1-
BRAF fusion as well as BRAF fusions involving HERPUD1, ZSCAN30, and GATM, and 
a RAF1 (CRAF) fusion involving HACL1.  Like the BRAF fusions we identified in 
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melanoma (Chapter III), the 5’ partner replaced the negative-regulatory RAS-binding 
domain (RBD), but left the kinase domain of BRAF / RAF1 intact.  Further, the SND1-
BRAF fusion elicited a gain-of-function oncogenic response in transduced Ba/F3’s and 
induced MAPK pathway signaling that was most potently inhibited by the MEK1/2 
inhibitor trametinib (258). 
 In Chapters III and V, we speculated that the different 5’ BRAF fusion partners 
may not only serve to replace the RBD, but may also influence the degree to which the 
MAPK pathway is activated.  Experimental evidence in our lab dictates that not all 
BRAF fusions activate the MAPK pathway at the same level (Chapter III and 
unpublished data).  In Chapter VI, we only studied the biological properties of the most 
common SND1-BRAF variant.  While we assume that each of the RAF fusions activates 
the MAPK pathway and may confer sensitivity to MEK1/2 inhibition, each RAF fusion 
variant identified herein should be compared and studied in future biochemical assays 
to confirm this hypothesis.  From a basic biological standpoint, these studies should 
also determine whether common structural or transcriptional motifs influence RAF 
fusion activity.   
RAF1 fusions are much less common than BRAF fusions, however, there are 
individual reports of RAF1 fusions in patients with pilocytic astrocytoma (SRGAP3-
RAF1) (259) and prostate cancer (ESRP1-RAF1) (181), and in cell lines of pancreatic 
ductal adenocarcinoma (ATG7-RAF1) and astrocytoma (BCL6-RAF1) origin (260).  Like 
BRAF fusions, RAF1 fusions can induce gain-of-function properties including MAPK 
pathway activation and increased cellular proliferation (181, 259).  Future studies should 
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therefore investigate the pre-clinical sensitivity of cells/tumors harboring RAF1 fusions 
to MEK1/2 and RAF inhibitors such as trametinib and TAK-632, respectively. 
Chapter V describes a novel phase II clinical trial testing the efficacy of trametinib 
in metastatic melanomas harboring atypical BRAF mutations or BRAF fusions 
(NCT02296112).  Given the high rate of BRAF fusions in cancer as a whole, a future 
clinical trial should investigate the efficacy of trametinib (or a different MEK1/2 inhibitor) 
in any solid or liquid tumor harboring a BRAF fusion, a.k.a., a basket trial.  Instead of 
investigating one tumor type at a time, several patients with any cancer type fitting the 
trial criteria (i.e. tumor harboring an atypical BRAF mutation or a BRAF fusion) can be 
tested.  If responses are observed in a specific tumor type(s), such cohorts can be 
expanded.  Once pre-clinical data are more conclusive, these trials could be expanded 
to include tumors with RAF1 fusions as well. 
 
Additional Genomic Alterations in PACC Summary and Future Directions 
 In addition to RAF fusions, our study uncovered additional alterations that impact 
the MAPK pathway [NF1 (neurofibromatosis type 1)], and the PI3K/AKT/mTOR pathway 
[PTEN (phosphatase and tensin homolog), TSC1 (tuberous sclerosis protein 1), RPTOR 
(regulatory-associated protein of mTOR, a.k.a. Raptor)].  As discussed in the main 
Introduction and in Chapter V, NF1 is a negative regulator of RAS.  When NF1 function 
is lost, RAS is free to activate the PI3K/AKT and MAPK pathways (72).  In our PACC 
cohort, NF1 was either aberrantly spliced or deleted, providing rationale for the use of 
MEK1/2 and/or PI3K/AKT inhibitors in such tumors.  Interestingly, NF1 mutations often 
co-occurred with deleterious mutations in other tumor suppressors (TP53, RB1) or with 
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PRKAR1A (cAMP-dependent protein kinase type Iα regulatory subunit).  Loss-of-
function germline mutations in PRKAR1A are associated with Carney complex leading 
to an increased risk of PACC (251), however, our data suggest that PRKAR1A somatic 
mutations may also contribute to this disease subtype.  In melanoma, we observed NF1 
loss-of-function commonly co-occurred with atypical BRAF alterations and BRAF 
fusions (Chapter V).  In PACC, ‘hits’ in addition to NF1 loss-of-function may also be 
required to promote full tumorigenic properties.   
 The PI3K/AKT/mTOR alterations in PTEN, TSC1 and RPTOR may provide 
rationale for targeted inhibition of this pathway in PACC, also.  PTEN is a phosphatase 
inhibitor of AKT; downstream of PTEN/AKT, TSC1 and RPTOR are negative and 
positive regulators of mTOR, respectively.  Therefore PI3K inhibitors such as BKM-120 
or mTOR inhibitors such as everolimus may be useful in cases with upregulation of the 
PI3K/AKT/mTOR pathway. 
 Finally, in four PACC cases, the cyclin-dependent kinase inhibitors CDKN2A 
(p16INK4A) and CDKN2B (p15INK4B) were both deleted.  More interesting was that 
these deletions were coincident in three samples harboring BRAF fusions [SND1(ex1-
9)-BRAF(ex9-18); SND1(ex1-14)-BRAF(ex11-18); GATM(ex1-2)-BRAF(ex11-18)] and 
the sample harboring a BRAF V600E/K601E mutation (Table 6.1).  In these cases, the 
loss of cell cycle checkpoint inhibition may reduce sensitivity to MEK1/2 inhibition.  As is 
being currently evaluated in NRAS-mutant melanoma (NCT02065063 and 
NCT01781572), combination MEK1/2 and CDK4/6 (cyclin-dependent kinases 4 & 6) 
inhibition would be a logical next step. 
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Future Directions in Understanding DNA Repair Gene Inactivation in PACC 
 In addition to identifying RAF fusions and other activators of the PI3K/AKT and 
MAPK pathways, in 45% of PACCs we identified genomic alterations in a number of 
DNA repair genes [BRCA1 & 2 (breast cancer 1 & 2, early onset), ATM (ataxia 
telangiectasia mutated), MSH2 (MutS protein homolog 2), BRIP1 (BRCA1-interacting 
protein 1), PALB2 (Partner and localizer of BRCA2)].  Importantly, these alterations 
were mutually exclusive of samples harboring RAF fusions.  These mutations were also 
inactivating, meaning tumor-suppressive repair mechanisms were likely disrupted.   
BRCA1 and 2 are responsible for BRIP1- and PALB2-assisted DNA double-
strand break repair.  BRCA1 can also mediate single-strand break and mismatch 
repairs.  Alterations in these three genes have been cited recently in patients with a 
family history of PDAC (261).  Though we do not know the family history of the PACC 
patients in our cohort, testing for BRCA1/2 alterations may be a useful patient screening 
technique, nonetheless.  ATM is a serine-threonine kinase that also mediates double-
strand break repair through activation of p53, and MDM2 (Mouse double minute 2 
homolog), an E3-ubiquitin ligase.  Previously, one ATM mutation was identified in the 
previous WES study of PACC (129).  MSH2 assists BRCA1 in mediating DNA mismatch 
repair.  Mutations in MSH2 and other mismatch repair genes have cited previously in 
PACC (262). 
For patients whose tumors are DNA repair deficient, several inhibitors are 
available.  BRCA1 & 2 are assisted by PARP1 (poly-ADP ribose polymerase 1) in DNA 
single-strand break repair.  Therefore, tumors lacking functional BRCA1/2 can display 
sensitivity to PARP inhibition with PARP inhibitors such as olaparib, veliparib, and 
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others.  Currently, a phase III clinical trial is planned to evaluate olaparib in BRCA1/2-
deficient PDACs (NCT02184195) and may therefore be a viable treatment option in 
PACC BRCA1/2-deficient patients as well.  For PACCs with inactivating mutations in 
ATM, no targeted therapies are currently available.  Regardless, such tumors may be 
more responsive to “traditional” chemotherapeutic DNA-damaging agents such as 
cisplatin than tumors without such alterations.  Further investigation is required to 
determine the best course of treatment for ATM-null patients. 
 
Development of PACC Cell Line and Animal Models 
 Similar to the lack of patient genomic data, there is also a lack of appropriate 
experimental models in which to study PACC.  Currently, there are no transgenic mouse 
models of PACC.  A handful of rat and mouse PACC cell lines are available (TGP49, 
TGP47, 266-6, AR42J), but only one documented human PACC cell line, Panc-4 (127).  
Interestingly, Panc-4 expressed high levels of the receptor tyrosine kinase, KIT, and 
was sensitive to the small molecule inhibitor, imatinib.  Further, the tumor from the 
patient which Panc-4 was derived exhibited a transient clinical response to imatinib 
(127), demonstrating the feasibility of using targeted therapies in this disease.   
In addition to deriving cell lines for in vitro biological studies, PACC patient 
tumors could also be designated for xenograft models (patient-derived xenografts, or 
PDXs).  Both model types would be useful to perform genomic studies and screen 
appropriate drugs with the potential to be directly applied to patients from which they 
were generated.  Similarly, novel, potentially actionable mutations identified from further 
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genomic profiling of PACC patient tumors could be expressed in these new PACC cell 
lines instead of non-PACC tumor lines to assess tumorigenicity and drug sensitivity. 
 
SUMMARY 
 Advances in treatment for patients with PACC have been hindered due to late-
stage diagnosis, high mortality rates, a lack of molecular drug targets, and the rarity of 
this tumor type.  Herein, we elucidated the genetic landscape of PACC, uncovering 
novel BRAF and RAF1 fusions and mutually-exclusive mutations leading to inactivation 
of DNA-repair genes.  Our findings provide a rationale for the use of MEK1/2 inhibitions 
in RAF-fusion tumors and DNA damaging therapies in DNA-repair deficient tumors.  
Despite these major findings, much work remains.  First and foremost, additional PACC 
cohorts should be independently evaluated to validate our genomic data. Second, 
clinical studies are required to determine the efficacy of MEK1/2 inhibitors in patient 
PACC tumors harboring RAF fusions or other MAPK-activating alterations.  
Furthermore, the significance of less-common alterations (i.e. NF1, concurrent 
CDKN2A/2B and RAF fusions) toward predicting and modifying drug response should 
be investigated.  The derivation of novel PACC cell lines and animal models will greatly 
aid these studies.  Collectively, we have uncovered novel targets for treatment in a 
devastating disease that previously had no such targets. 
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APPENDIX 
 
APPENDIX 1:  Supplementary Information for Chapter I 
No supplementary materials, methods, tables or figures accompany this chapter. 
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APPENDIX 2:  Supplementary Information for Chapter II 
No supplementary materials or methods accompany this chapter. 
See following pages for Appendix 2 tables and figures. 
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Appendix Table A2.1.  Putative Novel Somatic Mutations Identified by Whole-Genome 
Sequencing 
Type of change Number 
SNPs 339,057 
     Coding 2,303 
          Missense 1,420 
          Nonsense 82 
          Synonymous 799 
          Unknown 2 
    Non-coding, transcribed 12,300 
          UTR5a 221 
          UTR3 a 1,283 
    ncRNAb 8,270 
          Upstream 1,245 
          Downstream 1,258 
          Upstream, downstream 23 
     Intronic 86,879 
          Splicing 51 
          Other 86,828 
     Intergenic 237,575 
Indels 46,145 
     Coding 32 
     Non-coding 2,562 
           UTR5 10 
           UTR3 360 
          ncRNA 1,653 
           Upstream 224 
           Downstream 310 
          Upstream, downstream 5 
      Intronic 18,118 
           Splicing 6 
           Other  18,112 
      Intergenic 25,433 
Copy number variations 269 
      Gain 248 
      Loss 21 
Structural variants 75 
      Deletion 40 
      Insertion 16 
      Intra-chromosomal translocation 8 
      Inter-chromosomal translocation 11 
aUTR, untranslated region 
bncRNA, non-coding RNA 
 
 
 
 
157 
 
Appendix Table A2.2.  Summary of SNP Calls Using SAMtools 
 Germline (Blood) Tumor Tumor-specific 
# SNPs 3,515,571 (3,513,463a) 3,755,527 (3,753,472 a) 440,602 (440,371 a) 
# known SNPs 3,394,411 3,340,562 101,314 
   # dbSNP131 3,275,746 3,223,338 86,632 
   # 1000 Genomes 3,285,430 3,234,091 73,949 
# novel SNPs 119,052 412,910 339,057 
Ti/Tvb 2.136 2.296 3.842 
Ti/Tv (hom) c 2.116 2.113 1.478 
Ti/Tv (het) d 2.152 2.420 4.101 
Overlap_ genotype 404,791 381,531 n/a 
Concordance 99.920% 99.425% n/a 
Concordance (hom) 99.853% 98.773% n/a 
Concordance (het) 99.967% 99.951% n/a 
a The number of SNPs satisfying the format requirement of ANNOVAR software. 
bTi; transition, Tv; transversion. 
cHom; homozygote 
dHet; heterozygote 
en/a; not applicable 
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Appendix Table A2.3.  Summary of Indel Calls Using Pindel 
Insertion or Deletion Type # Germline (blood) # Tumor # Tumor-specific 
Insertions 335,579 (335,568a) 349,887 (349,874a) 20,822 (20,820a) 
Known insertions 180,523 212,458 3,296 
   dbSNP131 112,837 114,141 2,069 
   1000 Genomes 138,639 139,370 1,534 
Novel insertions 155,045 167,416 17,524 
Deletions 436,165 (436,155 a) 459,591 (459,580 a) 33,782 (33,781 a) 
Known deletions 209,094 212,238 5,160 
   dbSNP131 138,615 140,655 2,455 
   1000 Genomes 154,656 155,937 3,168 
Novel deletions 227,061 247,342 28,621 
aThe number of insertions/deletions that is the valid input of ANNOVAR software 
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Appendix Table A2.4.  Results of Structural Variant Validation by Direct Sequencing 
Typea Gene Ab Chr Ac 
Pos A 
(bp)d Gene Bb 
Chr 
Bc 
Pos B 
(bp)d 
Genotype       
(direct 
sequencing)e 
Blood Tumor
Del SEMA3E 7 83225022  7 83225088 WT Del 
Del 
CSMD3 
(dist=1087837), 
TRPS1 
(dist=883562) 
8 115537079  8 115537162 WT Del 
Del 
FAM84B 
(dist=626085), 
POU5F1B 
(dist=230982) 
8 128196796  8 128196875 WT Del 
Del USP48 1 22072066  1 22072129 WT Del 
Del 
LOC388630 
(dist=93691,SKINTL 
(dist=11014) 
1 48556253  1 48556373 WT Del 
Ins EPB41L2 6 131240359 EPB41L2 6 131239373 ND Ins 
Del 
NONE 
(dist=NONE), 
MIR4300 
(dist=257221) 
11 81278327  11 81344562 ND Del 
Ins C21orf34 21 17748805 C21orf34 21 17747812 ND Ins 
Del 
AQP4, CDH2, 
CHST9, KCTD1, 
PSMA8, SS18, 
TAF4B, ZNF521 
18 22331879  18 27520374 ND Del 
Del 
NCRNA00295 
(dist=84994), NONE 
(dist=NONE) 
3 116520881  3 116524606 ND Del 
Del 
MCTP2 
(dist=313118), 
LOC400456 
(dist=482175) 
15 95340299  15 95340344 WT Del 
Del 
PHOX2B 
(dist=28749), 
TMEM33 
(dist=157355) 
4 41779736  4 41779782 WT Del 
Itx 
GPD2 
(dist=119673), 
GALNT5 
(dist=551752) 
2 157562588f
GPD2 
(dist=66825), 
GALNT5 
(dist=604600) 
2 157509740 ND Itx 
Ins 
UCK1 (dist=42497), 
RAPGEF1 
(dist=2998) 
9 134449159 
UCK1 
(dist=39852), 
RAPGEF1 
(dist=5643) 
9 134446514 ND Ins 
Ins 
DAB2 
(dist=118678), 
PTGER4 
(dist=1136019) 
5 39544013 
DAB2 
(dist=116488), 
PTGER4 
(dist=1138209)
5 39541823 ND Ins 
aType of structural variants: Del, deletion; Ins, insertion; Itx, intrachromosomal translocation. 
bAnnotated genes  at the first (A) or second (B) breakpoint. For deletions, all genes involved in the 
regions between the first and the second breakpoints were reported. For other structural variants,  only 
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genes  at  the first and second breakpoints  are reported. In the cases that no genes are identified at the 
breakpoints, the nearest neighboring genes and their distances are reported. 
cChromosome location of the first (A) or second (B) breakpoint. 
dPosition in basepairs (bp) of the first (A) or second (B) breakpoint on the chromosome. 
eWT, wildtype; ND (not detected), wild-type sequence is not amplified by the PCR primers. 
fNegative orientation at this position, all others are positive orientation. 
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Appendix Table A2.5.  PCR Primers Used for Direct Sequencing Validation of SNPs 
Predicted by SAMtools 
Gene 
Name Primer name Primer sequencea 
ACSM5 ACSM5_ex14_F GTTTTCCCAGTCACGACCCCAAAGCACATTTTGTTCCTA ACSM5_ex14_R CAGGAAACAGCTATGACTCTTGTGGAGTCTTCGGAGGT 
AKD1 AKD1_ex11_F GTTTTCCCAGTCACGACCAAGGACAAGTGCAGGATGTT AKD1_ex11_R CAGGAAACAGCTATGACTGGCATAGGTGGAAGCAGAT 
ALPK2 ALPK2_ex8_f GTTTTCCCAGTCACGACCTACGGAAAAGTGACTGCTGAA ALPK2_ex8_r CAGGAAACAGCTATGACCACGCCATAGCTCTCCTTCT 
APC APC_ex14_7684_f GTTTTCCCAGTCACGACTCCAGTGAAAAAGCAAAAAGTG  APC_ex14_7931_r CAGGAAACAGCTATGACTCAATTCTCACCCAAACATCC 
ARID1A ARID1A_ex20_f GTTTTCCCAGTCACGACACTCTGCCTCTCCCAACTGA ARID1A_ex20_5586_r CAGGAAACAGCTATGACCTTGCTCTCGAAGTGGGTCT 
ARSF ARSF_ex7_F GTTTTCCCAGTCACGACGCAGCTTGGAGAAGAAGGAA ARSF_ex7_R CAGGAAACAGCTATGACGACCACTCTGTCCCATAGGC 
ATF7 ATF7_ex8_F GTTTTCCCAGTCACGACAGGTATTTCCCAGGCTGTCC ATF7_ex8_R CAGGAAACAGCTATGACCAGGGAGTCCTTAGCTTTGC 
ATR 
ATR_EX6_1414_f GTTTTCCCAGTCACGACTCCCTTCAGATTTCCCTTGA 
ATR_EX6_r CAGGAAACAGCTATGACCAGTGAAAAGTTTGTGTTCTAAGGTT 
AXL AXL_ex11_f GTTTTCCCAGTCACGACGGCCTCCATCCCACTCTTA AXL_ex11_r CAGGAAACAGCTATGACCATCACTCCTCCTGCACCA 
BAI3 
BAI3_ex14_f GTTTTCCCAGTCACGACTTGTTGCTCTGATAAATACAATTTTGA 
BAI3_ex14_r CAGGAAACAGCTATGACTCTGAAACCGAGAATAAGTTGTCC 
BEST3 BEST3_ex6_589_F GTTTTCCCAGTCACGACAGAAGAAGCTACAGGAGGCAGA BEST3_ex6_887_R CAGGAAACAGCTATGACTCGGCTGCTGTGATCAATAC 
BIRC6 BIRC6_ex46_8697_f GTTTTCCCAGTCACGACTCTTATTCGTCCGGGTGATG BIRC6_ex46_r CAGGAAACAGCTATGACGCCCCTAAACAGAAGTCCTCA 
BRAF BRAF_ex15_F GTTTTCCCAGTCACGACTCATAATGCTTGCTCTGATAGGA BRAF_ex15_R CAGGAAACAGCTATGACGGCCAAAAATTTAATCAGTGGA 
BRCA2 BRCA2_ex3_f 
GTTTTCCCAGTCACGACTGCCTTAACAAAAGTAATCCATA
GTC 
BRCA2_ex3_r CAGGAAACAGCTATGACGAGACTGATTTGCCCAGCAT 
CASC5 CASC5_ex17_F 
GTTTTCCCAGTCACGACAATGACAAATATCCTGCCTTAGG
A 
CASC5_ex17_R CAGGAAACAGCTATGACAAGATGTCAGGATTTGCCACTT 
CCKAR CCKAR_ex4_F GTTTTCCCAGTCACGACAGACATGAAGTTGCCAAGG CCKAR_ex4_R CAGGAAACAGCTATGACCCGTGACTGTGCTTCTTGAC 
CCNE1 CCNE1_ex7_f GTTTTCCCAGTCACGACTCCACCTGAAGTGTGAGTGC CCNE1_ex7_r CAGGAAACAGCTATGACTCCAGGACACAGAGATCCAAC 
CDK5RAP2 
CDK5RAP2_exon29_f GTTTTCCCAGTCACGACTTGGCTTCTGGTAATTCCTAACA 
CDK5RAP2_exon29_r CAGGAAACAGCTATGACTCACAGAGCCACAGGATTCA 
CDK5RAP2_exon33_f GTTTTCCCAGTCACGACGGCCTCTTCTAGCCCTCCTA 
CDK5RAP2_exon33_r CAGGAAACAGCTATGACCTTCCTGGTCCCTCTTCTCA 
CFTR CFTR_ex14_1799_F 
GTTTTCCCAGTCACGACGGATTTTGGTCACTTCTAAAATG
G 
CFTR_ex14_2179_R CAGGAAACAGCTATGACCCTCTTCGATGCCATTCATT 
CSMD1 CSMD1_ex4_F 
GTTTTCCCAGTCACGACTTTCTGATGCTAGAGGTTTTCTC
A 
CSMD1_ex4_R CAGGAAACAGCTATGACTGCTTTCAGGAGCAGAATGA 
DHX30 DHX30_ex13_F GTTTTCCCAGTCACGACCGATTTGGACCTTGTGACTGA 
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DHX30_ex13_R CAGGAAACAGCTATGACTGATGAAACAGGCGCAGATA 
DNMT3B DNMT3B_ex3_F GTTTTCCCAGTCACGACGACGGACTGAGAGCAAATCC DNMT3B_ex_3_R CAGGAAACAGCTATGACAAAGCATCTAGCTCGGCAAC 
DRD2 
DRD2_ex4_F GTTTTCCCAGTCACGACGGCAAGCTTCATAGAGGTGTG 
DRD2_ex4_R CAGGAAACAGCTATGACTCAGTCCAGGGTAGTGATAGGC 
DSC1 DSC1_ex12_F GTTTTCCCAGTCACGACTGTCTGAAATCTGGGAAGCAT DSC1_ex12_R CAGGAAACAGCTATGACAAGCTCATCACAATGGCACTAA 
DYRK2 
DYRK2_ex3_1382_f GTTTTCCCAGTCACGACATCCCCGTTACTGCACTGTC 
DYRK2_ex3_1881_r CAGGAAACAGCTATGACGAGCTACTCCTTTTCAACCCAGT 
EHBP1 EHBP1_ex11_F GTTTTCCCAGTCACGACAGGCAGCGAAACGTGTAATC EHBP1_ex11_R CAGGAAACAGCTATGACACCGCAGTAAGCAGACAACC 
EPHB2 EPHB2_ex3_570_f GTTTTCCCAGTCACGACGCGTGTCTTCTACCGCAAGT EPHB2_ex3_r CAGGAAACAGCTATGACCCCTAGAGTGCCTCATGGTC 
EPHB6 EPHB6_ex18_f GTTTTCCCAGTCACGACCTCCACTCCAACCTCATGCT EPHB6_ex18_r CAGGAAACAGCTATGACGGGTGAGTCCAGACAAGGAA 
EPPK1 EPPK1_ex1_6540_F GTTTTCCCAGTCACGACGATCACAGCTTCTGAACTCCTCA EPPK1_ex1_6944_R CAGGAAACAGCTATGACGTGTAGGGGTCGGTGTAGCC 
ERG 
ERG_ex5_f GTTTTCCCAGTCACGACAGGCAGGTTTGAGGAGGTCT 
ERG_ex5_r CAGGAAACAGCTATGACGACTGTCTGGGACTGGCTTC 
ERG_ex6_f GTTTTCCCAGTCACGACCGGGTGAGAATTTTAGACCACTA 
ERG_ex6_r CAGGAAACAGCTATGACTGTCGTCAATGGAACAAACC 
FGFRL1 FGFRL1_ex7_1010_f GTTTTCCCAGTCACGACGTGCTCTCCTGGTCTTTGTGT FGFRL1_ex7_1414_r CAGGAAACAGCTATGACGGTACAACTTAGGGCCAGCA 
FLT4 FLT4_ex23_f GTTTTCCCAGTCACGACCCAAAGGAGCACAGTTCAGG FLT4_ex23_r CAGGAAACAGCTATGACCCAAGGAGCTCACCTCACC 
FOXO3 FOXO3_ex2_f GTTTTCCCAGTCACGACGCAGCAGAGTGAGACCTTGTCT FOXO3_ex2_1033_r CAGGAAACAGCTATGACGCGAGAGAGGCGCATCAT 
FRAS1 
FRAS1_ex42_f GTTTTCCCAGTCACGACCCCACTCTCCCAACTTTATCC 
FRAS1_ex42_r CAGGAAACAGCTATGACCCCCAAATGCCAACCTTA 
FRAS1_ex54_f GTTTTCCCAGTCACGACATGCCAAGAACCAAATGGAA 
FRAS1_ex54_r CAGGAAACAGCTATGACTGAAAAGCAAAGTTGGGAAGA 
GALK2 GALK2_ex1_f GTTTTCCCAGTCACGACGGCGGGAGCTGTTTATCTC GALK2_ex1_r CAGGAAACAGCTATGACCCAAGGGTTCCACTTGCTC 
GALNTL6 GALNTL6_ex6_F GTTTTCCCAGTCACGACACCCCAGGATTCATCAGTCA GALNTL6_ex6_R CAGGAAACAGCTATGACTGCCAATTTTATGGCATTACC 
GDAP1 
GDAP1_ex1_F GTTTTCCCAGTCACGACCCGGCGAAACTACATTTCC 
GDAP1_ex1_R CAGGAAACAGCTATGACTCATCTCCGATCGATTCTCC 
GDAP1_ex3_F GTTTTCCCAGTCACGACGCATCAGGCCATTTCAAACT 
GDAP1_ex3_R CAGGAAACAGCTATGACATGCACATCCATGAAGCAAA 
GPR98 
GPR98_ex24_F GTTTTCCCAGTCACGACCCACTAGGCTTGCTGCAGTT 
GPR98_ex24_R CAGGAAACAGCTATGACAGTGCAAATACAACTTCAAAAGGA 
GPR98_ex70_14115_F GTTTTCCCAGTCACGACTGCTGATGGAGAGAGTGAAGC 
GPR98_ex70_14414_R CAGGAAACAGCTATGACGATGATATTCGAAGCCCAACA 
GRIN2A Seq_GRIN2A_ex3F GTTTTCCCAGTCACGACCCTGCCTCTCACTCTTCACC Seq_GRIN2A_ex3R CAGGAAACAGCTATGACCAGCAGAGCTACCACGTTCA 
GRK5 GRK5_ex3_f GTTTTCCCAGTCACGACGAGTTTGCCAGTCACCTTCC GRK5_ex3_r CAGGAAACAGCTATGACCCTCAGACAATTTTGCATTCC 
GRM1 GRM1_ex9_f GTTTTCCCAGTCACGACAGGTGGAGGCAATACAGAGC GRM1_ex9_r CAGGAAACAGCTATGACTGCACCACATCTGTTTCCAT 
GRM8 GRM8_ex_9_2265_f GTTTTCCCAGTCACGACCAGTATCCTCTTGATGGTCACTT
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G 
GRM8_ex_9_r CAGGAAACAGCTATGACAAGAATAGCACAGACTGAAGCATCT 
HECW2 
HECW2_ex19_F GTTTTCCCAGTCACGACACAGCCAGCCATTTTGTACC 
HECW2_ex19_R CAGGAAACAGCTATGACGCTAACACCAAAGATGTACCTGAA 
HIPK4 HIPK4_ex_3_1068_f GTTTTCCCAGTCACGACCGAGACCACCCACTACTACCA HIPK4_ex_3_1304_r CAGGAAACAGCTATGACTGCAGACTCAGGTCATCCAG 
HYDIN 
HYDIN_ex46_7312_F GTTTTCCCAGTCACGACGAGGACAGTGAAGGGGACAA 
HYDIN_ex46_7726_R CAGGAAACAGCTATGACCAAAGTCTGGTGTCTGGATGTCT 
IL21R IL21R_ex3_f GTTTTCCCAGTCACGACCCCTCGGGATCTTGCATT IL21R_ex3_r CAGGAAACAGCTATGACATCTGTGGACTCTAGCCGTGTT 
IL2RB Seq_IL2RB_ex6F GTTTTCCCAGTCACGACAGGTCATGGCTGACTGCTCT Seq_IL2RB_ex6R CAGGAAACAGCTATGACACATGGACCAGGACAGGAAG 
IL7R Seq_IL7R_ex5F GTTTTCCCAGTCACGACTGGGAGATTTAGGCAACACC Seq_IL7R_ex5R CAGGAAACAGCTATGACGCAAAGCACTCTGAGGGAAC 
IMPG2 IMPG2_ex13_2410_F GTTTTCCCAGTCACGACAGTGCTGACAGGCTCTGGTT IMPG2_ex13_R CAGGAAACAGCTATGACTCCCTGGCTCAGACCTTATG 
INSR 
Seq_INS_ex9F GTTTTCCCAGTCACGACGGTGCCCTCATGATGTCTTT 
Seq_INS_ex9R CAGGAAACAGCTATGACCCTTCCGACACTGAGACACA 
Seq_INS_ex13F GTTTTCCCAGTCACGACAATGGGTTGTGGGAAAATGA 
Seq_INS_ex13R CAGGAAACAGCTATGACAAGGGCCTTACCTCATCACC 
IP6K1 Seq_IP6K1_ex4F GTTTTCCCAGTCACGACCTGTGGGTCTGTCATTGTGG Seq_IP6K1_ex4R CAGGAAACAGCTATGACACACGACCTATGGACCCAGT 
IRAK3 Seq_IRAK3_ex10F 
GTTTTCCCAGTCACGACTTGACTCATTGATTTCCTGTTAG
C 
Seq_IRAK3_ex10R CAGGAAACAGCTATGACAATCCAGGCCTCTCTTCTCC 
ITK Seq_ITK_ex8F GTTTTCCCAGTCACGACTCATGCATTTGCTTTTGAGTTT Seq_ITK_ex8R CAGGAAACAGCTATGACGGCTGAAGTGCAGTGGTACA 
KCNH3 KCNH3_ex9_F GTTTTCCCAGTCACGACGGCTCTTCCGCTTTAGGTG KCNH3_ex9_R CAGGAAACAGCTATGACGAGAGAAGGGAGGCACAGG 
KDR Seq_KDR_ex23F GTTTTCCCAGTCACGACTGATGCATGAGGTCACAACA Seq_KDR_ex23R CAGGAAACAGCTATGACTCCTGAACACAGGTCCTGAA 
KERA KERA_ex2_580_F GTTTTCCCAGTCACGACCTCATGCAGCTAAACATGGC KERA_ex2_R CAGGAAACAGCTATGACGGGCAACACATTTGCTCTTC 
KLK12 KLK12_ex6_F GTTTTCCCAGTCACGACGGATTGGCCCCTAGAGACAG KLK12_ex6_R CAGGAAACAGCTATGACGAGGTGGAGGAAACAGGTCA 
KRAS KRAS_ex5_f GTTTTCCCAGTCACGACTCAGTTGCCTGAAGAGAAACATAKRAS_ex5_f CAGGAAACAGCTATGACAGTCTGCATGGAGCAGGAA 
LCK Seq_LCK_ex7F GTTTTCCCAGTCACGACGTTCTTTCGTCGCTTTGTCC Seq_LCK_ex7R CAGGAAACAGCTATGACGCCTCGTATTGACACCACCT 
LRP1B Seq_LRP1B_ex57F GTTTTCCCAGTCACGACGGAAGCAAGGGATGCACTTA Seq_LRP1B_ex57R CAGGAAACAGCTATGACCGGTGTCATCTTGGGAGTGT 
LYST 
LYST_ex12_4216_F GTTTTCCCAGTCACGACAGCAACGGTGTTTCATCACA 
LYST_ex12_4542_R CAGGAAACAGCTATGACTGTACCATCAAAACTGCTATCTGG 
MALT1 MALT1_ex16_F 
GTTTTCCCAGTCACGACCTGTTGATGCCAATAATAAACCA
G 
MALT1_ex16_2246_R CAGGAAACAGCTATGACACACCATGGAATGGGTCTTG 
MAP2K2 MAP2K2_ex2_f GTTTTCCCAGTCACGACCAGCATGGATCCTTTCCTTC MAP2K2_ex2_r CAGGAAACAGCTATGACGGACAGAGCCTGGAGCTAATC 
MAP3K13 MAP3K13_ex11_2208_f GTTTTCCCAGTCACGACGCCAGAACAGTATGGGTCCT MAP3K13_ex11_r CAGGAAACAGCTATGACAGGCCACTCTCATCATTACACT
164 
 
T 
MAP3K15 MAP3K15_ex6_f GTTTTCCCAGTCACGACCTTTAAGTGCGGAGGCTGTC MAP3K15_ex6_r CAGGAAACAGCTATGACCCCTGAGGACAAAGACTGGA 
MAPK4 MAPK4_ex6_f GTTTTCCCAGTCACGACGCCATTACCTGTCCATCACC MAPK4_ex6_1297_r CAGGAAACAGCTATGACCCACCTTGTAGTCGCAGGAG 
MAPKAPK
2 
Seq_MAPKAPK2_ex5F GTTTTCCCAGTCACGACTCCAGCAGGGTTGCTATTTT 
Seq_MAPKAPK2_ex5R CAGGAAACAGCTATGACAGAGGAGGGGCTGAGAAAAG 
MAPKBP1 Seq_MAPKBP1_ex3F GTTTTCCCAGTCACGACGGAGCCCTTCTGAGCTCTTT Seq_MAPKBP1_ex3R CAGGAAACAGCTATGACCACTTCCCCATCTGGCTTTA 
MEF2C MEF2C_ex5_f GTTTTCCCAGTCACGACAAATAAGGGCTGTCTGTCTTGAA MEF2C_ex5_r CAGGAAACAGCTATGACGGATGGTAAGCCATGAAGGA 
MELK Seq_MELK_ex5F GTTTTCCCAGTCACGACACCTTACTCGGTTCCATTCC Seq_MELK_ex5R CAGGAAACAGCTATGACGAGGTCCCTGTGAGCATAGC 
MKKS 
MKKS_ex3_575_F GTTTTCCCAGTCACGACGCCACATCATTTTAGGAAAGAGTT 
MKKS_ex3_874_R CAGGAAACAGCTATGACGGACAAGATCTACGTGGTCACTG 
MMP9 MMP9_ex12_F GTTTTCCCAGTCACGACGGGAAGATGCTGCTGTTCA MMP9_ex12_R CAGGAAACAGCTATGACGCTGGGATCTTGTCTGTGCT 
MYST3 MYST3_ex17_F GTTTTCCCAGTCACGACTTTGGCAAACAACATCCTCA MYST3_ex17_3202_R CAGGAAACAGCTATGACCGATCTCAAACGTGGGTTCT 
NBAS NBAS_ex41_F GTTTTCCCAGTCACGACTACAGGGCCAAACAGTTCCT NBAS_ex41_R CAGGAAACAGCTATGACGGCACACATCCCACATAAGA 
NCKAP5L NCKAP5L_ex8_590_F GTTTTCCCAGTCACGACTGGAAGAGACTGACCCCTTG NCKAP5L_ex8_1030_R CAGGAAACAGCTATGACCCAGGAAGGCCTGTAGGTAA 
NF1 
Seq_NF1_ex3F GTTTTCCCAGTCACGACTCTGGGAGGTAAAATGGAAGA 
Seq_NF1_ex3R CAGGAAACAGCTATGACGGACTGTCCTCTTGGTCCAC 
Seq_NF1_ex48F GTTTTCCCAGTCACGACCCTCAGCAGATGCTTGTTCA 
Seq_NF1_ex48R CAGGAAACAGCTATGACTGTTCTGGCAAAACTCTCAAAA 
NOTCH1 Seq_Notch1_ex26F GTTTTCCCAGTCACGACGCAACAGCTCCTTCCACTTC Seq_Notch1_ex26R CAGGAAACAGCTATGACGAGAGTTGCGGGGATTGAC 
NRK NRK_ex13_2018_F 
GTTTTCCCAGTCACGACGGTTTTACTCACAACCAGAACAG
G 
NRK_ex13_R CAGGAAACAGCTATGACAACATCCGCATGAGCTATCA 
OR2B3 OR2B3_ex1_437_F GTTTTCCCAGTCACGACCCTTCTCATGGCTCATTGGT OR2B3_ex1_823_R CAGGAAACAGCTATGACAAACCATCTTTCCCCAGTCC 
OSCAR OSCAR_ex5_651_F GTTTTCCCAGTCACGACGGTCATCAGCTGGGAAGGT OSCAR_ex5_1050_R CAGGAAACAGCTATGACGATGGAGGCTTCAACTCCTG 
PAXIP1 
PAXIP1_ex4_F GTTTTCCCAGTCACGACCCTACTGTGCAGTGGAAGCA 
PAXIP1_ex4_R CAGGAAACAGCTATGACCAGGTCATAAATCCAACCATACAA 
PCSK5 PCSK5_ex11_F GTTTTCCCAGTCACGACGCCTGGCATGGAGTAACAAT PCSK5_ex11_R CAGGAAACAGCTATGACGCTCAGAATCCTAGCCGTTC 
PIK3CB Seq_PIK3CB_ex9F GTTTTCCCAGTCACGACTTTTCATGGGAGGAGATCCA Seq_PIK3CB_ex9R CAGGAAACAGCTATGACAAGAAGGCTCCCTGATCCAT 
PRUNE2 PRUNE2_ex8_3286_F GTTTTCCCAGTCACGACACACTTTTGCACAGCAGCAC PRUNE2_ex8_3640_R CAGGAAACAGCTATGACGCTGCCCACTTTTCTCATTC 
PTEN PTEN_exon5_F 
GTTTTCCCAGTCACGACTGAGGTTATCTTTTTACCACAGT
TG 
PTEN_exon5_R CAGGAAACAGCTATGACCCAGGAAGAGGAAAGGAAAA 
PTK7 Seq_PTK7_ex16F GTTTTCCCAGTCACGACGAGGGGGTCACAGCAGAAC Seq_PTK7_ex16R CAGGAAACAGCTATGACCCAACAGCATACCAGATCCA 
PTPRB Seq_PTPRB_ex15F GTTTTCCCAGTCACGACACAGCCTTTGGTTCAACTGG Seq_PTPRB_ex15R CAGGAAACAGCTATGACCTGGAAGCTACTTCCCACCA 
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Seq_PTPRB_ex31F GTTTTCCCAGTCACGACTGCATGAGAACAGGCCCTCCT 
Seq_PTPRB_ex31R CAGGAAACAGCTATGACTGCCCACCTCTGTGATACTCTGGA 
PTPRD Seq_PTPRD_ex43F GTTTTCCCAGTCACGACTGAAGGGAGCTCATGGTTTC Seq_PTPRD_ex43R CAGGAAACAGCTATGACCTGGCATCTGTGACCTTGAA 
PTPRK 
Seq_PTPRK_ex14F GTTTTCCCAGTCACGACCAGCAGCAACAGAAGAACCA 
Seq_PTPRK_ex14R CAGGAAACAGCTATGACCAGGTGCTGACAACATTGTTAAA 
Seq_PTPRK_ex28F GTTTTCCCAGTCACGACCCCTCTACAGCCACAGGAAG 
Seq_PTPRK_ex28R CAGGAAACAGCTATGACGGGAGGTCCATAAGATGCAA 
RASGRF1 RASGRF1_ex17_F GTTTTCCCAGTCACGACCCTGGTACCCTGAAGACACAG RASGRF1_ex17_R CAGGAAACAGCTATGACTAAACACCCACAGCAGAGCA 
RGSL1 
RGSL1_ex2_F GTTTTCCCAGTCACGACGCATGACCCTAGAGGCTGTC 
RGSL1_ex2_R CAGGAAACAGCTATGACTGGAGATTTTACAGGTGGTTCTG 
RPS6KA6 Seq_RPS6KA6_ex4F GTTTTCCCAGTCACGACTCCCTCTATGGGAAGGCATA Seq_RPS6KA6_ex4R CAGGAAACAGCTATGACCAGGTTAGAAAAACTGCCACAA 
RTCD1 RTCD1_ex7_F GTTTTCCCAGTCACGACTCACATATCTCAAGGCTACCACA RTCD1_ex7_650_R CAGGAAACAGCTATGACAATGGCAAAACACCAGCAAC 
SATB1 SATB1_ex9_f GTTTTCCCAGTCACGACCTGCACTGTTGATCACCTTGA SATB1_ex9_r CAGGAAACAGCTATGACTCTGAGGAGTGGCTATTGGAA 
SERPINA3 SERPINA3_ex2_196_F GTTTTCCCAGTCACGACCTGAAGGCCCCTGATAAGAA SERPINA3_ex2_482_R CAGGAAACAGCTATGACTACAGCCTCTTGGCATCCTC 
SLIT1 SLIT1_ex28_F GTTTTCCCAGTCACGACGCGGCTATAAGGTGAGTGGA SLIT1_ex28_R CAGGAAACAGCTATGACCCCTCTGGCTATGATTTGGA 
SLITRK3 SLITRK3_ex2_2088_F GTTTTCCCAGTCACGACGGACCTTACTGGCATCCAAA SLITRK3_ex2_2482_R CAGGAAACAGCTATGACTAAGCTGGGAGCTGGACACT 
SMEK1 Seq_SMEK1_ex15F GTTTTCCCAGTCACGACATGGGGGACGACTATTGACA Seq_SMEK1_ex15R CAGGAAACAGCTATGACGGCAAAATGGGAGTCAAGAA 
STK33 Seq_STK33_ex11F GTTTTCCCAGTCACGACACCCATCTCTTCCCATCCTT Seq_STK33_ex11R CAGGAAACAGCTATGACAACCACAGGCCAACTTTCTT 
STON2 STON2_ex4_1058_F GTTTTCCCAGTCACGACAAAGCCAAAGAGATTCCCTCA STON2_ex4_1304_R CAGGAAACAGCTATGACGGGATCCTCAACATCATTGG 
TEKT4 TEKT4_ex1_286_F GTTTTCCCAGTCACGACGGCTGCGGAGACCAACTT TEKT4_ex1_R CAGGAAACAGCTATGACTGCTTGGAAGTCAGGGGTCT 
TIAM2 TIAM2_ex6_F GTTTTCCCAGTCACGACTCCCTCTGAACCTGAGTTGAA TIAM2_ex6_R CAGGAAACAGCTATGACCACCAAGATGTGAGCCAAGA 
TLN2 TLN2_ex20_F GTTTTCCCAGTCACGACGCTTGTGGCATTTGACTATCC TLN2_ex20_R CAGGAAACAGCTATGACTGTGAACCTTGACTTGGCTTT 
TNKS TNKS_ex16_F GTTTTCCCAGTCACGACTTCTTCTTTGTAGCATGGAGCA TNKS_ex16_R CAGGAAACAGCTATGACTGTCCTGGGCATTAACATCA 
TNK2 Seq_TNK2_ex12F GTTTTCCCAGTCACGACAGGAGGAGACCAGCCAGTG Seq_TNK2_ex12R CAGGAAACAGCTATGACGCTCGGGCAGCAAGTAATAG 
TRANK1 TRANK1_ex12_2956_F GTTTTCCCAGTCACGACCACAGCTTCAGCACCAACAT TRANK1_ex12_3516_R CAGGAAACAGCTATGACGGTGGACTTGGAAAGCTCAA 
TSKS TSKS_ex1_F GTTTTCCCAGTCACGACCTGGCAGTCCAAAGAGATCC TSKS_ex1_R CAGGAAACAGCTATGACCCCGACCACCACTGTCTACT 
TSSC1 TSSC1_ex8_F GTTTTCCCAGTCACGACTCAGCGGAAAACTGCCTTAT TSSC1_ex8_R CAGGAAACAGCTATGACTGCGTGCCCTTACTTCTCTT 
UPK3B UPK3B_ex5_F GTTTTCCCAGTCACGACGGGATATGAGACAGCCAGAC UPK3B_ex5_665_R CAGGAAACAGCTATGACATGGTAGAGGCTGCCAAGAA 
VCAN VCAN_ex7_3018_F GTTTTCCCAGTCACGACCATTGATCAGACTCGCCTTG VCAN_ex7_3266_R CAGGAAACAGCTATGACACTGGGACCCTCTCAGAACC 
WDFY4 WDFY4_ex19_F GTTTTCCCAGTCACGACGAGGAGGATCTAGGGCTCCA 
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WDFY4_ex19_R CAGGAAACAGCTATGACCATTAGATGCCAACCCTACCA 
WNK1 
Seq_WNK1_ex1F GTTTTCCCAGTCACGACGCCACTTCCCAGGTAGCC 
Seq_WNK1_ex1R CAGGAAACAGCTATGACCGTCTTAAAGGAGCCTCTGC 
Seq_WNK1_ex9F GTTTTCCCAGTCACGACATTACCATGCCCCAGAATTG 
Seq_WNK1_ex9R CAGGAAACAGCTATGACTGTGGATGAAGTGCAGATCC 
WT1 Seq_WT1_ex2F GTTTTCCCAGTCACGACCGCTGACACTGTGCTTCTCT Seq_WT1_ex2R CAGGAAACAGCTATGACACAGTGCCATTGGGGTAATG 
aThe sequences are shown 5’>3’ and bold nucleotides are the M13 tags used for sequencing. 
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Appendix Table A2.6.  PCR Primers Used for Direct Sequencing Validation of Structural 
Variants Predicted by CREST 
Primer namea Primer sequenceb 
CHR1_22072066_F GTTTTCCCAGTCACGACCACTTTCGGGAGGCTGAAGT 
CHR1_22072066_R CAGGAAACAGCTATGACTTCCTGCCTCCTTTGTTCAG 
CHR1_48556253_F GTTTTCCCAGTCACGACTGTGGTAATGGCACCTGTCTC 
CHR1_48556253_R CAGGAAACAGCTATGACCCAAGCAATCAAAACCATCC 
CHR2_157562588_F GTTTTCCCAGTCACGACTCAGAAAAAAAGTCTTCATTT 
CHR2_157562588_R CAGGAAACAGCTATGACTCCCTTTAGAGTTTCCTAGC 
CHR3_116520881_F GTTTTCCCAGTCACGACAAGGCAACTGGAGTGGTCAA 
CHR3_116520881_R  CAGGAAACAGCTATGACGGTGGGGGATCTGGACTTAT 
CHR4_41779736_F GTTTTCCCAGTCACGACTCTCAGGGCTTTGTCCAGTC 
CHR4_41779736_R CAGGAAACAGCTATGACGCAGGGGTAGGAAGTGTGAA 
CHR5_39544013_F GTTTTCCCAGTCACGACTACAGAAAAATTCCAAACTCCTTAACC 
CHR5_39544013_R CAGGAAACAGCTATGACTTATATTCCTTTGCAACCTTTGTAACTT 
CHR6_131240359_F  GTTTTCCCAGTCACGACAATGTCTCAGAAAGGACACCTCA 
CHR6_131240359_R CAGGAAACAGCTATGACAAAGGAGCTTGTTAGAAATGTAGTTGA 
CHR7_83225022_F GTTTTCCCAGTCACGACTTTCTCAGGATCCAATTCAGC 
CHR7_83225022_R CAGGAAACAGCTATGACCAGGCAAGACACAAGGAAGG 
CHR8 115537079_F GTTTTCCCAGTCACGACGACCGAAAGAATGTGGGTGT 
CHR8 115537079_R CAGGAAACAGCTATGACCATTTTATTTTCTCCAATCAAGCC 
CHR8_128196796_F  GTTTTCCCAGTCACGACACCCGCAGTTCTGCACAT 
CHR8_128196796_R  CAGGAAACAGCTATGACGTAGGAAATTGGAAATGGGTAGGT 
CHR9_134449159_F  GTTTTCCCAGTCACGACTTTCTCCCTTTAATTTGTTAACGTG 
CHR9_134449159_R  CAGGAAACAGCTATGACGGACAGAGCCAGCTCCAG 
CHR11_81278327_F  GTTTTCCCAGTCACGACTCTCCTTCAGGATGTTACCTATGC 
CHR11 81278327_R  CAGGAAACAGCTATGACTTCAGGGGATCTGATGTTGG 
CHR15_95340299_F  GTTTTCCCAGTCACGACTTTGGCCTCTGTCTTACACCA 
CHR15_95340299_R CAGGAAACAGCTATGACCAGCCATTTTAATAGGTGCAAAG 
CHR18_22331879_F  GTTTTCCCAGTCACGACGGCTTGTTGGGCTCTTCTTAC 
CHR18_22331879_R  CAGGAAACAGCTATGACGGTAGGATTCTGCCACTGGA 
CHR21 17748805_F GTTTTCCCAGTCACGACCTGCTCAATGTTACAATATAATTAC 
CHR21 17748805_R CAGGAAACAGCTATGACAAGCCACAGTAGGATATTC 
aThe primer name includes the chromosome number (CHRx) and the position, in basepairs, of the first 
breakpoint on the chromosome indicated. See Supplementary Table S6 for the SVs validated by direct 
sequencing. 
bThe sequences are shown 5’>3’ and bold nucleotides are the M13 tags used for sequencing. 
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Appendix Figure A2.1. Overview of Approaches for Identification of Somatic Mutations. 
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Appendix Figure A2.2. Flow Diagram of SNP Analysis Pipeline. Raw reads were mapped 
to the reference genome (hg19) using ELANDv2 and then FastQC was used to perform 
quality control checks on sequence data, followed by removing repeats, duplications and the 
reads that failed the platform quality check. SAMtools was then used to call SNPs and 
somatic SNPs. ANNOVAR was applied to filter known somatic SNP variants and to annotate 
novel somatic SNPs. 
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Appendix Figure A2.3. Catalogue of Somatic Alterations in the Metastatic Melanoma 
that Underwent Whole-Genome Sequencing. Circos plot. Chromosomes are presented in 
circularly arranged ideograms, demarcated by a megabase (Mb) scale on the outer ring in a 
clockwise direction. Other tracks (from outside to inside) contain somatic mutations: SNPs 
(purple dots, shown by d, respectively); deletions (green triangles:  validated; gray triangles:  
without validation); copy number variations (red, green and yellow lines represent copy 
number gain, loss and no change (neutral state), respectively); intra-chromosomal 
translocations (red curves:  validated; grey curves: without validation); and inter-
chromosomal translocations (green curves). 
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Appendix Figure A2.4. Spectrum of Substitutions. Frequency of substitutions for the 
twelve possible mutations; shown on the y-axis are the various possible nucleotide 
substitutions; the x-axis represents the frequency of mutations across the genome with that 
type of mutation. 
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Appendix Figure A2.5. Somatic Indel Size Distribution. (A) Distribution of insertion size 
(1-82bp). (B) Distribution of deletion size (1-8,790bp). Since the number of indels > 20 base 
pairs (bp) is small, we grouped these indels into one bin. 
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Appendix Figure A2.6. FREEC Predictions of Somatic Copy Number Variations 
(CNVs) in the Whole-Genome Sequenced Melanoma Compared to Matched Normal 
Blood. Red: gains; Blue: losses; Green: no change. 
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APPENDIX 3:  Supplementary Information for Chapter III 
No supplementary materials, methods, or tables accompany this chapter. 
 
 
Appendix Figure A3.1.  Signaling properties of WT PAPSS1.  Immunoblotting of lysates 
from 293H cells transfected with empty vector (1μg) or plasmids encoding BRAF V600E-
FLAG (80ng) or WT PAPSS1-FLAG (1μg) demonstrates that WT PAPSS1 does not cause 
MAPK pathway signaling. kDa, kilodalton; ng, nanogram; μg, microgram; WT, wild-type. 
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APPENDIX 4:  Supplementary Information for Chapter IV 
Materials and Methods 
Ras-GTP assay 
To detect active Ras (Ras-GTP) levels, we used the Active Ras Pull-Down and 
Detection Kit from ThermoScientific (#16117).  Cells were plated evenly into 10-cm 
dishes with serum-containing media.  24hr later, media was aspirated and serum-
containing or serum-free media added back for 12hr.  Lysates were harvested and 
resuspended in 300uL of the kit’s Lysis/Binding/Wash buffer supplemented with 
protease and phosphatase inhibitors as described in the main methods 
(“Immunoblotting”).  Lysates were quantified with the BCA Assay (ThermoScientific 
#23225).  For the Ras-GTP pulldown, lysates were normalized to 500μg in 500μL 
Lysis/Binding/Wash buffer.  For whole-cell lysate controls, lysates were normalized to 
30μg in 20μL buffer + Laemmli dye.  In vitro GTPγS and GDP treatment, and the active 
Ras precipitation were performed as per manufacturer’s instructions.  Both the 
precipitations and whole-cell lysates were subjected to SDS-PAGE and transfer to 
PVDF as described in the main methods (“Immunoblotting”).  Active (pulldown) and total 
(WCL) Ras was detected using the anti-Ras antibody provided with the kit as per 
manufacturer’s instructions. 
 
Phosphorylated Receptor Tyrosine Kinase (RTK) Arrays 
To assess phosphorylated RTK status, we used R&D Systems’ Proteome Profiler 
Human Phospho-RTK Array kit (ARY001B).  Cells were plated evenly into 6-cm dishes 
and cultured in the presence of serum.  After 48hr, lysates were harvested in the kit’s 
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Lysis Buffer 17, which was supplemented with protease and phosphatase inhibitors as 
described above.  Lysates were quantified by Bradford assay and normalized to 400μg 
per 1.5mL lysate + Lysis Buffer 17 solution.  Phospho-RTK array membranes were 
blocked as per manufacturer’s instructions and the lysate solutions added to the 
membranes.  All remaining steps were performed as per manufacturer’s instructions, 
except Perkin Elmer reagents described above instead of the kit’s reagents were used 
for chemiluminescent signal detection. 
 
Ligand Protein Array 
To test for differential expression of ERBB ligands, we used the R&D Systems 
Angiogenesis Array (ARY007), which probes for the following ERBB ligands:  
amphiregulin (AREG), epidermal growth factor (EGF), heparin-binding EGF (HB-EGF), 
and neuregulin β1 / heregulin (NRGβ1/HRG).  Cells were plated evenly into 6-cm 
dishes in serum-containing media.  24hr later, the media was changed to a reduced 
volume of serum-free media for a period of 48hr, after which the media was harvested 
and centrifuged to pellet cellular debris.  1mL of the conditioned, serum-free media from 
each sample was added to the prepared protein array membranes.  All remaining steps 
were performed as per manufacturer’s instructions, except for the substitution of Perkin 
Elmer chemiluminesecent reagents for the kit reagents. 
 
HER3 siRNA Knockdown 
Cells were plated evenly into 6-cm dishes in serum-containing media.  The 
following day, cells were transfected using Lipofectamine RNAiMAX (Invitrogen / Life 
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Technologies) as per manufacturer’s instructions with 30pmol final concentration of 
scrambled pool or siRNA against HER3.  24 hr after transfection, cells were treated with 
DMSO or 50nM trametinib for another 24 hr.  Cells were harvested for immunoblotting 
as described in the main methods section. 
 
Next-Generation Sequencing and Analysis:  Vanderbilt Cancer Panel for MiSeq 
See also, Meador, et al., Molec Cancer Therapeutics, 2014 (24).  From literature 
review and mutation database research (Catalogue of Somatic Mutations in Cancer), 
we identified 66 genes that are mutated at a rate of greater than 1% in a majority of 
solid and liquid tumors (Appendix Table A4.3).  We instructed Illumina’s online Design 
Studio program to design amplicon probes for use with the Illumina MiSeq platform 
against all exons of the 66 genes allowing an extension of 25 bases into the introns on 
either side of each exon.  We also instructed the program not to avoid designing 
amplicon probes around common single-nucleotide polymorphic (SNP) regions, 
because some somatic SNPs are often included in genomic SNP databases (example, 
EGFR c.2369C>T, p.T790M in lung cancers resistant to first-line EGFR therapy) but are 
still important for biological function.  Only 1536 amplicons are allowed per MiSeq probe 
panel; therefore, we split the genes into two capture panels (Appendix Table A4.3).  
The number of target exons, cumulative target base-pairs, total number of amplicons 
per panel and the base-pair gap amount (i.e. base-pairs that were targeted but deemed 
unsuitable for an amplicon location) are listed in Appendix Table A4.3 as well.  Overall, 
the Illumina Design Studio was able to design probes against 95% and 93% of the 
intended exon targets in VCP1 and VCP2, respectively.  Following sequencing, samples 
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were analyzed for single-nucleotide variants (SNVs), and small insertions and deletions 
(indels) as follows:  The Burrows-Wheeler Aligner (BWA) (263) was used to align 
sequencing reads to the UCSC human reference genome hg19. After alignment, 
SAMtools (166) was used to convert the alignment files to a sorted, indexed binary 
alignment map (BAM) format. To obtain the best sequence alignment for mutation-
calling purposes, the BAM files were realigned using the Genome Analysis Toolkit 
(GATK) software (194). Following reaglinment, the HaplotypeCaller program in GATK 
was used in its default setting to detect SNVs and indels from the BAM files. Finally, low 
quality variants were filtered out using VariantFiltration in GATK. Only high-confidence 
SNPs and indels were kept for downstream analysis. 
 
 
 
 
 
 
 
 
 
 
179 
 
Appendix Table A4.1.  Panel of 16 SNaPshot Pan-Negative Melanoma Cell Lines 
Cell Line Source Culture Conditions 
CHL-1 ATCC DMEM + 10% FBS + 1% pen/strep 
D35 QIMR (N. Hayward / C. Schmidt) RPMI-1640 + 10% FBS + 1% pen/strep 
HMCB ATCC DMEM + 10% FBS + 1% pen/strep 
M285 
UCLA (T. Ribas) RPMI-1640 + 20% FBS + 1% pen/strep M368  
M375 
MeWo ATCC DMEM + 10% FBS + 1% pen/strep 
MM329 QIMR (N. Hayward / C. Schmidt) RPMI-1640 + 10% FBS + 1% pen/strep 
VP-Mel-20 
VUMC RPMI-1640 + 20% FBS + 1% pen/strep VP-Mel-21 
VP-Mel-36 
WM3681 
Wistar Institute (M. 
Herlyn) 
4:1 MCDB-153 and Leibovitz’s L-15 + 2% 
FBS + 1% pen/strep + 5ug/mL bovine 
insulin + 1.68 mM calcium chloride 
WM3912 
WM3918 
WM3928 / 
WM3928F 
WM8 / WM1382 
ATCC, American Type Cell Culture 
QIMR, Queensland Institute of Medical Research 
UCLA, University of California, Los Angeles 
VUMC, Vanderbilt University Medical Center 
MCDB-153 media, Sigma #M7403 
Leibovitz’s L-15 media, Gibco/Life Technologies, #11415-064
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Appendix Table A4.2. Previous Studies Citing Observation of Paradoxical MEK1/2 Activation in Response to MEK1/2 
Inhibition 
  
MEK1/2 and ERK1/2  
Response by Genotype   
Reference 
MEK1/2 
Inhibitor   
BRAF 
V600 
RAS-
mutant WT 
Cited Mechanism of 
Paradoxical MEK Activation 
Ishii, Cancer Res, 
2013 (203) PD-0325901 
pMEK1/2 ↔ ↑ ↔ RAS mutation pERK1/2 ↓ ↓ ↓ 
Emery, PNAS, 2009 
(205) AZD6244 
pMEK1/2 ↔↑ n/a n/a MEK1 mutation (AZD6244-resistant line derived 
from a patient) pERK1/2 ↓ n/a n/a 
Villanueva, Cell 
Reports, 2013 (206) 
Trametinib or  
AZD6244 
pMEK1/2 ↔↑ n/a n/a Concurrent BRAF amplification and MEK2 
mutation (also confers resistance to RAFi) pERK1/2 ↓ n/a n/a 
Wagle, Cancer 
Discovery, 2014 
(207) 
Trametinib 
pMEK1/2 ↔↑ n/a n/a MEK2 mutation 
pERK1/2 ↓ n/a n/a   
von Euw, Molec 
Cancer, 2012 (204) TAK-733 
pMEK1/2 ↔ ↑ n/a RAS mutation 
pERK1/2 ↓ ↓ n/a Also tested GNAQ/11-mut lines: same paradox 
Pratilas, PNAS, 
2009 (208) PD-0325901 
pMEK1/2 ↔↓ n/a ↑ WT cells are driven by RTK signaling pERK1/2 ↓ n/a ↓ 
Cells highlighted in red indicate instances of paradoxical MEK1/2 activation (↑) upon MEK1/2 inhibition. 
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Appendix Table A4.3.  Vanderbilt Cancer Panel (VCP) Design Summary 
Refer also to Meador, et al., Molec Cancer Therapeutics, 2014, (24) for details. 
VCP1 
 
VCP2 
Number of Target Exons = 594 Number of Target Exons = 457 
Cumulative Target bp = 195838 bp Cumulative Target bp =  210570 bp 
# Amplicons = 1494 (max 1536) # Amplicons =  1448 (max 1536) 
# Gaps = 80 # Gaps = 123 
Total Gap Distance = 9734 bp Total Gap Distance = 15361 bp 
Amplicon Coverage = 95% Amplicon Coverage = 93% 
Low-Scoring Targets = 13 Low-Scoring Targets = 13 
    
Gene Chr #Exons Gene Chr #Exons 
AKT1 14 16 AKT2 19 14 
ALK 2 29 AKT3 1 15 
BRAF 7 18 ARAF X 16 
CDK4 12 8 BCL2 18 4 
DDR2 1 19 BCL2L1 20 4 
EGFR 7 31 ERBB3 12 29 
ERBB2 17 31 ERBB4 2 28 
FGFR1 8 23 FGFR4 5 20 
FGFR2 10 24 HRAS 11 8 
FGFR3 4 19 JAK1 1 25 
GNA11 19 7 JAK2 9 25 
GNAQ 9 7 JAK3 19 24 
IDH1 2 10 KDR 4 30 
IDH2 15 11 MCL1 1 5 
KIT 4 22 MYC 8 3 
KRAS 12 6 MYCL1 1 5 
MAP2K1 15 11 MYCN 2 3 
MAP2K2 19 11 NOTCH1 19 33 
MET 7 22 NOTCH2 1 35 
MLH1 3 22 NOTCH3 9 34 
MLH3 14 13 NTRK1 1 19 
MSH2 2 16 NTRK2 9 24 
MTOR 1 58 NTRK3 15 21 
NF1 17 59 PTCH1 9 30 
NF2 22 20 PTCH2 1 24 
NRAS 1 7 RAF1 3 17 
PDGFRA 4 23 RB1 13 27 
PIK3CA 3 21 RET 10 21 
PTEN 10 9 SMAD4 18 12 
RICTOR 5 38 STK11 19 10 
RPTOR 17 34 TP53 17 15 
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SMO 7 12 IGF1R 15 21 
TSC1 9 24   
TSC2 16 43   
    
Total Genes = 34 Total Genes = 32 
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Appendix Table 4.4.  Mutations Identified in Class I & II Cell Lines by the Vanderbilt Cancer Panel for the Illumina MiSeq
BRAF V600E
SK-Mel-28 M285 M368 WM3912 CHL-1 HMCB MeWo Function Gene Nucleotide Change Amino Acid Change Exon # Chr Position Ref Allele Mutant Allele SNP ID Allele Frequencya DP Scoreb QD Scorec
Y nonsynonymous SNV BRAF:NM_004333 c.T1799A p.V600E 15 chr7 140453136 A T rs113488022 0.143 1750 27.78
Y nonsynonymous SNV CDK4:NM_000075 c.C70T p.R24C 2 chr12 58145431 G A rs11547328 0.071 972 20.96
Y nonsynonymous SNV EGFR:NM_005228 c.C2095T p.P699S 18 chr7 55241647 C T . 0.071 1750 14.82
Y nonsynonymous SNV EGFR:NM_005228 c.C2257T p.P753S 19 chr7 55242487 C T rs121913231 0.143 637 24.04
Y frameshift insertion NF1:NM_001128147 c.111_112insCACA p.E37fs 2 chr17 29483051 - CACA . 0.071 1747 2.88
Y frameshift deletion NF1:NM_001128147 c.495_498del p.T165fs 5 chr17 29496924 TGTT - . 0.071 1750 10.98
Y Y Y nonsynonymous SNV NF1:NM_001128147 c.T528A p.D176E 5 chr17 29496957 T A rs112306990 0.214 1750 25.57
Y Y Y nonsynonymous SNV PDGFRA:NM_006206 c.G1841A p.G614E 13 chr4 55143609 G A . 0.214 1750 11.55
Y nonsynonymous SNV PDGFRA:NM_006206 c.C599G p.T200S 4 chr4 55130065 C G rs149951350 0.071 1632 11.80
Y nonframeshift insertion TSC1:NM_001162427 c.2976_2977insAGC p.E993delinsSE 22 chr9 135771987 - GCT . 0.071 1750 5.54
BRAF V600E
SK-Mel-28 M285 M368 WM3912 CHL-1 HMCB MeWo Function Gene Nucleotide Change Amino Acid Change Exon # Chr Position Ref Allele Mutant Allele SNP ID Allele Frequencya DP Scoreb QD Scorec
Y Y Y nonsynonymous SNV ERBB4:NM_001042599 c.G2834T p.C945F 23 chr2 212288912 C A . 0.214 1275 5.79
Y nonsynonymous SNV NOTCH1:NM_017617 c.G7657T p.A2553S 34 chr9 139390534 C A rs182522714 0.071 1750 7.05
Y nonsynonymous SNV RET:NM_020630 c.C833A p.T278N 4 chr10 43600607 C A rs35118262 0.143 1582 27.50
a, frequency of the mutant allele where 0.143 is equal to 14.3%
b, approximate read depth, or, the number of reads spanning a particular locus
c, variant confidence, or, quality by read depth
Vanderbilt Cancer Panel #1
Class I Class II
Vanderbilt Cancer Panel #2
Class I Class II
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Appendix Figure A4.1.  Paradoxical activation of MEK1/2 in Class II Pan-Negative 
Melanomas is Sustained for at Least 48 Hours.  Additionally, Class II melanomas display 
less cleaved PARP and less induction of pro-apoptotic Bim than the BRAF V600E-mutant 
line SK-Mel-28.  GSK1120212 = trametinib; Hr SStv, hours of serum-starvation; kDa, 
kilodaltons; nM, nanomolar; p, phosphorylated. 
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Appendix Figure A4.2.  No Significant Differences Were Observed in Ras-GTP (active Ras) Between Class I and II Cell 
Lines. (A) Immunoblot of the Ras-GTP pulldown results. (B) Quantification of immunoblot results using ImageJ.  Overall, both 
Class I and II pan-negative cell lines display lower Ras activity than an NRAS-mutant cell line.  Ctrl(s), control(s); IP, 
immunoprecipitation; WCL, whole-cell lysate. 
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Appendix Figure A4.3.  Class II Pan-Negative Melanomas Display Increased Levels of Phosphorylated ERBBs 1, 2, and 3.  
(A)  Analysis of phosphorylated receptor tyrosine kinase arrays comparing V600-mutant, Class I and Class II pan-negative 
melanomas reveals increased activity of EGFR, HER2 and HER3 in Class II lines.  (B)  No significant differences were observed 
in total levels of EGFR, HER2, or HER3 between Class I and II lines. 
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Appendix Figure A4.4.  Class II Pan-Negative Cell Lines are Sensitive to ERBB 
Inhibition.  (A)  Class I and II lines were treated with increasing doses of trametinib, afatinib 
or the combination as described in the methods and assessed for cell viability.  Class I lines 
are most sensitive to trametinib (Figure 1), but unlike Class II lines, are resistant to afatinib.  
(B) (see next page) Graph of IC50’s derived from cell viability assays in (A).  (C) (see next 
page) Immunoblot analysis of signaling following siRNA knockdown of HER3 in Class II lines 
reveals that although HER3 knockdown can attenuate AKT activation, it is less effective than 
small-molecule ERBB inhibition with afatinib (Figure 2c) and is less effective against ERK1/2 
activation.  nM, nanomolar; p, phosphorylated; si-scr, scrambled control siRNA; siHER3, 
HER3 siRNA. 
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Appendix Figure A4.4.  Continued from previous page. 
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 Appendix Figure A4.5.  Analysis of 61 Pan-Negative, Metastatic Melanomas in The 
Cancer Genome Atlas Reveals an Inverse Relationship between DUSP4 and EGFR 
Expression.  (A) Based on expression values from RNA sequencing analysis, the 
Spearman’s Rank Correlation was calculated for the expression of EGFR compared to 
DUSP4 in 61 pan-negative melanomas.  These data reveal a slight, yet statistically significant 
(p=0.03978) inverse relationship between DUSP4 RNA expression and EGFR RNA 
expression, where rho (slope) = -0.2644.  (B) Heat map of expression levels of DUSP4, 
HER2/ERBB2, HER3/ERBB3 and EGFR across the 61 pan-negative melanomas again 
shows an inverse relationship between EGFR and DUSP4 expression. 
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 Appendix Figure A4.6.  Amphiregulin Expression is Higher in Class II Pan-Negative Melanomas Compared with Class I’s.  
(A)  Protein array analysis of the expression of HB-EGF, EGF, HRG/NRGβ1, and AREG in serum-free conditioned media from 
HCT116 (positive control), Class I and Class II cell lines reveals that HB-EGF and AREG may be expressed at higher levels in 
Class II cells as quantified by ImageJ in (B).  (C)  ELISA for HB-EGF confirms a potential trend toward higher HB-EGF expression 
Class II cells versus Class I cells, however, it is not statistically significant.  Please refer to Figure 4.4d for AREG ELISA. AREG, 
amphiregulin; EGF, epidermal growth factor; HB-EGF, heparin-binding EGF; HRG, heregulin a.k.a. neuregulin-β1; SF media, 
serum-free media. 
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APPENDIX 5:  Supplementary Information for Chapter V 
No supplementary materials, methods, tables or figures accompany this chapter. 
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APPENDIX 6:  Supplementary Information for Chapter VI 
No supplementary materials, methods, or figures accompany this chapter. 
See the following pages for Appendix 6 tables. 
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HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL
ABL1 CCND1 EPHA3 GATA1 KRAS NPM1 SETD2
AKT1 CCND2 EPHA5 GATA2 LRP1B NRAS SF3B1
AKT2 CCND3 EPHB1 GATA3 MAP2K1 NTRK1 SMAD2
AKT3 CCNE1 ERBB2 GID4 (C17orf39) MAP2K2 NTRK2 SMAD4
ALK CD79A ERBB3 GNA11 MAP2K4 NTRK3 SMARCA4
APC CD79B ERBB4 GNA13 MAP3K1 NUP93 SMARCB1
AR CDC73 ERG GNAQ MCL1 PAK3 SMO
ARAF CDH1 ESR1 GNAS MDM2 PALB2 SOCS1
ARFRP1 CDK12 EZH2 GPR124 MDM4 PAX5 SOX10
ARID1A CDK4 FAM123B (WTX) GRIN2A MED12 PBRM1 SOX2
ARID2 CDK6 FAM46C GSK3B MEF2B PDGFRA SPEN
ASXL1 CDK8 FANCA HGF MEN1 PDGFRB SPOP
ATM CDKN1B FANCC HRAS MET PDK1 SRC
ATR CDKN2A FANCD2 IDH1 MITF PIK3CA STAG2
ATRX CDKN2B FANCE IDH2 MLH1 PIK3CG STAT4
AURKA CDKN2C FANCF IGF1R MLL PIK3R1 STK11
AURKB CEBPA FANCG IKBKE MLL2 PIK3R2 SUFU
AXL CHEK1 FANCL IKZF1 MPL PPP2R1A TET2
BAP1 CHEK2 FBXW7 IL7R MRE11A PRDM1 TGFBR2
BARD1 CIC FGF10 INHBA MSH2 PRKAR1A TNFAIP3
BCL2 CREBBP FGF14 IRF4 MSH6 PRKDC TNFRSF14
BCL2L2 CRKL FGF19 IRS2 MTOR PTCH1 TOP1
BCL6 CRLF2 FGF23 JAK1 MUTYH PTEN TP53
BCOR CSF1R FGF3 JAK2 MYC PTPN11 TSC1
BCORL1 CTCF FGF4 JAK3 MYCL1 RAD50 TSC2
BLM CTNNA1 FGF6 JUN MYCN RAD51 TSHR
BRAF CTNNB1 FGFR1 KAT6A (MYST3) MYD88 RAF1 VHL
BRCA1 DAXX FGFR2 KDM5A NF1 RARA WISP3
BRCA2 DDR2 FGFR3 KDM5C NF2 RB1 WT1
BRIP1 DNMT3A FGFR4 KDM6A NFE2L2 RET XPO1
BTK DOT1L FLT1 KDR NFKBIA RICTOR ZNF217
CARD11 EGFR FLT3 KEAP1 NKX2-1 RNF43 ZNF703
CBFB EMSY (c11orf30) FLT4 KIT NOTCH1 RPTOR
CBL EP300 FOXL2 KLHL6 NOTCH2 RUNX1
HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL
ALK BCR BCL2 BRAF EGFR ETV1 ETV4
ETV5 ETV6 EWSR1 MLL MYC NTRK1 PDGFRA
RAF1 RARA RET ROS1 TMPRSS2
Appendix Table A6.1A: Genes analyzed for base substitutions, short insertions/deletions, and copy number alterations (DNA).
Appendix Table A6.1B: Genes analyzed for rearrangements (DNA).
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HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL
ABL1 BARD1 CCND2 CIITA ELP2 FBXO31 GATA2 HIST1H2BO JUN MAP3K14 MYD88 PBRM1 PTPN2 SF3B1 SUFU U2AF1
ACTB BCL10 CCND3 CKS1B EP300 FBXW7 GATA3 HIST1H3B KAT6A (MYST3) MAP3K6 MYO18A PC PTPN6 (SHP-1) SGK1 SUZ12 U2AF2
AKT1 BCL11B CCNE1 CPS1 EPHA3 FGF10 GID4 (C17orf39) HNF1A KDM2B MAP3K7 NCOR2 PCBP1 PTPRO SMAD2 TAF1 VHL
AKT2 BCL2 CCT6B CREBBP EPHA5 FGF14 GNA11 HRAS KDM4C MAPK1 NCSTN PCLO RAD21 SMAD4 TBL1XR1 WDR90
AKT3 BCL2L2 CD22 CRKL EPHA7 FGF19 GNA12 HSP90AA1 KDM5A MCL1 NF1 PDCD1 RAD50 SMARCA1 TCF3 (E2A) WHSC1 (MMSET or NSD2)
ALK BCL6 CD274 (PDL1) CRLF2 EPHB1 FGF23 GNA13 ICK KDM5C MDM2 NF2 PDCD11 RAD51 SMARCA4 TCL1A (TCL1) WISP3
AMER1 
(FAM123B  or 
WTX)
BCL7A CD36 CSF1R ERBB2 FGF3 GNAQ ID3 KDM6A MDM4 NFE2L2 PDCD1LG2 (PDL2) RAF1 SMARCB1 TET2 WT1
APC BCOR CD58 CSF3R ERBB3 FGF4 GNAS IDH1 KDR MED12 NFKBIA PDGFRA RARA SMC1A TGFBR2 XBP1
APH1A BCORL1 CD70 CTCF ERBB4 FGF6 GPR124 IDH2 KEAP1 MEF2B NKX2-1 PDGFRB RASGEF1A SMC3 TLL2 XPO1
AR BIRC3 CD79A CTNNA1 ERG FGFR1 GRIN2A IGF1R KIT MEF2C NOD1 PDK1 RB1 SMO TMEM30A YY1AP1
ARAF BLM CD79B CTNNB1 ESR1 FGFR2 GSK3B IKBKE KLHL6 MEN1 NOTCH1 PHF6 RELN SOCS1
TMSB4XP8 
(TMSL3) ZMYM3
ARFRP1 BRAF CDC73 CUX1 ETS1 FGFR3 GTSE1 IKZF1 KMT2A (MLL) MET NOTCH2 PIK3CA RET SOCS2 TNFAIP3 ZNF217
ARHGAP26 
(GRAF) BRCA1 CDH1 CXCR4 ETV6 FGFR4 HDAC1 IKZF2 KMT2C (MLL3) MIB1 NPM1 PIK3CG RHOA SOCS3 TNFRSF11A ZNF24 (ZSCAN3)
ARID1A BRCA2 CDK12 DAXX EXOSC6 FHIT HDAC4 IKZF3 KMT2D (MLL2) MITF NRAS PIK3R1 RICTOR SOX10 TNFRSF14 ZNF703
ARID2 BRD4 CDK4 DDR2 EZH2 FLCN HDAC7 IL7R KRAS MKI67 NT5C2 PIK3R2 RNF43 SOX2 TNFRSF17 ZRSR2
ASMTL BRIP1 CDK6 DDX3X FAF1 FLT1 HGF INHBA LEF1 MLH1 NTRK1 PIM1 ROS1 SPEN TOP1
ASXL1 BRSK1 CDK8 DNM2 FAM46C FLT3 HIST1H1C INPP4B LRP1B MPL NTRK2 PLCG2 RPTOR SPOP TP53
ATM BTG2 CDKN1B DNMT3A FANCA FLT4 HIST1H1D INPP5D (SHIP) LRRK2 MRE11A NTRK3 POT1 RUNX1 SRC TP63
ATR BTK CDKN2A DOT1L FANCC FLYWCH1 HIST1H1E IRF1 MAF MSH2 NUP93 PPP2R1A S1PR2 SRSF2 TRAF2
ATRX BTLA CDKN2B DTX1 FANCD2 FOXL2 HIST1H2AC IRF4 MAFB MSH3 NUP98 PRDM1 SDHA STAG2 TRAF3
AURKA C11orf30 (EMSY) CDKN2C DUSP2 FANCE FOXO1 HIST1H2AG IRF8 MAGED1 MSH6 P2RY8 PRKAR1A SDHB STAT3 TRAF5
AURKB CAD CEBPA DUSP9 FANCF FOXO3 HIST1H2AL IRS2 MALT1 MTOR PAG1 PRKDC SDHC STAT4 TSC1
AXIN1 CARD11 CHD2 EBF1 FANCG FOXP1 HIST1H2AM JAK1 MAP2K1 MUTYH PAK3 PRSS8 SDHD STAT5A TSC2
AXL CBFB CHEK1 ECT2L FANCL FRS2 HIST1H2BC JAK2 MAP2K2 MYC PALB2 PTCH1 SERP2 STAT5B TSHR
B2M CBL CHEK2 EED FAS (TNFRSF6) GADD45B HIST1H2BJ JAK3 MAP2K4 MYCL (MYCL1) PASK PTEN SETBP1 STAT6 TUSC3
BAP1 CCND1 CIC EGFR FBXO11 GATA1 HIST1H2BK JARID2 MAP3K1 MYCN PAX5 PTPN11 SETD2 STK11 TYK2
HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL
ALK BCL6 BRAF CRLF2 EPOR ETV4 ETV6 FGFR2 IGK JAK1 KMT2A (MLL) NTRK1 PDGFRB RARA ROS1 TRG
BCL2 BCR CCND1 EGFR ETV1 ETV5 EWSR1 IGH IGL JAK2 MYC PDGFRA RAF1 RET TMPRSS2
HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL HUGO SYMBOL
ABI1 BCL11B CCND2 CRLF2 ERBB2 FOXO1 HOXA11 ITK MALT1 MYH11 NUMA1 PDGFRB RALGDS SET TCL1A (TCL1) TTL
ABL1 BCL2 CCND3 CSF1 ERG FOXO3 HOXA13 JAK1 MDS2 MYH9 NUP214 PER1 RAP1GDS1 SH3GL1 TEC TYK2
ABL2 BCL3 CD274 (PDL1) CTNNB1 ETS1 FOXO4 HOXA3 JAK2 MECOM NACA NUP98 PHF1 RARA SLC1A2 TET1 USP6
ACSL6 BCL6 CDK6 DDIT3 ETV1 FOXP1 HOXA9 JAK3 MKL1 NBEAP1 (BCL8) NUTM2A PICALM RBM15 SNX29 (RUNDC2A) TFE3
WHSC1 (MMSET 
or NSD2)
AFF1 BCL7A CDX2 DDX10 ETV4 FSTL3 HOXC11 JAZF1 MLF1 NCOA2 OMD PIM1 RET SRSF3 TFG WHSC1L1
AFF4 BCL9 CHIC2 DDX6 ETV5 FUS HOXC13 KAT6A (MYST3) MLLT1 (ENL) NDRG1 P2RY8 PLAG1 RHOH SS18 TFPT YPEL5
ALK BCOR CHN1 DEK ETV6 GAS7 HOXD11 KDSR MLLT10 (AF10) NF1 PAFAH1B2 PML RNF213 SSX1 TFRC ZBTB16
ARHGAP26 
(GRAF) BCR CIC DUSP22 EWSR1 GLI1 HOXD13 KIF5B MLLT3 NF2 PAX3 POU2AF1 ROS1 SSX2 TLX1 ZMYM2
ARHGEF12 BIRC3 CIITA EGFR FCGR2B GMPS HSP90AA1 KMT2A (MLL) MLLT4 (AF6) NFKB2 PAX5 PPP1CB RPL22 SSX4 TLX3 ZNF384
ARID1A BRAF CLP1 EIF4A2 FCRL4 GPHN HSP90AB1 LASP1 MLLT6 NIN PAX7 PRDM1 RPN1 STAT6 TMPRSS2 ZNF521
ARNT BTG1 CLTC ELF4 FEV HERPUD1 IGH LCP1 MN1 NOTCH1 PBX1 PRDM16 RUNX1 STL TNFRSF11A
ASXL1 CAMTA1 CLTCL1 ELL FGFR1 HEY1 IGK LMO1 MNX1 NPM1 PCM1 PRRX1 RUNX1T1 (ETO) SYK TOP1
ATF1 CARS CNTRL (CEP110) ELN FGFR1OP HIP1 IGL LMO2 MSI2 NR4A3 PCSK7 PSIP1 RUNX2 TAF15 TP63
ATG5 CBFA2T3 COL1A1 EML4 FGFR2 HIST1H4I IKZF1 LPP MSN NSD1
PDCD1LG2 
(PDL2) PTCH1 SEC31A TAL1 TPM3
ATIC CBFB CREB3L1 EP300 FGFR3 HLF IL21R LYL1 MUC1 NTRK1 PDE4DIP PTK7 SEPT5 TAL2 TPM4
BCL10 CBL CREB3L2 EPOR FLI1 HMGA1 IL3 MAF MYB NTRK2 PDGFB RABEP1 SEPT6 TBL1XR1 TRIM24
BCL11A CCND1 CREBBP EPS15 FNBP1 HMGA2 IRF4 MAFB MYC NTRK3 PDGFRA RAF1 SEPT9 TCF3 (E2A) TRIP11
Appendix Table A6.2B: Genes analyzed for rearrangements (DNA).
Appendix Table 6.2C: Genes analyzed for rearrangements (RNA).
Appendix Table A6.2A: Genes analyzed for base substitutions, short insertions/deletions, and copy number alterations (DNA).
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APPENDIX 7:  Supplementary Information for Chapter VII 
No supplementary materials, methods, tables or figures accompany this chapter. 
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